Document:

QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.1  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN REDACTED PROVISIONS OF THIS AGREEMENT. THE REDACTED PROVISIONS ARE IDENTIFIED BY THREE ASTERISKS ENCLOSED BY BRACKETS AND
UNDERLINED. THE CONFIDENTIAL PORTIONS HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.  

  
 

    CREDIT AGREEMENT    
  

SPECIALTY
LABORATORIES, INC.

and

BNP PARIBAS

as Agent 

FIRST
UNION NATIONAL BANK

UNION BANK OF CALIFORNIA, N.A.

and

U.S. BANK NATIONAL ASSOCIATION

as Co-Syndication Agents 

and
CERTAIN FINANCIAL INSTITUTIONS

as Lenders 

$40,000,000

March 26, 2002 

  

 
 

TABLE OF CONTENTS    

	 
	 	 
	 	Page

	CREDIT AGREEMENT	 	1
	ARTICLE I—Definitions and References	 	1
	 	Section 1.1.	 	Defined Terms	 	1
	 	Section 1.2.	 	Exhibits and Schedules; Additional Definitions	 	11
	 	Section 1.3.	 	Amendment of Defined Instruments	 	12
	 	Section 1.4.	 	References and Titles	 	12
	 	Section 1.5.	 	Calculations and Determinations	 	12
	 	Section 1.6.	 	Joint Preparation; Construction of Indemnities and Releases	 	12
	

ARTICLE II—The Loans	
 	

12
	 	Section 2.1.	 	Commitments to Lend; Notes	 	12
	 	Section 2.2.	 	Requests for New Loans	 	13
	 	Section 2.3.	 	Continuations and Conversions of Existing Loans	 	14
	 	Section 2.4.	 	Use of Proceeds	 	14
	 	Section 2.5.	 	Interest Rates and Fees	 	15
	 	Section 2.6.	 	Mandatory Prepayments	 	15
	 	Section 2.7.	 	Optional Prepayments	 	16
	

ARTICLE III—Payments to Lenders	
 	

16
	 	Section 3.1.	 	General Procedures	 	16
	 	Section 3.2.	 	Capital Reimbursement	 	17
	 	Section 3.3.	 	Increased Cost of Eurodollar Loans	 	17
	 	Section 3.4.	 	Availability	 	17
	 	Section 3.5.	 	Funding Losses	 	18
	 	Section 3.6.	 	Reimbursable Taxes	 	18
	 	Section 3.7.	 	Change of Applicable Lending Office	 	19
	 	Section 3.8.	 	Replacement of Lenders	 	19
	

ARTICLE IV—Conditions Precedent to Lending	
 	

19
	 	Section 4.1.	 	Documents to be Delivered	 	19
	 	Section 4.2.	 	Additional Conditions Precedent	 	20
	

ARTICLE V—Representations and Warranties	
 	

21
	 	Section 5.1.	 	No Default	 	21
	 	Section 5.2.	 	Organization and Good Standing	 	21
	 	Section 5.3.	 	Authorization	 	21
	 	Section 5.4.	 	No Conflicts or Consents	 	21
	 	Section 5.5.	 	Enforceable Obligations	 	22
	 	Section 5.6.	 	Initial Financial Statements	 	22
	 	Section 5.7.	 	Other Obligations and Restrictions	 	22
	 	Section 5.8.	 	Full Disclosure	 	22
	 	Section 5.9.	 	Litigation	 	22
	 	Section 5.10.	 	Labor Disputes and Acts of God	 	22
	 	Section 5.11.	 	ERISA Plans and Liabilities	 	22
	 	Section 5.12.	 	Environmental and Other Laws	 	23
	 	Section 5.13.	 	Names and Places of Business	 	23
	 	Section 5.14.	 	Borrower's Subsidiaries	 	23
	 	Section 5.15.	 	Government Regulation	 	23
	 	Section 5.16.	 	Insider	 	24

i

 

	 	Section 5.17.	 	Solvency	 	24
	 	Section 5.18.	 	Title to Properties; Licenses	 	24
	

ARTICLE VI—Affirmative Covenants of Borrower	
 	

24
	 	Section 6.1.	 	Payment and Performance	 	24
	 	Section 6.2.	 	Books, Financial Statements and Reports	 	24
	 	Section 6.3.	 	Other Information and Inspections	 	25
	 	Section 6.4.	 	Notice of Material Events and Change of Address	 	25
	 	Section 6.5.	 	Maintenance of Properties	 	26
	 	Section 6.6.	 	Maintenance of Existence and Qualifications	 	26
	 	Section 6.7.	 	Payment of Trade Liabilities, Taxes, etc.	 	26
	 	Section 6.8.	 	Insurance	 	27
	 	Section 6.9.	 	Performance on Borrower's Behalf	 	27
	 	Section 6.10.	 	Interest	 	27
	 	Section 6.11.	 	Compliance with Agreements and Law	 	27
	 	Section 6.12.	 	Environmental Matters; Environmental Reviews	 	28
	 	Section 6.13.	 	Evidence of Compliance	 	28
	 	Section 6.14.	 	Bank Accounts; Offset	 	28
	 	Section 6.15.	 	Guaranties of Substantial Subsidiaries	 	28
	 	Section 6.16.	 	Agreement to Deliver Security Documents	 	29
	 	Section 6.17.	 	Financial Covenants	 	29
	

ARTICLE VII—Negative Covenants of Borrower	
 	

29
	 	Section 7.1.	 	Indebtedness	 	29
	 	Section 7.2.	 	Limitation on Liens	 	29
	 	Section 7.3.	 	Hedging Contracts	 	30
	 	Section 7.4.	 	Limitation on Mergers, Issuances of Securities	 	30
	 	Section 7.5.	 	Limitation on Sales of Property	 	30
	 	Section 7.6.	 	Limitation on Dividends and Redemptions	 	30
	 	Section 7.7.	 	Limitation on Investments and New Businesses	 	30
	 	Section 7.8.	 	Limitation on Credit Extensions	 	31
	 	Section 7.9.	 	Transactions with Affiliates	 	31
	 	Section 7.10.	 	Prohibited Contracts	 	31
	

ARTICLE VIII—Events of Default and Remedies	
 	

31
	 	Section 8.1.	 	Events of Default	 	31
	 	Section 8.2.	 	Remedies	 	33
	

ARTICLE IX—Agent	
 	

33
	 	Section 9.1.	 	Appointment and Authority	 	33
	 	Section 9.2.	 	Exculpation, Agent's Reliance, Etc.	 	34
	 	Section 9.3.	 	Credit Decisions	 	34
	 	Section 9.4.	 	Indemnification	 	34
	 	Section 9.5.	 	Rights as Lender	 	35
	 	Section 9.6.	 	Sharing of Set-Offs and Other Payments	 	35
	 	Section 9.7.	 	Investments	 	35
	 	Section 9.8.	 	Benefit of Article IX	 	35
	 	Section 9.9.	 	Resignation	 	35
	 	Section 9.10	 	Certain Titles	 	36
	

ARTICLE X—Miscellaneous	
 	

36
	 	Section 10.1.	 	Waivers and Amendments; Acknowledgments	 	36

ii

 

	 	Section 10.2.	 	Survival of Agreements; Cumulative Nature	 	37
	 	Section 10.3.	 	Notices	 	37
	 	Section 10.4.	 	Payment of Expenses; Indemnity	 	38
	 	Section 10.5.	 	Joint and Several Liability; Parties in Interest; Assignments	 	39
	 	Section 10.6.	 	Confidentiality	 	41
	 	Section 10.7.	 	Governing Law	 	41
	 	Section 10.8.	 	Limitation on Interest	 	41
	 	Section 10.9.	 	Termination; Limited Survival	 	42
	 	Section 10.10.	 	Severability	 	42
	 	Section 10.11.	 	Counterparts; Fax	 	42
	 	Section 10.12.	 	Waiver of Jury Trial, Punitive Damages, etc.	 	42

Schedules and Exhibits:  

	Schedule 1	 	—	 	Disclosure Schedule
	Schedule 2	 	—	 	Security Schedule
	Schedule 3	 	—	 	Insurance Schedule
	Schedule 4	 	—	 	Lenders Schedule
	

Exhibit A	
 	

—	
 	

Promissory Note
	Exhibit B	 	—	 	Borrowing Notice
	Exhibit C	 	—	 	Continuation/Conversion Notice
	Exhibit D	 	—	 	Certificate Accompanying Financial Statements
	Exhibit E	 	—	 	Opinion of Counsel for Restricted Persons
	Exhibit F	 	—	 	Assignment and Acceptance
	Exhibit G	 	—	 	Borrowing Base Report
	Exhibit H	 	—	 	Financial Covenants
	Exhibit I	 	—	 	Guaranty Agreement
	Exhibit J	 	—	 	Pledge Agreement

iii

 
 

CREDIT AGREEMENT    
  

        THIS CREDIT AGREEMENT is made as of March 26, 2002, by and between Specialty Laboratories, Inc., a California corporation (herein called
"Borrower"), and BNP Paribas, a bank organized and existing under the laws of France, individually and as agent (herein called "Agent") and the Lenders referred to below. In consideration of the
mutual covenants and agreements contained herein the parties hereto agree as follows: 

 
 

ARTICLE I—Definitions and References    
  

        Section 1.1.    Defined Terms.    As used in this Agreement, each of the following terms has the meaning given
to such term in this Section 1.1 or in the sections and subsections referred to below: 

        "Adjusted Base Rate" means the Base Rate plus the Base Rate Margin, provided that the Adjusted Base Rate charged by any Person shall never
exceed the Highest Lawful Rate. 

        "Adjusted LIBOR Rate" means, for any Eurodollar Loan for any Interest Period therefor, the rate per annum equal to the sum of
(a) the Eurodollar Margin plus (b) the rate per annum (rounded upwards, if necessary, to the nearest 1/100 of 1%) determined by Agent to be equal to the quotient obtained by dividing
(i) the LIBOR Rate for such Eurodollar Loan for such Interest Period by (ii) 1 minus the Reserve Requirement for such Eurodollar Loan for such Interest Period, provided that no Adjusted
LIBOR Rate charged by any Person shall ever exceed the Highest Lawful Rate. The Adjusted LIBOR Rate for any Eurodollar Loan shall change whenever the Eurodollar Margin or the Reserve Requirement
changes. 

        "Affiliate" of any Person means any other Person controlling, controlled by or under common control with such Person. For purposes of this
definition, the term "control" when used with respect to any Person means the power to direct the management of policies of such Person, directly or indirectly, whether through the ownership of voting
securities, by contract or otherwise, and the terms "controlling" and "controlled" have meanings correlative to the foregoing. 

        "Agent" means BNP Paribas, as Agent hereunder, and its successors in such capacity. 

        "Agreement" means this Credit Agreement. 

        "Applicable Lending Office" means, with respect to each Lender, such Lender's Domestic Lending Office in the case of Base Rate Loans and
such Lender's Eurodollar Lending Office in the case of Eurodollar Loans. 

        "Approved Fund" means any Person (other than a natural Person) that is engaged in making, purchasing, holding or otherwise investing in
commercial loans and similar extensions of credit in the ordinary course of its business and that is administered or managed by (i) a Lender, (ii) an Affiliate of a Lender, or
(iii) an entity or an Affiliate of an entity that administers or manages a Lender. 

        "Base Rate" means the higher of (a) Agent's [***]* and (b) the
[***]*. If Agent's Prime Rate changes after the date hereof the Base Rate shall be automatically increased or decreased, as the case may be,
without notice to Borrower from time to time as of the effective time of each change in Agent's Prime Rate. 

        "Base Rate Loan" means a Loan which does not bear interest at the Eurodollar Rate. 

        "Base Rate Margin" means, on each day prior to [***]*, and on each day thereafter: 

	(a)
	[***]*
when the Pricing Senior Leverage Ratio is less than or equal to
[***]*,

	(b)
	[***]*
when the Pricing Senior Leverage Ratio is greater than [***]*. 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 

From
and after [***]*, the Base Rate Margin in effect on any day is based upon the Pricing Senior Leverage Ratio, as determined from financial
statements delivered pursuant to Section 6.2(a) or Section 6.2(b) then most recently received by Agent, effective as of the date such financial statements are received by Agent. In the
event Borrower at any time fails to deliver financial statements in compliance with either Section 6.2(a) or Section 6.2 (b), until such time as each Lender Party receives the applicable
financial statements, the Base Rate Margin shall mean on each day during such period, [***]*. 

        "Borrower" means Specialty Laboratories, Inc., a California corporation. 

        "Borrowing" means a borrowing of new Loans of a single Type pursuant to Section 2.2 or a Continuation or Conversion of existing
Loans into a single Type (and, in the case of Eurodollar Loans, with the same Interest Period) pursuant to Section 2.3. 

        "Borrowing Base" means, at the particular time in question, 85% of Borrower's Eligible Accounts; provided, however, that in no event shall
the Borrowing Base ever exceed the Maximum Credit Amount. 

        "Borrowing Base Report" means a report in the form attached hereto as Exhibit G, appropriately completed, together with a detailed
aged schedule of all Eligible Accounts as of the date specified in such report, listing face amounts and dates of invoices of each such Eligible Account and the name and address of each account debtor
obligated on such Eligible Accounts (and, upon request of Agent, copies of invoices, credit reports, and any other matters and information relating to the Eligible Accounts). 

        "Borrowing Notice" means a written or telephonic request, or a written confirmation, made by Borrower which meets the requirements of
Section 2.2. 

        "Business Day" means a day, other than a Saturday or Sunday, on which commercial banks are open for business with the public in New York
City, New York or San Francisco, California. Any Business
Day in any way relating to Eurodollar Loans (such as the day on which an Interest Period begins or ends) must also be a day on which, in the judgment of Agent, significant transactions in dollars are
carried out in the interbank eurocurrency market. 

        "Cash Equivalents" means Investments in: 

	(a)
	marketable
obligations, maturing within twelve months after acquisition thereof, issued or unconditionally guaranteed by the United States of America or an instrumentality or agency
thereof and entitled to the full faith and credit of the United States of America;

	(b)
	demand
deposits, and time deposits (including certificates of deposit) maturing within twelve months from the date of deposit thereof, with any office of any Lender or with a domestic
office of any national or state bank or trust company which is organized under the Laws of the United States of America or any state therein, which has capital, surplus and undivided profits of at
least $500,000,000, and whose long term certificates of deposit are rated at least Aa3 by Moody's or AA- by S & P;

	(c)
	repurchase
obligations with a term of not more than seven days for underlying securities of the types described in subsection (a) above entered into with any commercial bank
meeting the specifications of subsection (b) above;

	(d)
	open
market commercial paper, maturing within 270 days after acquisition thereof, which are rated at least [***]* by
Moody's or [***]* by S & P (at the time acquired by a Restricted Person); and

	(e)
	money
market or other mutual funds substantially all of whose assets comprise securities of the types described in subsections (a) through (d) above. 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

2

 

        "Change of Control" means the occurrence of either of the following events: (a) any Person or two or more Persons acting as a group
shall acquire beneficial ownership (within the meaning of Rule 13d-3 of the Securities and Exchange Commission under the Securities Act of 1934, as amended, and including
holding proxies to vote for the election of directors other than proxies held by Borrower's management or their designees to be voted in favor of Persons nominated by Borrower's Board of Directors) of
50% or more of the outstanding voting securities of Borrower, measured by voting power (including both common stock and any preferred stock or other equity securities entitling the holders thereof to
vote with the holders of common stock in elections for directors of Borrower) or (b) one-half or more of the directors of Borrower shall consist of Persons not nominated by
Borrower's Board of Directors (not including as Board nominees any directors which the Board is obligated to nominate pursuant to shareholders agreements, voting trust arrangements or similar
arrangements). 

        "Collateral" means all property of any kind which is subject to a Lien in favor of Lenders (or in favor of Agent for the benefit of
Lenders) or which, under the terms of any Security Document, is purported to be subject to such a Lien. 

        "Consolidated" refers to the consolidation of any Person, in accordance with GAAP, with its properly consolidated subsidiaries. References
herein to a Person's Consolidated financial statements, financial position, financial condition, liabilities, etc. refer to the consolidated financial statements, financial position, financial
condition, liabilities, etc. of such Person and its properly consolidated subsidiaries. 

        "Continuation" shall refer to the continuation pursuant to Section 2.3 hereof of a Eurodollar Loan as a Eurodollar Loan from one
Interest Period to the next Interest Period. 

        "Continuation/Conversion Notice" means a written or telephonic request, or a written confirmation, made by Borrower which meets the
requirements of Section 2.3. 

        "Conversion" shall refer to a conversion pursuant to Section 2.3 or Article III of one Type of Loan into another Type of
Loan. 

        "Default" means any Event of Default and any default, event or condition which would, with the giving of any requisite notices and the
passage of any requisite periods of time, constitute an Event of Default. 

        "Default Rate" means, at the time in question (a) with respect to any Base Rate Loan, the rate per annum equal to
[***]* then in effect and (b) with respect to any Eurodollar Loan, the rate per annum equal to
[***]* then in effect for such Loan, provided in each case that no Default Rate charged by any Person shall ever exceed the Highest Lawful Rate. 

        "Disclosure Report" means either a notice given by Borrower under Section 6.4 or a certificate given by Borrower's chief financial
officer under Section 6.2(b). 

        "Disclosure Schedule" means Schedule 1 hereto. 

        "Distribution" means (a) any dividend or other distribution made by a Restricted Person on or in respect of any stock, partnership
interest, or other equity interest in such Restricted Person or any other Restricted Person (including any option or warrant to buy such an equity interest), or (b) any payment made by a
Restricted Person to purchase, redeem, acquire or retire any stock, partnership interest, or other equity interest in such Restricted Person or any other Restricted Person (including any such option
or warrant). 

        "Domestic Lending Office" means, with respect to any Lender, the office of such Lender specified as its "Domestic Lending Office" below
its name on the Lenders Schedule, or such other office as such Lender may from time to time specify to Borrower and Agent. 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

3

 

        "Eligible Accounts" means at any time, an amount equal to the aggregate net invoice or ledger amount owing on all trade accounts
receivable of Borrower for goods sold or leased or services rendered in the ordinary course of business, in which Agent (for the benefit of Lenders) has a perfected, first priority lien, after
deducting (without duplication): (i) each such account that is unpaid 60 days or more after the original invoice date thereof, (ii) the amount of all discounts, allowances,
rebates, credits and adjustments to such accounts, (iii) the amount of all contra accounts, setoffs, defenses or counterclaims asserted by or available to the account debtors, (iv) all
accounts with respect to which goods are placed on consignment or subject to a guaranteed sale or other terms by reason of which payment by the account debtor may be conditional, (v) the amount
billed for or representing retainage, if any, until all prerequisites to the immediate payment of retainage have been satisfied, (vi) all accounts owing by account debtors for which there has
been instituted a proceeding in bankruptcy or reorganization under the United States Bankruptcy Code or other law, whether state or federal, now or hereafter existing for relief of debtors,
(vii) all accounts owing by any affiliates of Borrower, (viii) all accounts in which the account debtor is the United States or any department, agency or instrumentality of the United
States, except to the extent an acknowledgment of assignment to Agent of such account in compliance with the Federal Assignment of Claims Act and other applicable laws has been executed by Borrower in
favor of Agent, (ix) all accounts due Borrower by any account debtor whose principal place of business is located outside the United States of America and its territories, (x) all
accounts subject to any provision prohibiting assignment or requiring notice of or consent to such assignment, (xi) that portion of all account balances owing by any single account debtor which
exceeds twenty percent (20%) of the aggregate of all accounts otherwise deemed eligible hereunder which are owing to Borrower by all account debtors, and (xii) if more than twenty percent (20%)
of the then balance owing by any single
account debtor does not qualify as an Eligible Account under the foregoing provisions, then the aggregate amount of all accounts owing by such account debtor shall be excluded from Eligible Accounts. 

        "Eligible Transferee" means a Person which either (a) is a Lender, an Affiliate of a Lender or an Approved Fund, or (b) is
consented to as an Eligible Transferee by Agent and, so long as no Default or Event of Default is continuing, by Borrower, which consents in each case will not be unreasonably withheld (provided that
no Person organized outside the United States may be an Eligible Transferee if Borrower would be required to pay withholding taxes on interest or principal owed to such Person). 

        "Environmental Laws" means any and all Laws relating to the environment or to emissions, discharges, releases or threatened releases of
pollutants, contaminants, chemicals, or industrial, toxic or hazardous substances or wastes into the environment including ambient air, surface water, ground water, or land, or otherwise relating to
the manufacture, processing, distribution, use, treatment, storage, disposal, transport, or handling of pollutants, contaminants, chemicals, or industrial, toxic or hazardous substances or wastes. 

        "ERISA" means the Employee Retirement Income Security Act of 1974, as amended from time to time, together with all rules and regulations
promulgated with respect thereto. 

        "ERISA Affiliate" means any corporation or trade or business which for purposes of Title IV of ERISA is a member of the same controlled
group of corporations as Borrower which, within the meaning of Section 414(b) of the Internal Revenue Code, and the regulations promulgated and rulings issued thereunder or under common control
with Borrower, within the meaning of Section 414(c) of the Internal Revenue Code, and the regulations promulgated and rulings issued thereunder. 

        "ERISA Termination Event" means (a) the occurrence with respect to any Plan of (1) a reportable event described in Sections
4043(b)(5) or (6) of ERISA or (2) any other reportable event described in Section 4043(b) of ERISA other than a reportable event not subject to the provision for
thirty-day notice to the Pension Benefit Guaranty Corporation pursuant to a waiver by such corporation under Section 4043(a) of ERISA, or (b) the withdrawal of Borrower or
any Affiliate thereof from a Plan 

4

 

during a plan year in which it was a "substantial employer" as defined in Section 4001(a)(2) of ERISA, or (c) the filing of a notice of intent to terminate any Plan or the treatment of
any Plan amendment as a termination under Section 4041 of ERISA, or (d) the institution of proceedings to terminate any Plan by the Pension Benefit Guaranty Corporation under
Section 4042 of ERISA, or (e) any other event or condition which might constitute grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to
administer, any Plan. 

        "Eurodollar Lending Office" means, with respect to any Lender, the office of such Lender specified as its "Eurodollar Lending Office"
below its name on the Lenders Schedule (or, if no such office is specified, its Domestic Lending Office), or such other office of Lender as Lender may from time to time specify to Borrower and Agent. 

        "Eurodollar Loan" means a Loan that bears interest at the Adjusted LIBOR Rate. 

        "Eurodollar Margin" means, on each day prior to [***]*, and on each day thereafter: 

	(a)
	[***]*
when the Pricing Senior Leverage Ratio is less than or equal to
[***]*; and

	(b)
	[***]*
when the Pricing Senior Leverage Ratio is greater than [***]*. 

From
and after [***]*, the Eurodollar Margin in effect on any day (whether in the middle of an Interest Period or otherwise) is based upon the
Pricing Senior Leverage Ratio, as determined from financial statements delivered pursuant to Section 6.2(a) or Section 6.2(b) then most recently received by Agent, effective as of the
date such financial statements are received by Agent. In the event Borrower at any time fails to deliver financial statements in compliance with either Section 6.2(a) or Section 6.2 (b),
until such time as each Lender Party receives the applicable financial statements, the Eurodollar Margin shall mean on each day during such period,
[***]*. 

        "Event of Default" has the meaning given to such term in Section 8.1. 

        "Federal Funds Rate" means, for any period, a fluctuating interest rate (expressed as a per annum rate and rounded upwards, if necessary,
to the next 1/16 of 1%) equal for each day during such period to the weighted average of the rates on overnight Federal funds transactions with members of the Federal Reserve System
arranged by Federal funds brokers, as published for such day (or, if such day is not a Business Day, for the next preceding Business Day) by the Federal Reserve Bank of New York, or, if such rates are
not so published for any day which is a Business Day, the average of the quotations for such day on such transactions received by Agent from three Federal funds brokers of recognized standing selected
by Agent. All determinations of the Fed Funds Rate by Agent shall, in the absence of clear and demonstrable error, be binding and conclusive upon Borrower. 

        "Fiscal Quarter" means a three-month period ending on March 31, June 30, September 30 or December 31 of any
year. 

        "Fiscal Year" means a twelve-month period ending on December 31 of any year. 

        "GAAP" means generally accepted accounting principles in the United States of America as in effect from time to time, applied on a basis
consistent with those used in the preparation of the Initial Financial Statements (except for changes with which Borrower's independent public accounts concur). 

        "Guarantor" means any Person, from time to time guaranteeing some or all of the Obligations pursuant to a guaranty listed on the Security
Schedule or any other Person from time to time guaranteeing some or all of the Obligations and who has been accepted by Agent as a Guarantor. 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

5

 

        "Hazardous Substance" means (i) any chemical, compound, material, mixture or substance that is now or hereafter defined or listed
in, regulated under, or otherwise classified pursuant to, any Environmental Laws as a "hazardous substance," "hazardous material," "hazardous waste," "extremely hazardous waste or substance,"
"infectious waste," "toxic substance," "toxic pollutant," or any other formulation intended to define, list or classify substances by reason of deleterious properties, including ignitability,
corrosiveness, reactivity, carcinogenicity, toxicity or reproductive toxicity; (ii) petroleum, any fraction of petroleum, natural gas, natural gas liquids, liquified natural gas, synthetic gas
usable for fuel (or mixtures of natural gas and such synthetic gas), and ash produced by a resource recovery facility utilizing a municipal solid waste stream, and drilling fluids, produced waters and
other wastes associated with the exploration, development or production of crude oil, natural gas or geothermal resources; (iii) asbestos and any asbestos containing material;
(iv) "waste" as defined in section 13050(d) of the California Water Code; and (v) any other material that, because of its quantity, concentration or physical or chemical
characteristics, poses a significant present or potential hazard to human health or safety or to the environment if released into the workplace or the environment. 

        "Hedging Contract" means (a) any agreement providing for options, swaps, floors, caps, collars, forward sales or forward purchases
involving interest rates, commodities or commodity prices, equities, currencies, bonds, or indexes based on any of the foregoing, (b) any option, futures or forward contract traded on an
exchange, and (c) any other derivative agreement or other similar agreement or arrangement. 

        "Highest Lawful Rate" means, with respect to each Lender Party to whom Obligations are owed, the maximum nonusurious rate of interest that
such Lender Party is permitted under applicable Law to
contract for, take, charge, or receive with respect to such Obligations. All determinations herein of the Highest Lawful Rate, or of any interest rate determined by reference to the Highest Lawful
Rate, shall be made separately for each Lender Party as appropriate to assure that the Loan Documents are not construed to obligate any Person to pay interest to any Lender Party at a rate in excess
of the Highest Lawful Rate applicable to such Lender Party. 

        "Inactive Subsidiary" means a Subsidiary that (a) is not engaged in any active or passive business, (b) holds tangible
assets with a value not in excess of [***]* in the aggregate, and (c) produces no revenue. 

        "Indebtedness" of any Person means, without duplication, Liabilities in any of the following categories: 

        (a)  Liabilities
for borrowed money, 

        (b)  Liabilities
constituting an obligation to pay the deferred purchase price of property or services, 

        (c)  Liabilities
evidenced by a bond, debenture, note or similar instrument, 

        (d)  Liabilities
which (i) would under GAAP be shown on such Person's balance sheet as a liability, and (ii) are payable more than one year from the date of
creation thereof (other than reserves for taxes and reserves for contingent obligations), 

        (e)  Liabilities
arising under Hedging Contracts, 

        (f)    Liabilities
constituting principal under leases capitalized in accordance with GAAP, 

        (g)  Liabilities
arising under conditional sales or other title retention agreements, 

        (h)  Liabilities
owing under direct or indirect guaranties of Liabilities of any other Person or otherwise constituting obligations to purchase or acquire or to otherwise
protect or insure a creditor against loss in respect of Liabilities of any other Person (such as obligations under working capital maintenance agreements, agreements to keep-well, or
agreements to purchase Liabilities, assets, goods, securities or services), but excluding endorsements in the ordinary course of business of negotiable instruments in the course of collection, 

        (i)    Liabilities
(for example, repurchase agreements, mandatorily redeemable preferred stock and sale/leaseback agreements) consisting of an obligation to purchase or redeem
securities or other property, if such Liabilities arises out of or in connection with the sale or issuance of the same or similar securities or property, 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

6

 

        (j)    Liabilities
with respect to letters of credit or applications or reimbursement agreements therefor, 

        (k)  Liabilities
with respect to payments received in consideration of oil, gas, or other minerals yet to be acquired or produced at the time of payment (including
obligations under "take-or-pay" contracts to deliver gas in return for payments already received and the undischarged balance of any production payment created by such Person
or for the creation of which such Person directly or indirectly received payment), 

        (l)    Liabilities
with respect to other obligations to deliver goods or services in consideration of advance payments therefor,  or

        (m)  Liabilities
under any "synthetic" or other lease of property or related documents (including a separate purchase agreement) which obligate such Person or any of its
Affiliates (whether by purchasing or causing another Person to purchase any interest in the leased property or otherwise) to guarantee a minimum residual value of the leased property to the lessor. 

For
purposes of this definition, the amount of Liabilities described in the last clause of the preceding sentence with respect to any lease classified according to GAAP as an "operating lease," shall
equal the sum of (1) the present value of rentals and other minimum lease payments required in connection with such lease (calculated in accordance with SFAS 13 and other GAAP relevant
to the determination of whether such lease must be accounted for as an operating lease or capital lease), plus (2) the fair value of the property covered by the lease; provided, however, that
such amount shall not exceed the price, as of the date a determination of Indebtedness is required hereunder, for which the lessee can purchase the leased property pursuant to any valid ongoing
purchase option if, upon such a purchase, the lessee shall be excused from paying rentals or other minimum lease payments that would otherwise accrue after the purchase. 

        Notwithstanding
the foregoing, the "Indebtedness" of any Person shall not include Liabilities that were incurred by such Person on ordinary trade terms to vendors, suppliers, or other
Persons providing goods and services for use by such Person in the ordinary course of its business, unless and until such Liabilities are outstanding more than 90 days past the original invoice
or billing date therefor. 

        "Initial Financial Statements" means the audited annual Consolidated financial statements of Borrower dated as of December 31,
2001. 

        "Insurance Schedule" means Schedule 3 attached hereto. 

        "Interest Payment Date" means (a) with respect to each Base Rate Loan, the last Business Day of each calendar month, and
(b) with respect to each Eurodollar Loan, the last day of the Interest Period that is applicable thereto and, if such Interest Period is six months in length, the date specified by Agent which
is approximately three months after such Interest Period begins; provided that the last Business Day of each calendar month shall also be an Interest Payment Date for each such Loan so long as any
Event of Default exists under Section 8.1 (a) or (b). 

        "Internal Revenue Code" means the United States Internal Revenue Code of 1986, as amended from time to time and any successor statute or
statutes, together with all rules and regulations promulgated with respect thereto. 

        "Interest Period" means, with respect to each particular Eurodollar Loan in a Borrowing, the period specified in the Borrowing Notice or
Continuation/Conversion Notice applicable thereto, beginning on and including the date specified in such Borrowing Notice or Continuation/Conversion Notice (which must be a Business Day), and ending
one, three, or six months thereafter, as Borrower may elect in such notice; provided that: (m) any Interest Period which would otherwise end on a day which is not a Business Day shall be
extended to the next succeeding Business Day unless such Business Day falls in another calendar month, in which case such Interest Period shall end on the next preceding Business 

7

 

Day; (n) any Interest Period which begins on the last Business Day in a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such
Interest Period) shall end on the last Business Day in a calendar month; and (o) notwithstanding the foregoing, any Interest Period which would otherwise end after the Maturity Date shall end
on the Maturity Date (or, if the Maturity Date is not a Business Day, on the next preceding Business Day). 

        "Investment" means any investment, made directly or indirectly, in any Person or any property, whether by purchase, acquisition of shares
of capital stock, indebtedness or other obligations or securities or by
loan, advance, capital contribution or otherwise and whether made in cash, by the transfer of property, or by any other means. 

        "Law" means any statute, law, regulation, ordinance, rule, treaty, judgment, order, decree, permit, concession, franchise, license,
agreement or other governmental restriction of the United States or any state or political subdivision thereof or of any foreign country or any department, province or other political subdivision
thereof. Any reference to a Law includes any amendment or modification to such Law, and all regulations, rulings, and other Laws promulgated under such Law. 

        "Lender" means each signatory hereto (other than Borrower and any Restricted Person that is a party hereto), including BNP Paribas in its
capacity as a Lender hereunder rather than as Agent, and the successors of each such party as holder of a Note. 

        "Lender Parties" means Agent and all Lenders. 

        "Lenders Schedule" means Schedule 4 hereto. 

        "Liabilities" means, as to any Person, all indebtedness, liabilities and obligations of such Person, whether matured or unmatured,
liquidated or unliquidated, primary or secondary, direct or indirect, absolute, fixed or contingent, and whether or not required to be considered pursuant to GAAP. 

        "LIBOR" means, for any Eurodollar Loan within a Borrowing and with respect to the related Interest Period therefor, the rate determined by
Agent to be the average rate of interest per annum (rounded upwards, if necessary, to the next 1/16 of 1%) of the rates at which deposits of dollars are offered or available to Agent in
the London interbank market at approximately 11:00 a.m. (London time) on the second Business Day preceding the first day of such period. Agent shall consider deposits, for purposes of making
the determination described in the preceding sentence, that are offered: (i) for delivery on the first day of such Interest Period, as the case may be, (ii) in an amount equal or
comparable to the total in the appropriate amount of the Eurodollar Loan, and (iii) for a time equal or comparable to the length of such Interest Period. If Agent so chooses, it may determine
LIBOR for any Interest Period by reference to the rate reported by the British Banker's Association on Page 3750 of the Telerate Service at approximately 11:00 a.m. (London time) on the second
Business Day preceding the first day of such Interest Period. All determinations of LIBOR by Agent shall, in the absence of clear and demonstrable error, be binding and conclusive upon Borrower. 

        "Lien" means, with respect to any property or assets, any right or interest therein of a creditor to secure Liabilities owed to it or any
other arrangement with such creditor which provides for the payment of such Liabilities out of such property or assets or which allows such creditor to have such Liabilities satisfied out of such
property or assets prior to the general creditors of any owner thereof, including any lien, mortgage, security interest, pledge, deposit, production payment, rights of a vendor
under any title retention or conditional sale agreement or lease substantially equivalent thereto, tax lien, mechanic's or materialman's lien, or any other charge or encumbrance for security purposes,
whether arising by Law or agreement or otherwise, but excluding any right of offset which arises without agreement in the ordinary course of business. "Lien" also means any filed financing statement,
any registration of a pledge (such as with an issuer of uncertificated securities), or any other arrangement or action which would serve to perfect a Lien described in the preceding sentence, 

8

 

regardless of whether such financing statement is filed, such registration is made, or such arrangement or action is undertaken before or after such Lien exists. 

        "Loan Documents" means this Agreement, the Notes, the Security Documents, and all other agreements, certificates, documents, instruments
and writings at any time delivered in connection herewith or therewith (exclusive of term sheets and commitment letters) but specifically excluding all Hedging Contracts to which any Restricted Person
and any Lender or Affiliate of any Lender are parties. 

        "Loans" has the meaning given to such term in Section 2.1. 

        "Majority Lenders" means Lenders whose aggregate Percentage Shares equal or exceed sixty-six and two-thirds
percent (662/3%). 

        "Material Adverse Change" means a material and adverse change, from the state of affairs presented in the Initial Financial Statements or
as represented or warranted in any Loan Document, to (a) Borrower's Consolidated financial condition, (b) Borrower's Consolidated operations, properties or prospects, considered as a
whole, (c) Borrower's ability to timely pay the Obligations, or (d) the enforceability of the material terms of any Loan Documents. 

        "Material Properties" has the meaning given to such term in Section 5.2. 

        "Maturity Date" means March 21, 2005. 

        "Maximum Credit Amount" means the amount of $40,000,000. 

        "Moody's" means Moody's Investors Service, Inc., or its successor. 

        "Multiemployer Plan" means a multiemployer plan as defined in Section 3(37) of ERISA to which contributions have been made by
Borrower or any ERISA Affiliate during the preceding six years and which is covered by Title IV of ERISA. 

        "Note" has the meaning given to such term in Section 2.1. 

        "Obligations" means all Liabilities from time to time owing by any Restricted Person to any Lender Party under or pursuant to any of the
Loan Documents. "Obligation" means any part of the Obligations. 

        "Operative Documents" has the meaning given in that certain Common Definitions and Provisions Agreement of even date herewith between
Borrower and BNP Paribas Leasing Corporation, as from time to time amended, modified or restated. 

        "Percentage Share" means, with respect to any Lender (a) when used in Section 2.1, 2.2 or 2.5, in any Borrowing Notice or
when no Loans are outstanding hereunder, the percentage set forth below such Lender's name on Lenders Schedule, and (b) when used otherwise, the percentage obtained by dividing (i) the
sum of the unpaid principal balance of such Lender's Loans at the time in question, by (ii) the sum of the aggregate unpaid principal balance of all Loans at such time. 

        "Permitted Acquisitions" means (a) the acquisition of all of the capital stock or other equity interest in a Person or
(b) any acquisition of all or a substantial portion of the business, assets or operations of a Person, provided that (i) prior to and after giving effect to such acquisition no Default
or Event of Default shall have occurred and be continuing, (ii) [***]*, and (iv) any business entity being acquired must be
substantially in the same line of business as the Restricted Persons. 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

9

 

        "Permitted Investments" means (a) Cash Equivalents, (b) property used in the ordinary course of business of the Restricted
Persons, (c) current assets arising from the sale or lease of goods and services in the ordinary course of business by the Restricted Persons or from sales permitted under Section 7.5,
(d) Investments by Borrower in any of its wholly owned Subsidiaries which is a Guarantor,
(e) marketable obligations issued or unconditionally guaranteed by the United States of America or an instrumentality or agency thereof and entitled to the full faith and credit of the United
States of America, (f) commercial paper issued by a corporation (other than an Affiliate of Borrower) organized and in existence under the laws of the United States of America or any State
thereof or the District of Columbia and, at the time of purchase by any Restricted Person, given a rating of at least [***]*, (g) bonds
issued by a corporation (other than an Affiliate of Borrower) organized and in existence under the laws of the United States of America or any State thereof or the District of Columbia and, at the
time of purchase by any Restricted Person, given a rating of at least [***]*, (h) Permitted Acquisitions, and (i) equity investments
in any corporation (other than Affiliates of Borrower) organized and in existence under the laws of the United States, or any State thereof or the District of Columbia, so long as (1) the
primary line of business of such corporation is either medical diagnostics or biomedical research, (2) the Restricted Persons do not [***]*
of such corporation, and (3) the aggregate amount of all [***]* made by Restricted Persons in any calendar year does not exceed
[***]*. 

        "Permitted Liens" means: 

        (a)  statutory
Liens for taxes, assessments or other governmental charges or levies which are not yet delinquent or which are being contested in good faith by appropriate
action and for which adequate reserves have been maintained in accordance with GAAP; 

        (b)  landlords',
operators', carriers', warehousemen's, repairmen's, mechanics', materialmen's, or other like Liens which do not secure Indebtedness, in each case only to the
extent arising in the ordinary course of business and only to the extent securing obligations which are not delinquent or which are being contested in good faith by appropriate proceedings and for
which adequate reserves have been maintained in accordance with GAAP; 

        (c)  minor
defects and irregularities in title to any property, so long as such defects and irregularities neither secure Indebtedness nor materially impair the value of such
property or the use of such property for the purposes for which such property is held; 

        (d)  deposits
of cash or securities to secure the performance of bids, trade contracts, leases, statutory obligations and other obligations of a like nature (excluding appeal
bonds) incurred in the ordinary course of business; 

        (e)  Liens
under the Security Documents; 

        (f)    Liens
securing Indebtedness owed by Borrower pursuant to the Operative Documents; and 

        (g)  Liens
securing Indebtedness incurred for the purpose of purchasing or acquiring equipment, so long as the aggregate outstanding amount of such Indebtedness at any time
does not exceed [***]* and such Indebtedness is secured only by the equipment so purchased or acquired. 

        "Person" means an individual, a corporation, a partnership, an unincorporated organization, an association, a joint stock company, a joint
venture, a trust, an estate, a government or agency or political subdivision thereof or other entity, whether acting in an individual, fiduciary or other capacity. 

        "Plan" means any employee benefit plan within the meaning of Section 3(3) of ERISA and to which contributions have been made, by
Borrower or any ERISA Affiliate of Borrower during the preceding six years and which is covered by Title IV of ERISA, other than a Multiemployer Plan. 

        "Pricing Senior Leverage Ratio" means, as of the last day of any Fiscal Quarter, the ratio of (a) the remainder of
[***]* (all capitalized terms contained in this definition having the meanings set forth in Exhibit H). 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

10

 

        "Prime Rate" means the prime interest rate or equivalent charged by Agent in the United States of America as most recently announced or
published by Agent from time to time, which need not be the lowest interest rate charged by Agent. If for any reason Agent does not announce or publish a prime rate or equivalent, the prime rate or
equivalent announced or published by either CitiBank, N.A. or any New York branch or office of Credit Commercial de France as selected by Agent shall be used to compute the rate describe in the
preceding sentence. The prime rate or equivalent announced or published by such bank need not be the lowest rate charged by it. The Prime Rate may change from time to time without notice to Borrower
as of the effective time of each change in rates described in this definition. 

        "Rating Agency" means either S & P or Moody's. 

        "Regulation D" means Regulation D of the Board of Governors of the Federal Reserve System as from time to time in effect. 

        "Reserve Requirement" means, at any time, the maximum rate at which reserves (including any marginal, special, supplemental, or emergency
reserves) are required to be maintained under regulations issued from time to time by the Board of Governors of the Federal Reserve System (or any successor) by member banks of the Federal Reserve
System against "Eurocurrency liabilities" (as such term is used in Regulation D). Without limiting the effect of the foregoing, the Reserve Requirement shall reflect any other reserves required
to be maintained by such member banks with respect to (a) any category of liabilities which includes deposits by reference to which the Adjusted LIBOR Rate is to be determined, or
(b) any category of extensions of credit or other assets which include Eurodollar Loans. 

        "Restricted Person" means any of Borrower, each Guarantor and each Substantial Subsidiary of Borrower. 

        "S & P" means Standard & Poor's Ratings Services (a division of The McGraw Hill Companies), or its successor. 

        "Security Documents" means the instruments listed in the Security Schedule and all other security agreements, deeds of trust, mortgages,
chattel mortgages, pledges, guaranties, financing statements, continuation statements, extension agreements and other agreements or instruments now, heretofore, or hereafter delivered by any
Restricted Person to Agent in connection with this Agreement or any transaction contemplated hereby to secure or guarantee the payment of any part of the Obligations or the performance of any
Restricted Person's other duties and obligations under the Loan Documents. 

        "Security Schedule" means Schedule 2 hereto. 

        "Subsidiary" means, with respect to any Person, any Affiliate of which at least a majority of the securities or other ownership interests
having ordinary voting power then exercisable for the election of directors or other persons performing similar functions are at the time owned directly or indirectly by such Person. 

        "Substantial Subsidiary" means a Subsidiary which is not an Inactive Subsidiary. 

        "Tribunal" means any government, any arbitration panel, any court or any governmental department, commission, board, bureau, agency or
instrumentality of the United States of America or any state, province, commonwealth, nation, territory, possession, county, parish, town, township, village or municipality, whether now or hereafter
constituted or existing. 

        "Type" means, with respect to any Loans, the characterization of such Loans as either Base Rate Loans or Eurodollar Loans. 

        "Unrestricted Cash" means all cash and Cash Equivalents, other than cash or Cash Equivalents subject to any Lien (including a Lien granted
pursuant to the Cash Collateral Agreement). 

        Section 1.2.    Exhibits and Schedules; Additional Definitions.    All Exhibits and Schedules attached to this
Agreement are a part hereof for all purposes. Reference is hereby made to the Security Schedule and Exhibit H for the meaning of certain terms defined therein and used but not defined herein,
which definitions are incorporated herein by reference. 

11

  

        Section 1.3.    Amendment of Defined Instruments.    Unless the context otherwise requires or unless otherwise
provided herein the terms defined in this Agreement which refer to a particular agreement, instrument or document also refer to and include all renewals, extensions, modifications, amendments and
restatements of such agreement, instrument or document, provided that nothing contained in this section shall be construed to authorize any such renewal, extension, modification, amendment or
restatement. 

        Section 1.4.    References and Titles.    Words of any gender used in each Loan Document shall be held and
construed to include any other gender, and words in the singular number shall be held to include the plural and vice versa, unless the context otherwise requires. References in any Loan Document to
Exhibits, Schedules, Articles, Sections, subsections or other subdivisions shall refer to the corresponding Exhibits, Schedules, Articles, Sections, subsections or subdivisions of that Loan Document,
unless specific reference is made to another document or instrument. Exhibits and Schedules to any Loan Document shall be deemed incorporated by reference to such Loan Document. All capitalized terms
used in each Loan Document which refer to other documents shall be deemed to refer to such other documents as they may be renewed, extended, supplemented, amended or otherwise modified from time to
time, provided such documents are not renewed, extended or modified in breach of any provision contained in the Loan Documents or, in the case of any other document to which Agent or any Lender is a
party or of which Agent or any Lender is an intended beneficiary, without the consent of Agent and, to the extent required herein, Lenders. All accounting terms used but not specifically defined in
any Loan Document shall be construed in accordance with GAAP. The words "this Agreement", "herein", "hereof", "hereby", "hereunder" and words of similar import when used in each Loan Document refer to
that Loan Document as a whole and not to any particular subdivision unless expressly so limited. The phrases "this Paragraph", "this subparagraph", "this Section", "this subsection" and similar
phrases used in any operative document refer only to the Paragraph, subparagraph, Section, subsection or other subdivision described in which the phrase occurs. As used in the Loan Documents the word
"or" is not exclusive. As used in the Loan Documents, the words "include", "including" and similar terms shall be construed as if followed by "without limitation to". Unless otherwise specified,
references herein to any particular Person also refers to its successors and permitted assigns. 

        Section 1.5.    Calculations and Determinations.    All calculations under the Loan Documents of interest
chargeable with respect to the Loans and of fees shall be made on the basis of actual days elapsed (including the first day but excluding the last) and a year of 360 days. Each determination by
a Lender Party of amounts to be paid under Article III or any other matters which are to be determined hereunder by a Lender Party (such as any LIBOR Rate, Adjusted LIBOR Rate, Business Day,
Interest Period, or Reserve Requirement) shall, in the absence of manifest error, be conclusive and binding. Unless otherwise expressly provided herein or unless Majority Lenders otherwise consent all
financial statements and reports furnished to any Lender Party hereunder shall be prepared and all financial computations and determinations pursuant hereto shall be made in accordance with GAAP. 

        Section 1.6.    Joint Preparation; Construction of Indemnities and Releases.    This Agreement and the other
Loan Documents have been reviewed and negotiated by sophisticated parties with access to legal counsel and no rule of construction shall apply hereto or thereto which would require or allow any Loan
Document to be construed against any party because of its role in drafting such Loan Document. All indemnification and release provisions of this Agreement shall be construed broadly (and not
narrowly) in favor of the Persons receiving indemnification or being released. 

 
 

ARTICLE II—The Loans    
  

        Section 2.1. Commitments to Lend; Notes. Subject to the terms and conditions hereof, each Lender agrees to
make loans to Borrower (herein called such Lender's "Loans") upon Borrower's request from time to time prior to the Maturity Date, provided that after giving effect to such Loans, the aggregate 

12

 

outstanding amount of Loans does not exceed the Borrowing Base determined as of the date on which the requested Loans are to be made. The aggregate amount of all Loans in any Borrowing must be
greater than or equal to $1,000,000 or must equal the remaining availability under the Borrowing Base. The obligation of Borrower to repay to each Lender the aggregate amount of all Loans made by such
Lender, together with interest accruing in connection therewith, shall be evidenced by a single promissory note (herein called such Lender's "Note") made by Borrower payable to the order of such
Lender in the form of Exhibit A with appropriate insertions. The amount of principal owing on any Lender's Note at any given time shall be the aggregate amount of all Loans theretofore made by
such Lender minus all payments of principal theretofore received by such Lender on such Note. Interest on each Note shall accrue and be due and payable as provided herein and therein. Each Note shall
be due and payable as provided herein and therein, and shall be due and payable in full on the Maturity Date. Subject to the terms and conditions hereof, Borrower may borrow, repay, and reborrow
hereunder. 

        Section 2.2.    Requests for New Loans.    Borrower must give to Agent written notice (or telephonic notice
promptly confirmed in writing) of any requested Borrowing of new Loans to be advanced by Lenders. Each such notice constitutes a "Borrowing Notice" hereunder and must: 

        (a) specify
(i) the aggregate amount of any such Borrowing of new Base Rate Loans and the date on which such Base Rate Loans are to be advanced, or (ii) the
aggregate amount of any such Borrowing of new Eurodollar Loans, the date on which such Eurodollar Loans are to be advanced (which shall be the first day of the Interest Period which is to apply
thereto), and the length of the applicable Interest Period; and 

        (b) be
received by Agent not later than 10:00 a.m., New York, New York time, on (i) the day on which any such Base Rate Loans are to be made, or (ii) the third
Business Day preceding the day on which any such Eurodollar Loans are to be made. 

Each
such written request or confirmation must be made in the form and substance of the "Borrowing Notice" attached hereto as Exhibit B, duly completed. Each such telephonic request shall be
deemed a representation, warranty, acknowledgment and agreement by Borrower as to the matters which are required to be set out in such written confirmation. Upon receipt of any such Borrowing Notice,
Agent shall give each Lender prompt notice of the terms thereof. If all conditions precedent to such new Loans have been met, each Lender will on the date requested promptly remit to Agent at Agent's
office in New York, New York the amount of such Lender's new Loan in immediately available funds, and upon receipt of such funds, unless to its actual knowledge any conditions precedent to such Loans
have been neither met nor waived as provided herein, Agent shall promptly make such Loans available to Borrower. Unless Agent shall have received prompt notice from a Lender that such Lender will not
make available to Agent such Lender's new Loan, Agent may in its discretion assume that such Lender has made such Loan available to Agent in accordance with this section and Agent may if it chooses,
in reliance upon such assumption, make such Loan available to Borrower. If and to the extent such Lender shall not so make its new Loan available to Agent, such Lender and Borrower severally agree to
pay or repay to Agent within three days after demand the amount of such Loan together with interest thereon, for each day from the date such amount was made available to Borrower until the date such
amount is paid or repaid to Agent, with interest at (i) the Federal Funds Rate, if such Lender is making such payment and (ii) the interest rate applicable at the time to the other new
Loans made on such date, if Borrower is making such repayment. If neither such Lender nor Borrower pays or repays to Agent such amount within such three-day period, Agent shall in addition
to such amount be entitled to recover from such Lender and from Borrower, on demand, interest thereon at the Default Rate applicable to Base Rate Loans, calculated from the date such amount was made
available to Borrower. The failure of any Lender to make any new Loan to be made by it hereunder shall not relieve any other Lender of its obligation hereunder, if any, to make its new Loan, but no
Lender shall be responsible for the failure of any other Lender to make any new Loan to be made by such other Lender. 

13

 

        Section 2.3.    Continuations and Conversions of Existing Loans.    Borrower may make the following elections
with respect to Loans already outstanding: to convert Base Rate Loans to Eurodollar Loans, to convert Eurodollar Loans to Base Rate Loans on the last day of the Interest Period applicable thereto, and
to continue Eurodollar Loans beyond the expiration of such Interest Period by designating a new Interest Period to take effect at the time of such expiration. In making such elections, Borrower may
combine existing Loans made pursuant to separate Borrowings into one new Borrowing or divide existing Loans made pursuant to one Borrowing into separate new Borrowings, provided that Borrower may have
no more than three Borrowings of Eurodollar Loans outstanding at any time. To make any such election, Borrower must give to Agent written notice (or telephonic notice promptly confirmed in writing) of
any such Conversion or Continuation of existing Loans, with a separate notice given for each new Borrowing. Each such notice constitutes a "Continuation/Conversion Notice" hereunder and must: 

        (a) specify
the existing Loans which are to be Continued or Converted; 

        (b) specify
(i) the aggregate amount of any Borrowing of Base Rate Loans into which such existing Loans are to be continued or converted and the date on which such
Continuation or Conversion is to occur, or (ii) the aggregate amount of any Borrowing of Eurodollar Loans into which such existing Loans are to be continued or converted, the date on which such
Continuation or Conversion is to occur (which shall be the first day of the Interest Period which is to apply to such Eurodollar Loans), and the length of the applicable Interest Period; and 

        (c) be
received by Agent not later than 10:00 a.m., New York, New York time, on (i) the day on which any such Continuation or Conversion to Base Rate Loans is to occur, or
(ii) the third Business Day preceding the day on which any such Continuation or Conversion to Eurodollar Loans is to occur. 

Each
such written request or confirmation must be made in the form and substance of the "Continuation/Conversion Notice" attached hereto as Exhibit C, duly completed. Each such telephonic
request shall be deemed a representation, warranty, acknowledgment and agreement by Borrower as to the matters which are required to be set out in such written confirmation. Upon receipt of any such
Continuation/Conversion Notice, Agent shall give each Lender prompt notice of the terms thereof. Each Continuation/Conversion Notice shall be irrevocable and binding on Borrower. During the
continuance of any Default, Borrower may not make any election to convert existing Loans into Eurodollar Loans or continue existing Loans as Eurodollar Loans. If (due to the existence of a Default or
for any other reason) Borrower fails to timely and properly give any Continuation/Conversion Notice with respect to a Borrowing of existing Eurodollar Loans at least three days prior to the end of the
Interest Period applicable thereto, such Eurodollar Loans shall automatically be converted into Base Rate Loans at the end of such Interest Period. No new funds shall be repaid by Borrower or advanced
by any Lender in connection with any Continuation or Conversion of existing Loans pursuant to this section, and no such Continuation or Conversion shall be deemed to be a new advance of funds for any
purpose; such Continuations and Conversions merely constitute a change in the interest rate applicable to already outstanding Loans. 

        Section 2.4.    Use of Proceeds.    Borrower shall use all Loans to finance capital expenditures, finance
acquisitions permitted pursuant to Section 7.7, and provide working capital for its operations and for other general business purposes. In no event shall the funds from any Loan be used
directly or indirectly by any Person for personal, family, household or agricultural purposes or for the purpose, whether immediate, incidental or ultimate, of purchasing, acquiring or carrying any
"margin stock" (as such term is defined in Regulation U promulgated by the Board of Governors of the Federal Reserve System) or to extend credit to others directly or indirectly for the purpose
of purchasing or carrying any such margin stock. Borrower represents and warrants that Borrower is not engaged principally, or as one of Borrower's important activities, in the business of extending
credit to others for the purpose of purchasing or carrying such margin stock. 

14

 

        Section 2.5.    Interest Rates and Fees.    

        (a) Interest Rates. As provided in the Notes: (i) each Base Rate Loan shall bear interest on each day outstanding at the
Adjusted Base Rate in effect on such day, (ii) each Eurodollar Loan shall bear interest on each day during the related Interest Period at the related Adjusted Eurodollar Rate in effect on such
day, and (iii) if an Event of Default has occurred and is continuing, all Loans shall bear interest on each day outstanding at the applicable Default Rate. Past due payments of principal and
interest shall bear interest at the rates and in the manner set forth in the Notes. 

        (b) Commitment Fees. In consideration of each Lender's commitment to make Loans, Borrower will pay to Agent for the account of each
Lender a commitment fee determined on a daily basis by applying a rate of [***]* to such Lender's Percentage Share of the unused portion of the
Maximum Credit Amount on each day prior to the Maturity Date, determined for each such day by deducting from the amount of the Maximum Credit Amount at the end of such day the outstanding principal
amount of the Loans. This commitment fee shall be due and payable in arrears on the last day of each Fiscal Quarter and on the Maturity Date. Notwithstanding the foregoing, if during any Fiscal
Quarter, any Lender (a "Defaulting Lender") fails to make available a Loan, has not cured such failure and no Default or Event of Default was continuing on the date of such failure, Borrower shall
have no obligation to pay the Defaulting Lender its commitment fee for such Fiscal Quarter until such time as the Defaulting Lender makes available such Loan. 

        (c) Fees. In addition to all other amounts due to Agent under the Loan Documents, Borrower will pay to Agent the fees described in
a letter agreement of even date herewith between Agent and Borrower. 

        Section 2.6.    Mandatory Prepayments.     

        (a)  If
at any time the aggregate outstanding amount of the Loans exceeds the Borrowing Base, Borrower shall immediately upon demand prepay the principal of the Loans in an
amount at least equal to such excess. 

        (b) Borrower
understands and agrees that for a period of not less than fourteen (14) consecutive days during each Fiscal Year, Borrower shall have repaid the aggregate
outstanding amount of the Loans, together with all accrued but unpaid interest thereon. 

        (c)  Borrower
shall immediately prepay the principal of the Loans in an amount equal to the proceeds (net of expenses) from either of the following: 

          (i)  additional
equity issuances of Borrower; and 

        (ii)  any
sale, transfer, assignment or other disposition of any property, rights, assets or business of any Restricted Person (but without waiving the requirements of
Majority Lenders' consent to any sale, transfer, assignment or other disposition in violation of any Loan Document), except proceeds of any sale, transfer, assignment or other disposition of property
which is permitted by Section 7.5 (a) or Section 7.5(b). 

        (d)  Each
prepayment of principal under this section shall be accompanied by all interest then accrued and unpaid on the principal so prepaid. Any principal or interest
prepaid pursuant to this section shall be in addition to, and not in lieu of, all payments otherwise required to be paid under the Loan Documents at the time of such prepayment. 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

15

 

        Section 2.7.    Optional Prepayments.    Borrower may, upon five Business Days' notice to each Lender, from
time to time and without premium or penalty prepay the Notes, in whole or in part, so long as the aggregate amounts of all partial prepayments of principal on the Notes equals $1,000,000 or any higher
integral multiple of $1,000,000, so long as Borrower does not prepay any Eurodollar Loan, and so long as Borrower does not make any prepayments which would reduce the unpaid principal balance of any
Loan to less than $100,000 without first either (a terminating this Agreement or (b) providing assurance satisfactory to Agent in its discretion that Lenders' legal rights under the Loan
Documents are in no way affected by such reduction; provided that Borrower may prepay any Eurodollar Loan so long as such prepayment shall be accompanied by all reimbursement amounts payable pursuant
to Section 3.5. Each prepayment of principal under this section shall be accompanied by all interest then accrued and unpaid on the principal so prepaid. Any principal or interest prepaid
pursuant to this section shall be in addition to, and not in lieu of, all payments otherwise required to be paid under the Loan Documents at the time of such prepayment. 

 
 

ARTICLE III—Payments to Lenders    
  

        Section 3.1.    General Procedures.    Borrower will make each payment which it owes under the Loan Documents
to Agent for the account of the Lender Party to whom such payment is owed, in lawful money of the United States of America, without set-off, deduction or counterclaim, and in immediately
available funds. Each such payment must be received by Agent not later than 11:00 a.m., New York,
New York time, on the date such payment becomes due and payable. Any payment received by Agent after such time will be deemed to have been made on the next following Business Day. Should any such
payment become due and payable on a day other than a Business Day, the maturity of such payment shall be extended to the next succeeding Business Day, and, in the case of a payment of principal or
past due interest, interest shall accrue and be payable thereon for the period of such extension as provided in the Loan Document under which such payment is due. Each payment under a Loan Document
shall be due and payable at the place provided therein and, if no specific place of payment is provided, shall be due and payable at the place of payment of Agent's Note. When Agent collects or
receives money on account of the Obligations, Agent shall distribute all money so collected or received, and each Lender Party shall apply all such money so distributed, as follows: 

        (a) first,
for the payment of all Obligations which are then due (and if such money is insufficient to pay all such Obligations, first to any reimbursements due Agent under
Section 6.9 or 10.4 and then to the partial payment of all other Obligations then due in proportion to the amounts thereof, or as Lender Parties shall otherwise agree); 

        (b) then
for the prepayment of amounts owing under the Loan Documents (other than principal on the Notes) if so specified by Borrower; 

        (c) then
for the prepayment of principal on the Notes, together with accrued and unpaid interest on the principal so prepaid; and 

        (d) last,
for the payment or prepayment of any other Obligations. 

All
payments applied to principal or interest on any Note shall be applied first to any interest then due and payable, then to principal then due and payable, and last to any prepayment of principal
and interest in compliance with Sections 2.6 and 2.7. All distributions of amounts described in any of subsections (b), (c) or (d) above shall be made by Agent pro rata to each Lender
Party then owed Obligations described in such subsection in proportion to all amounts owed to all Lender Parties which are described in such subsection provided that if any Lender then owes payments
to Agent under Section 9.9, any amounts otherwise distributable under this section to such Lender shall be deemed to belong to Agent, to the extent of such unpaid payments, and Agent shall
apply such amounts to make such unpaid payments rather than distribute such amounts to such Lender. 

16

 

        Section 3.2.    Capital Reimbursement.    If either (a) the introduction or implementation of or the
compliance with or any change in or in the interpretation of any Law, or (b) the introduction or implementation of or the compliance with any request, directive or guideline from any central
bank or other governmental authority (whether or not having the force of Law) affects or would affect the amount of capital
required or expected to be maintained by any Lender Party or any corporation controlling any Lender Party, then, upon demand by such Lender Party, Borrower will pay to Agent for the benefit of such
Lender Party, from time to time as specified by such Lender Party, such additional amount or amounts which such Lender Party shall determine to be appropriate to compensate such Lender Party or any
corporation controlling such Lender Party in light of such circumstances, to the extent that such Lender Party reasonably determines that the amount of any such capital would be increased or the rate
of return on any such capital would be reduced by or in whole or in part based on the existence of the face amount of such Lender Party's Loans or commitments under this Agreement. 

        Section 3.3.    Increased Cost of Eurodollar Loans.    If any applicable Law (whether now in effect or
hereinafter enacted or promulgated, including Regulation D) or any interpretation or administration thereof by any governmental authority charged with the interpretation or administration
thereof (whether or not having the force of Law): 

        (a) shall
change the basis of taxation of payments to any Lender Party of any principal, interest, or other amounts attributable to any Eurodollar Loan or otherwise due under this
Agreement in respect of any Eurodollar Loan (other than taxes imposed on the overall net income of such Lender Party or any Applicable Lending Office of such Lender Party by any jurisdiction in which
such Lender Party or any such Applicable Lending Office is located); or 

        (b) shall
change, impose, modify, apply or deem applicable any reserve, special deposit or similar requirements in respect of any Eurodollar Loan (excluding those for which such
Lender Party is fully compensated pursuant to adjustments made in the definition of LIBOR Rate) or against assets of, deposits with or for the account of, or credit extended by, such Lender Party; or 

        (c) shall
impose on any Lender Party or the interbank eurocurrency deposit market any other condition affecting any Eurodollar Loan, the result of which is to increase the cost to
any Lender Party of funding or maintaining any Eurodollar Loan or to reduce the amount of any sum receivable by any Lender Party in respect of any Eurodollar Loan by an amount deemed by such Lender
Party to be material, 

then
such Lender Party shall promptly notify Agent and Borrower in writing of the happening of such event and of the amount required to compensate such Lender Party for such event (on an
after-tax basis, taking into account any taxes on such compensation), whereupon (i) Borrower shall pay such amount to Agent for the account of such Lender Party and
(ii) Borrower may elect, by giving to Agent and such Lender Party not less than three Business Days' notice, to convert all (but not less than all) of any such Eurodollar Loans into Base Rate
Loans. 

        Section 3.4.    Availability.    If (a) any change in applicable Laws, or in the interpretation or
administration thereof of or in any jurisdiction whatsoever, domestic or foreign, shall make it unlawful or impracticable for any Lender Party to fund or maintain Eurodollar Loans, or shall materially
restrict the authority of any Lender Party to purchase or take offshore deposits of dollars (i.e., "eurodollars"),
or (b) any Lender Party determines that matching deposits appropriate to fund or maintain any Eurodollar Loan are not available to it, or (c) any Lender Party determines that the formula
for calculating the LIBOR Rate does not fairly reflect the cost to such Lender Party of making or maintaining loans based on such rate, then, upon notice by such Lender Party to Borrower and Agent,
Borrower's right to elect Eurodollar Loans from such Lender Party shall be suspended to the extent and for the duration of such illegality, impracticability or restriction and all Eurodollar Loans of
such Lender Party which are then outstanding or are then the subject of any Borrowing Notice and which cannot lawfully or practicably be maintained or funded shall immediately become or remain, or
shall be funded as, Base Rate Loans of such Lender Party. Borrower agrees to indemnify each Lender Party and hold it harmless against all costs, expenses, claims, penalties, liabilities and damages
which may result from any such change in Law, interpretation or administration. Such indemnification shall be on an after-tax basis, taking into account any taxes imposed on the amounts
paid as indemnity. 

17

 

        Section 3.5.    Funding Losses.    In addition to its other obligations hereunder, Borrower will indemnify each
Lender Party against, and reimburse each Lender Party on demand for, any loss or expense incurred or sustained by such Lender Party (including any loss or expense incurred by reason of the liquidation
or reemployment of deposits or other funds acquired by a Lender Party to fund or maintain Eurodollar Loans), as a result of (a) any payment or prepayment (whether authorized or required
hereunder or otherwise) of all or a portion of a Eurodollar Loan on a day other than the day on which the applicable Interest Period ends, (b) any payment or prepayment, whether required
hereunder or otherwise, of a Loan made after the delivery, but before the effective date, of a Continuation/Conversion Notice, if such payment or prepayment prevents such Continuation/Conversion
Notice from becoming fully effective, (c) the failure of any Loan to be made or of any Continuation/Conversion Notice to become effective due to any condition precedent not being satisfied or
due to any other action or inaction of any Restricted Person, or (d) any Conversion (whether authorized or required hereunder or otherwise) of all or any portion of any Eurodollar Loan into a
Base Rate Loan or into a different Eurodollar Loan on a day other than the day on which the applicable Interest Period ends. Such indemnification shall be on an after-tax basis, taking
into account any taxes imposed on the amounts paid as indemnity. Notwithstanding the foregoing, Borrower shall not be obligated to pay any claim for compensation pursuant to this Section 3.5
arising or accruing more than nine (9) months prior to the date Borrower is notified of the applicable Lender Party's demand for such compensation. 

        Section 3.6.    Reimbursable Taxes.    Borrower covenants and agrees that: 

        (a) Borrower
will indemnify each Lender Party against and reimburse each Lender Party for all present and future income, stamp and other taxes, levies, costs and charges
whatsoever imposed, assessed, levied or collected on or in respect of this Agreement or any Eurodollar Loans (whether or not legally or correctly imposed, assessed, levied or collected), excluding,
however, any taxes imposed on or measured by the overall net income of Agent or such Lender Party or any Applicable Lending Office of such Lender Party by any jurisdiction in which such Lender Party
or any such Applicable Lending Office is located (all such non-excluded taxes, levies, costs and charges being collectively called
"Reimbursable Taxes" in this section). Such indemnification shall be on an after-tax basis, taking into account any taxes imposed on the amounts paid as indemnity. 

        (b) All
payments on account of the principal of, and interest on, each Lender Party's Loans and Note, and all other amounts payable by Borrower to any Lender Party hereunder,
shall be made in full without set-off or counterclaim and shall be made free and clear of and without deductions or withholdings of any nature by reason of any Reimbursable Taxes, all of
which will be for the account of Borrower. In the event of Borrower being compelled by Law to make any such deduction or withholding from any payment to any Lender Party, Borrower shall pay on the due
date of such payment, by way of additional interest, such additional amounts as are needed to cause the amount receivable by such Lender Party after such deduction or withholding to equal the amount
which would have been receivable in the absence of such deduction or withholding. If Borrower should make any deduction or withholding as aforesaid, Borrower shall within 60 days thereafter
forward to such Lender Party an official receipt or other official document evidencing payment of such deduction or withholding. 

        (c) If
Borrower is ever required to pay any Reimbursable Tax with respect to any Eurodollar Loan, Borrower may elect, by giving to Agent and such Lender Party not less than three
Business Days' notice, to convert all (but not less than all) of any such Eurodollar Loan into a Base Rate Loan, but such election shall not diminish Borrower's obligation to pay all Reimbursable
Taxes. 

        (d) Notwithstanding
the foregoing provisions of this section, Borrower shall be entitled, to the extent it is required to do so by Law, to deduct or withhold (and not to make any
indemnification or reimbursement for) income or other similar taxes imposed by the United States of America (other than 

18

 

any portion thereof attributable to a change in federal income tax Laws effected after the date hereof) from interest, fees or other amounts payable hereunder for the account of any Lender Party,
other than a Lender Party (i) who is a U.S. person for Federal income tax purposes or (ii) who has the Prescribed Forms on file with Agent (with copies provided to Borrower) for the
applicable year to the extent deduction or withholding of such taxes is not required as a result of the filing of such Prescribed Forms, provided that if Borrower shall so deduct or withhold any such
taxes, it shall provide a statement to Agent and such Lender Party, setting forth the amount of such taxes so deducted or withheld, the applicable rate and any other information or documentation which
such Lender Party may reasonably request for assisting such Lender Party to obtain any allowable credits or deductions for the taxes so deducted or withheld in the jurisdiction or jurisdictions in
which such Lender Party is subject to tax. As used in this section, "Prescribed Forms" means such duly executed forms or statements, and in such number of copies, which may, from time to time, be
prescribed by Law and which, pursuant to applicable provisions of (x) an income tax treaty between the United States and the country of residence of the Lender Party providing the forms or
statements, (y) the Internal Revenue Code, or (z) any applicable rules or regulations thereunder, permit Borrower to make payments hereunder for the account of such Lender Party free of
such deduction or withholding of income or similar taxes. 

        Section 3.7.    Change of Applicable Lending Office.    Each Lender Party agrees that, upon the occurrence of
any event giving rise to the operation of Sections 3.2 through 3.6 with respect to such Lender Party, it will, if requested by Borrower, use reasonable efforts (subject to overall policy
considerations of such Lender Party) to designate another Applicable Lending Office, provided that such designation is made on such terms that such Lender Party and its Applicable Lending Office
suffer no economic, legal or regulatory disadvantage, with the object of avoiding the consequence of the event giving rise to the operation of any such section. Nothing in this section shall affect or
postpone any of the obligations of Borrower or the rights of any Lender Party provided in Sections 3.2 through 3.6. 

        Section 3.8.    Replacement of Lenders.    If any Lender Party seeks reimbursement for increased costs under
Sections 3.2 through 3.6, then within ninety days thereafter—provided no Event of Default then exists—Borrower shall have the right (unless such Lender Party withdraws its
request for additional compensation) to replace such Lender Party by requiring such Lender Party to assign its Loans and Notes and its commitments hereunder to an Eligible Transferee reasonably
acceptable to Agent and to Borrower, provided that: (a) all Obligations of Borrower owing to such Lender Party being replaced (including such increased costs, but excluding principal and
accrued interest on the Notes being assigned) shall be paid in full to such Lender Party concurrently with such assignment, and (b) the replacement Eligible Transferee shall purchase the Note
being assigned by paying to such Lender Party a price equal to the principal amount thereof plus accrued and unpaid interest thereon. In connection with any such assignment Borrower, Agent, such
Lender Party and the replacement Eligible Transferee shall otherwise comply with Section 10.5. Notwithstanding the foregoing rights of Borrower under this section, however, Borrower may not
replace any Lender Party which seeks reimbursement for increased costs under Section 3.2 through 3.6 unless Borrower is at the same time replacing all Lender Parties which are then seeking such
compensation. 

 
 

ARTICLE IV—Conditions Precedent to Lending    
  

        Section 4.1.    Documents to be Delivered.    No Lender has any obligation to make its first Loan, unless Agent
shall have received all of the following, at Agent's office in New York, New York, duly executed and delivered and in form, substance and date satisfactory to Agent: 

        (a) This
Agreement and any other documents that Lenders are to execute in connection herewith. 

        (b) Each
Note. 

19

 

        (c) Each
Security Document listed in the Security Schedule. 

        (d) Certain
certificates of Borrower including: 

      (i) An
"Omnibus Certificate" of the Secretary and of the Chairman of the Board or President of Borrower, which shall contain the names and signatures of the officers of Borrower
authorized to execute Loan Documents and which shall certify to the truth, correctness and completeness of the following exhibits attached thereto: (1) a copy of resolutions duly adopted by the
Board of Directors of Borrower and in full force and effect at the time this Agreement is entered into, authorizing the execution of this Agreement and the other Loan Documents delivered or to be
delivered in connection herewith and the consummation of the transactions contemplated herein and therein, (2) a copy of the charter documents of Borrower and all amendments thereto, certified
by the appropriate official of Borrower's state of organization, and (3) a copy of any bylaws of Borrower; and 

      (ii) A
"Compliance Certificate" of the Chairman of the Board or President and of the chief financial officer of Borrower, of even date with such Loan, in which such officers
certify to the satisfaction of the conditions set out in subsections (a), (b), (c) and (d) of Section 4.2. 

        (e) Certificate
(or certificates) of the due formation, valid existence and good standing of Borrower in its state of organization, issued by the appropriate authorities of such
jurisdiction, and certificates of Borrower's good standing and due qualification to do business, issued by appropriate officials in any states in which Borrower owns property subject to Security
Documents. 

        (f) Documents
similar to those specified in subsections (d)(i) and (e) of this section with respect to each Guarantor and the execution by it of its guaranty of
Borrower's Obligations. 

        (g) A
favorable opinion of Brobeck, Phleger & Harrison LLP, counsel for Restricted Persons, substantially in the form set forth in Exhibit E. 

        (h) The
Initial Financial Statements. 

        (i) Certificates
or binders evidencing Restricted Persons' insurance in effect on the date hereof. 

        (j) True,
correct and complete executed copies of the Operative Documents. 

        (k) Payment
of all commitment, facility, agency and other fees required to be paid to any Lender pursuant to any Loan Documents or any commitment agreement heretofore entered
into. 

        Section 4.2.    Additional Conditions Precedent.    No Lender has any obligation to make any Loan (including
its first), unless the following conditions precedent have been satisfied: 

        (a) All
representations and warranties made by any Restricted Person in any Loan Document shall be true on and as of the date of such Loan (except to the extent that the facts
upon which such representations are based have been changed by the extension of credit hereunder) as if such representations and warranties had been made as of the date of such Loan. 

        (b) No
Default shall exist at the date of such Loan. 

        (c) No
Material Adverse Change shall have occurred since the date of the audited annual Initial Financial Statements. 

        (d) Each
Restricted Person shall have performed and complied with all agreements and conditions required in the Loan Documents to be performed or complied with by it on or prior
to the date of such Loan. 

        (e) The
making of such Loan not be prohibited by any Law and shall not subject any Lender to any penalty or other onerous condition under or pursuant to any such Law. 

20

 

        (f) Agent
shall have received all documents and instruments which Agent has then requested, in addition to those described in Section 4.1 (including opinions of legal
counsel for Restricted Persons and Agent; corporate documents and records; documents evidencing governmental authorizations, consents, approvals, licenses and exemptions; and certificates of public
officials and of officers and representatives of Borrower and other Persons), as to (i) the accuracy and validity of or compliance with all representations, warranties and covenants made by any
Restricted Person in this Agreement and the other Loan Documents, (ii) the satisfaction of all conditions contained herein or therein, and (iii) all other matters pertaining hereto and
thereto. All such additional documents and instruments shall be satisfactory to Agent in form, substance and date. 

        (g)  Prior
to the making of the first Loan, Agent shall have completed its review of such financial statements, contracts, operating plans, compliance with applicable
regulations, projected financial performance, accounting and operating procedures and systems, cash collection systems, reimbursement systems and other information systems of the Restricted Persons as
Agent may require. 

 
 

ARTICLE V—Representations and Warranties    
  

        To confirm each Lender's understanding concerning Restricted Persons and Restricted Persons' businesses, properties and obligations and to induce each Lender to
enter into this Agreement and to extend credit hereunder, Borrower represents and warrants to each Lender that: 

        Section 5.1.    No Default.    No event has occurred and is continuing which constitutes a Default. 

        Section 5.2.    Organization and Good Standing.    Each Restricted Person is duly organized, validly existing
and in good standing under the Laws of its jurisdiction of organization, having all powers required to carry on its business and enter into and carry out the transactions contemplated hereby. Each
Restricted Person is duly qualified, in good standing, and authorized to do business in all other jurisdictions within the United States wherein (a) the character of the properties owned or
held by it, the loss of ownership or control of which would result in a Material Adverse Change ("Material Properties"), or (b) the nature of the business transacted by it makes such
qualification necessary, except such jurisdictions, if any, where the failure to be so qualified and in good standing, whether considered individually or when aggregated with all other such failures,
would not have a material adverse effect on Borrower's ability to perform its obligations under this Agreement. 

        Section 5.3.    Authorization.    Each Restricted Person has duly taken all action necessary to authorize the
execution and delivery by it of the Loan Documents to which it is a party and to authorize the consummation of the transactions contemplated thereby and the performance of its obligations thereunder.
Borrower is duly authorized to borrow funds hereunder. 

        Section 5.4.    No Conflicts or Consents.    The execution and delivery by the various Restricted Persons of
the Loan Documents to which each is a party, the performance by each of its obligations under such Loan Documents, and the consummation of the transactions contemplated by the various Loan Documents,
do not and will not (a) conflict with any provision of (i) any Law, (ii) the organizational documents of any Restricted Person, or (iii) any agreement, judgment, license,
order or permit applicable to or binding upon any Restricted Person, except where any such conflict could not reasonably be expected to result in a Material Adverse Change, (b result in the
acceleration of any Indebtedness owed by any Restricted Person, or (c) result in or require the creation of any Lien upon any assets or properties of any Restricted Person except as expressly
contemplated or permitted in the Loan Documents. Except as expressly contemplated in the Loan Documents no consent, approval, authorization or order of, and no notice to or filing with, any Tribunal
or third party is required in connection with the execution,
delivery or performance by any Restricted Person of any Loan Document or to consummate any transactions contemplated by the Loan Documents. 

21

 

        Section 5.5.    Enforceable Obligations.    This Agreement is, and the other Loan Documents when duly executed
and delivered will be, legal, valid and binding obligations of each Restricted Person which is a party hereto or thereto, enforceable in accordance with their terms except as such enforcement may be
limited by bankruptcy, insolvency or similar Laws of general application relating to the enforcement of creditors' rights. 

        Section 5.6.    Initial Financial Statements.    Borrower has heretofore delivered to each Lender true, correct
and complete copies of the Initial Financial Statements. The Initial Financial Statements fairly present Borrower's Consolidated financial position at the respective dates thereof and the Consolidated
results of Borrower's operations and Borrower's Consolidated cash flows for the respective periods thereof. Since the date of the annual Initial Financial Statements no Material Adverse Change has
occurred, except as reflected in the quarterly Initial Financial Statements or in Section 5.6 of the Disclosure Schedule. All Initial Financial Statements were prepared in accordance with GAAP. 

        Section 5.7.    Other Obligations and Restrictions.    No Restricted Person has any outstanding Liabilities of
any kind (including contingent obligations, tax assessments, and unusual forward or long-term commitments) which are, in the aggregate, material to Borrower or material with respect to
Borrower's Consolidated financial condition and not shown in the Initial Financial Statements or disclosed in Section 5.7 of the Disclosure Schedule or a Disclosure Report. Except as shown in
the Initial Financial Statements or disclosed in Section 5.7 of the Disclosure Schedule or a Disclosure Report, no Restricted Person is subject to or restricted by any franchise, contract,
deed, charter restriction, or other instrument or restriction which could cause a Material Adverse Change. 

        Section 5.8.    Full Disclosure.    No certificate, statement or other information delivered herewith or
heretofore by any Restricted Person to any Lender in connection with the negotiation of this Agreement or in connection with any transaction contemplated hereby contains any untrue statement of a
material fact or omits to state any material fact known to any Restricted Person (other than industry-wide risks normally associated with the types of businesses conducted by Restricted
Persons or risks covered by insurance policies maintained by such Restricted Person) necessary to make the statements contained herein or therein not misleading as of the date made or deemed made. 

        Section 5.9.    Litigation.    Except as disclosed in the Initial Financial Statements or in Section 5.9
of the Disclosure Schedule: (a) there are no actions, suits or legal, equitable, arbitrative or administrative proceedings pending, or to the knowledge of any Restricted Person threatened,
against any Restricted Person before any Tribunal which could reasonably be expected to cause a Material Adverse Change, and (b) there are no outstanding judgments, injunctions, writs, rulings
or orders by any such Tribunal
against any Restricted Person or any Restricted Person's stockholders, partners, directors or officers which could reasonably be expected to cause a Material Adverse Change. 

        Section 5.10.    Labor Disputes and Acts of God.    Except as disclosed in Section 5.10 of the
Disclosure Schedule or a Disclosure Report, neither the business nor the properties of any Restricted Person has been affected by any fire, explosion, accident, strike, lockout or other labor dispute,
drought, storm, hail, earthquake, embargo, act of God or of the public enemy or other casualty (whether or not covered by insurance), which could cause a Material Adverse Change. 

        Section 5.11.    ERISA Plans and Liabilities.    All currently existing Plans are listed in Section 5.11
of the Disclosure Schedule or a Disclosure Report. Except as disclosed in the Initial Financial Statements or in Section 5.11 of the Disclosure Schedule or a Disclosure Report, no ERISA
Termination Event has occurred with respect to any Plan and all ERISA Affiliates are in compliance with ERISA in all material respects. No ERISA Affiliate is required to contribute to, or has any
other absolute or contingent liability in respect of, any Multiemployer Plan as defined in Section 4001 of ERISA. Except as set forth in Section 5.11 of the Disclosure Schedule or a
Disclosure Report: (a) no "accumulated funding deficiency" (as defined in Section 412(a) of the Internal Revenue Code) exists with respect to any Plan, whether or not waived by the
Secretary of the Treasury or his delegate, and 

22

 

(b) the current value of each Plan's benefits does not exceed the current value of such Plan's assets available for the payment of such benefits by more than
[***]*. 

        Section 5.12.    Environmental and Other Laws.    Except as disclosed in Section 5.12 of the Disclosure
Schedule or a Disclosure Report: (a) Restricted Persons are conducting their businesses in material compliance with all applicable Laws, including Environmental Laws, and have and are in
compliance with all licenses and permits required under any such Laws, except for such failures to comply which could not reasonably be expected to cause a Material Adverse Change; (b) to the
best knowledge of Borrower, none of the operations or properties of any Restricted Person is the subject of federal, state or local investigation evaluating whether any material remedial action is
needed to respond to a release of any Hazardous Substances into the environment or to the improper storage or disposal (including storage or disposal at offsite locations) of any Hazardous Substances;
(c) to the best knowledge of Borrower, no Restricted Person (and to the best knowledge of Borrower, no other Person) has filed any notice under any Law indicating that any Restricted Person is
responsible for the improper release into the environment, or the improper storage or disposal, of any material amount of any Hazardous Substances or that any Hazardous Substances have been improperly
released, or are improperly stored or disposed of, upon any property of any Restricted Person; (d) no Restricted Person has transported or arranged for the transportation of any Hazardous
Substance to any location which is (i) listed on the National Priorities List under the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended, listed for
possible inclusion on such National Priorities List by the Environmental Protection Agency in its Comprehensive Environmental Response, Compensation and Liability Information System List, or listed on
any similar state list or (ii) the subject of federal, state or local enforcement actions or other investigations which may lead to claims against any Restricted Person for clean-up
costs, remedial work, damages to natural resources or for personal injury claims (whether under Environmental Laws or otherwise); and (e) no Restricted Person otherwise has any known material
contingent liability under any Environmental Laws or in connection with the release into the environment, or the storage or disposal, of any Hazardous Substances. Each Restricted Person
undertook, at the time of its acquisition of each of its material properties, all appropriate inquiry into the previous ownership and uses of the Property and any potential environmental liabilities
associated therewith. 

        Section 5.13.    Names and Places of Business.    No Restricted Person has, during the preceding five years,
had, been known by, or used any other trade or fictitious name, except as disclosed in Section 5.13 of the Disclosure Schedule and except for any residual business associated with any trade
name terminated prior to such five-year period. Except as otherwise indicated in Section 5.13 of the Disclosure Schedule or a Disclosure Report, the chief executive office and
principal place of business of each Restricted Person are (and for the preceding five years have been) located at the address of Borrower set out on the signature pages hereto. Except as indicated in
Section 5.13 of the Disclosure Schedule or a Disclosure Report, no Restricted Person has any other office or place of business. 

        Section 5.14.    Borrower's Subsidiaries.    Borrower does not, as of the date hereof, have any Subsidiary or
own any stock in any other corporation or association except those listed in Section 5.14 of the Disclosure Schedule or a Disclosure Report. Borrower does not, as of the date hereof, have any
Restricted Subsidiaries. Neither Borrower nor any Restricted Person is a member of any general or limited partnership, joint venture or association of any type whatsoever except those listed in
Section 5.14 of the Disclosure Schedule or a Disclosure Report. Except as otherwise revealed in a Disclosure Report, Borrower owns, directly or indirectly, the equity interest in each of its
Subsidiaries which is indicated in Section 5.14 of the Disclosure Schedule. 

        Section 5.15.    Government Regulation.    Neither Borrower nor any other Restricted Person owing Obligations
is subject to regulation under the Public Utility Holding Company Act of 1935, the Federal Power Act, the Investment Company Act of 1940 (as any of the preceding acts have been amended) or any other
Law which regulates the incurring by such Person of Indebtedness, including Laws relating to common contract carriers or the sale of electricity, gas, steam, water or other public utility services. 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

23

  

        Section 5.16.    Insider.    No Restricted Person, nor any Person having "control" (as that term is defined in
12 U.S.C. §375b(9) or in regulations promulgated pursuant thereto) of any Restricted Person, is a "director" or an "executive officer" or "principal shareholder" (as those terms are
defined in 12 U.S.C. §375b(8) or (9) or in regulations promulgated pursuant thereto) of any Lender, of a bank holding company of which any Lender is a Subsidiary or of any
Subsidiary of a bank holding company of which any Lender is a Subsidiary. 

        Section 5.17.    Solvency.    Upon giving effect to the issuance of the Notes, the execution of the Loan
Documents by Borrower and the consummation of the transactions contemplated hereby, Borrower will be solvent (as such term is used in applicable bankruptcy, liquidation, receivership, insolvency or
similar Laws). 

        Section 5.18.    Title to Properties; Licenses.    Each Restricted Person has good and defensible title to all
of the Collateral and to all of its Material Properties, free and clear of all Liens, encumbrances, or adverse claims other than Permitted Liens. Each Restricted Person possesses all licenses,
permits, franchises, patents, copyrights, trademarks and trade names, and other Intellectual Property (as defined in the Security Documents) (or otherwise possesses the right to use such Intellectual
Property without violation of the rights of any other Person) which are necessary to carry out its business as presently conducted and as presently proposed to be conducted hereafter. Except where
failure to possess any of the foregoing will not result in a Material Adverse Change, no Restricted Person is in violation in any material respect of the terms under which it possesses such
Intellectual Property or the right to use any Intellectual Property. 

 
 

ARTICLE VI—Affirmative Covenants of Borrower    
  

        To conform with the terms and conditions under which each Lender is willing to have credit outstanding to Borrower, and to induce each Lender to enter into this
Agreement and extend credit hereunder, Borrower warrants, covenants and agrees that until the full and final payment of the Obligations and the termination of this Agreement, unless Majority Lenders
have previously agreed otherwise: 

        Section 6.1.    Payment and Performance.    Subject to all applicable cure periods, Borrower will pay all
amounts due under the Loan Documents in accordance with the terms thereof and will observe, perform and comply with every covenant, term and condition expressed or implied in the Loan
Documents. Borrower will cause each other Restricted Person to observe, perform and comply with every such term, covenant and condition in any Loan Document to which such Restricted Person is a party. 

        Section 6.2.    Books, Financial Statements and Reports.    Each Restricted Person will at all times maintain
full and accurate books of account and records consistent with a standard system of accounting, and will furnish the following statements and reports to each Lender Party at Borrower's expense: 

        (a)  As
soon as available, and in any event within ninety (90) days after the end of each Fiscal Year, complete Consolidated and consolidating financial statements of
Borrower together with all notes thereto, prepared in reasonable detail in accordance with GAAP, together with an unqualified opinion, based on an audit using generally accepted auditing standards, by
Ernst & Young L.L.P., or other independent certified public accountants selected by Borrower and acceptable to Majority Lenders, stating that such Consolidated financial statements have been so
prepared. These financial statements shall contain a Consolidated and consolidating balance sheet as of the end of such Fiscal Year and Consolidated and consolidating statements of earnings, of cash
flows, and of changes in owners' equity for such Fiscal Year, each setting forth in comparative form the corresponding figures for the preceding Fiscal Year. In addition, within ninety
(90) days after the end of each Fiscal Year Borrower will furnish a report signed by such accountants (i) stating that they have read this Agreement, (ii) containing 

24

 

calculations showing compliance (or non-compliance) at the end of such Fiscal Year with the requirements of the financial covenants set forth in Exhibit H attached hereto, and
(iii) further stating that in making their examination and reporting on the Consolidated financial statements described above they did not conclude that any Default existed at the end of such
Fiscal Year or at the time of their report, or, if they did conclude that a Default existed, specifying its nature and period of existence. 

        (b)  As
soon as available, and in any event within sixty (60) days after the end of each Fiscal Quarter, Borrower's Consolidated and consolidating balance sheet as of
the end of such Fiscal Quarter and Consolidated and consolidating statements of Borrower's earnings and cash flows for the period from the beginning of the then current Fiscal Year to the end of such
Fiscal Quarter, all in reasonable detail and prepared in accordance with GAAP, subject to changes resulting from normal year-end adjustments. In addition Borrower will, together with each
such set of financial statements and each set of financial statements furnished under subsection (a) of this section, furnish a certificate in the form of Exhibit D signed by the chief
financial officer of Borrower stating that such financial statements are accurate and complete (subject to normal year-end adjustments), stating that he has reviewed the Loan Documents,
containing calculations showing compliance (or non-compliance) at the end of such Fiscal Quarter with the financial covenants set forth in Exhibit H attached hereto and stating that
no Default exists at the end of such Fiscal Quarter or at the time of such certificate or specifying the nature and period of existence of any such Default. 

        (c)  Promptly
upon their becoming available, copies of all financial statements, reports, notices and proxy statements sent by any Restricted Person to its stockholders and
all registration statements, periodic
reports and other statements and schedules filed by any Restricted Person with any securities exchange, the Securities and Exchange Commission or any similar governmental authority. 

        (d)  As
soon as possible, and in any event within thirty (30) days after the end of each calendar month, a Borrowing Base Report. 

        Section 6.3.    Other Information and Inspections.    Each Restricted Person will furnish to each Lender any
information which Agent may from time to time request concerning any provision of the Loan Documents, any Collateral, or any matter in connection with Restricted Persons' businesses, properties,
prospects, financial condition and operations. Each Restricted Person will permit representatives appointed by Agent (including independent accountants, auditors, agents, attorneys, appraisers and any
other Persons) to visit and inspect during normal business hours any of such Restricted Person's property, including its books of account, other books and records, and any facilities or other business
assets, and to make extra copies therefrom and photocopies and photographs thereof, and to write down and record any information such representatives obtain, and each Restricted Person shall permit
Agent or its representatives to investigate and verify the accuracy of the information furnished to Agent or any Lender in connection with the Loan Documents and to discuss all such matters with its
officers, employees and representatives. 

        Section 6.4.    Notice of Material Events and Change of Address.    Borrower will promptly notify each Lender
in writing, stating that such notice is being given pursuant to this Agreement, of: 

        (a)  occurrence
of any Material Adverse Change, 

        (b)  the
occurrence of any Default, 

        (c)  the
acceleration of the maturity of any Indebtedness owed by any Restricted Person or of any default by any Restricted Person under any indenture, mortgage, agreement,
contract or other instrument to which any of them is a party or by which any of them or any of their properties is bound, if such acceleration or default could cause a Material Adverse Change, 

        (d)  the
occurrence of any ERISA Termination Event, 

25

 

        (e)  [***]*
or more, any notice of potential liability under any Environmental Laws which might exceed such amount, or
any other material adverse claim asserted against any Restricted Person or with respect to any Restricted Person's properties, 

        (f)    the
filing of any suit or proceeding against any Restricted Person in which an adverse decision could reasonably be expected to cause a Material Adverse Change, 

        (g)  the
commencement of any federal or state governmental or quasi-governmental investigation that could reasonably be expected to affect the eligibility of any Restricted
Person for government reimbursement, including without limitation, any investigation relating to the Medicare or Medicaid programs or the Clinical Laboratory Improvement Act, and 

        (h)  the
change in the Fiscal Year of any Restricted Person. 

Upon
the occurrence of any of the foregoing Restricted Persons will take all necessary or appropriate steps to remedy promptly any such Material Adverse Change, Default, acceleration, default or ERISA
Termination Event, to protect against any such adverse claim, to defend any such suit or proceeding, and to resolve all controversies on account of any of the foregoing. Borrower will also notify
Agent and Agent's counsel in writing at least twenty Business Days prior to the date that any Restricted Person changes its name or the location of its chief executive office or principal place of
business or the place where it keeps its books and records concerning the Collateral, furnishing with such notice any necessary financing statement amendments or requesting Agent and its counsel to
prepare the same. 

        Section 6.5.    Maintenance of Properties.    Each Restricted Person will maintain, preserve, protect, and keep
all Collateral and all Material Properties in good condition and in compliance with all applicable Laws, and will from time to time make all repairs, renewals and replacements needed to enable the
business and operations carried on in connection therewith to be promptly and advantageously conducted at all times in the manner customary for companies in similar businesses. 

        Section 6.6.    Maintenance of Existence and Qualifications.    Each Restricted Person will maintain and
preserve its existence and its rights and franchises in full force and effect and will qualify to do business in all states or jurisdictions where required by applicable Law, except where the failure
to maintain and preserve such existence, rights or franchises, or so to qualify will not cause a Material Adverse Change. 

        Section 6.7.    Payment of Trade Liabilities, Taxes, etc.    Each Restricted Person will (a) timely file
all required tax returns; (b) timely pay all taxes, assessments, and other governmental charges or levies imposed upon it or upon its income, profits or property; (c) within ninety
(90) days past the date the same becomes due, pay all Liabilities owed by it on ordinary trade terms to vendors, suppliers and other Persons providing goods and services used by it in the
ordinary course of its business; (d) pay and discharge when due all other Liabilities now or hereafter owed by it; and (e) maintain appropriate
accruals and reserves for all of the foregoing in accordance with GAAP. Each Restricted Person may, however, delay paying or discharging any of the foregoing so long as it either (a) is in good
faith contesting the validity thereof by appropriate proceedings and has set aside on its books adequate reserves therefor or (b) has timely requested an extension of such payment obligation in
accordance with applicable Law, or (c) has reasonably determined that the failure to timely pay could not reasonably be expected to result in a Material Adverse Change. 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

26

 

        Section 6.8.    Insurance.    

        (a)  Each
Restricted Person shall at all times maintain (at its own expense) insurance for its property in accordance with the Insurance Schedule and insurance with respect
to all Collateral in such amounts, against such risks, in such form and which such financially sound and reputable insurers as shall be satisfactory to Agent from time to time. Upon demand by Agent
any insurance policies covering Collateral shall be endorsed (b) to provide for payment of losses to Agent as its interests may appear, (c) to provide that such policies may not be
canceled or reduced or affected in any material manner for any reason without thirty days prior notice to Agent, (d) to provide for any other matters specified in any applicable Security
Document or which Agent may reasonably require; and (e) to provide for insurance against fire, casualty and any other hazards normally insured against, in the amount of the full value (less a
reasonable deductible not to exceed amounts customary in the industry for similarly situated businesses and properties) of the property insured. Each Restricted Person shall at all times maintain or
cause to be maintained insurance against its liability for injury to persons or property in accordance with the Insurance Schedule, which insurance shall be by financially sound and reputable
insurers. Without limiting the foregoing, each Restricted Person shall at all time maintain liability insurance in accordance with Insurance Schedule; provided that in lieu of such insurance Borrower
and each other Restricted Person may maintain or cause to be maintained a system or system of self-insurance reasonably satisfactory to Majority Lenders that will accord with the approved
practices of companies in similar businesses and with similar assets. 

        (b)  Each
policy for liability insurance shall provide for all losses to be paid on behalf of Agent (for the benefit of Lenders) and Restricted Persons as their respective
interests may appear, and each policy insuring loss or damage to Collateral shall provide for all losses to be paid directly to Agent. Each such policy shall in addition (A) name the
appropriate Restricted Person and Agent and Lenders as insured parties thereunder (without any representation or warranty by or obligation upon Agent or Lenders) as their interests may appear,
(B) contain the agreement by the insurer that any loss thereunder shall be payable to Agent notwithstanding any action, inaction or breach of representation or warranty by any Restricted
Person, (C) provide that there shall be no recourse against Agent or Lenders for payment of premiums or other amounts with respect thereto and (D) provide that at least thirty
(30) days' prior
written notice of cancellation or of lapse shall be given to Agent by the insurer. Each Restricted Person will, if so requested by Agent, deliver to Agent certificates evidencing such insurance and,
as often as Agent may reasonably request, a report of a reputable insurance broker with respect to such insurance. Each Restricted Person will also, at the request of Agent, duly execute and deliver
instruments of assignment of such insurance policies and cause the respective insurers to acknowledge notice of such assignment. Agent is hereby authorized to enforce payment under all such insurance
policies and to compromise and settle any claims thereunder, in its own name or in the name of the Restricted Persons. 

        Section 6.9.    Performance on Borrower's Behalf.    If any Restricted Person fails to pay any taxes (subject
to the conditions of Section 3.6), insurance premiums, expenses, attorneys' fees or other amounts it is required to pay under any Loan Document, Agent may pay the same. Borrower shall
immediately reimburse Agent for any such payments and each amount paid by Agent shall constitute an Obligation owed hereunder which is due and payable on the date such amount is paid by Agent. 

        Section 6.10.    Interest.    Borrower hereby promises to each Lender Party to pay interest at the Default Rate
applicable to Base Rate Loans on all Obligations (including Obligations to pay fees or to reimburse or indemnify any Lender) which Borrower has in this Agreement promised to pay to such Lender Party
and which are not paid when due to such Lender Party. Such interest shall accrue from the date such Obligations become due to the applicable Lender Party until they are paid. 

        Section 6.11.    Compliance with Agreements and Law.    Each Restricted Person will perform all material
obligations it is required to perform under the terms of each indenture, mortgage, deed of trust, security agreement, lease, franchise, agreement, contract or other instrument or obligation to which
it is a party or by which it or any of its properties is bound. Each Restricted Person will conduct its business and affairs in compliance with all Laws applicable thereto and will maintain in good
standing all licenses that may be necessary or appropriate to carry on its business, except where such failure could not be expected to result in a Material Adverse Change. 

27

 

        Section 6.12.    Environmental Matters; Environmental Reviews.     

        (a)  Each
Restricted Person will comply in all material respects with all Environmental Laws now or hereafter applicable to such Restricted Person, as well as all contractual
obligations and agreements with respect to environmental remediation or other environmental matters, and shall obtain, at or prior to the time required by applicable Environmental Laws, all
environmental, health and safety permits, licenses and other authorizations necessary for its operations and will maintain such authorizations in full force and effect. No Restricted Person will do
anything or permit anything to be done which will subject any of its Material Properties to any material remedial obligations under, or result in noncompliance with applicable permits and licenses
issued under, any applicable Environmental Laws,
assuming disclosure to the applicable governmental authorities of all relevant facts, conditions and circumstances, except where such noncompliance could not reasonably be expected to result in a
Material Adverse Change. Upon Agent's reasonable request, at any time and from time to time, but so long as no Event of Default has occurred and is continuing, not more than once per calendar year,
Borrower will provide at its own expense an environmental inspection of any of the Restricted Persons' Material Properties and audit of their environmental compliance procedures and practices, in each
case from an engineering or consulting firm approved by Agent. 

        (b)  Borrower
will promptly furnish to Agent all written notices of violation, orders, claims, citations, complaints, penalty assessments, suits or other proceedings received
by any Restricted Person, or of which Borrower otherwise has notice, pending or threatened against any Restricted Person by any governmental authority with respect to any alleged violation of or
non-compliance with any Environmental Laws or any permits, licenses or authorizations in connection with any Restricted Person's ownership or use of its properties or the operation of its
business. 

        (c)  Borrower
will promptly furnish to Agent all requests for information, notices of claim, demand letters, and other notifications, received by Borrower in connection with
any Restricted Person's ownership or use of its properties or the conduct of its business, relating to potential responsibility with respect to any investigation or clean-up of Hazardous
Substance at any location. 

        Section 6.13.    Evidence of Compliance.    Each Restricted Person will furnish to each Lender at such
Restricted Person's or Borrower's expense all evidence which Agent from time to time reasonably requests in writing as to the accuracy and validity of or compliance with all representations,
warranties and covenants made by any Restricted Person in the Loan Documents, the satisfaction of all conditions contained therein, and all other matters pertaining thereto. 

        Section 6.14.    Bank Accounts; Offset.    To secure the repayment of the Obligations Borrower hereby grants to
each Lender a security interest, a lien, and a right of offset, each of which shall be in addition to all other interests, liens, and rights of any Lender at common Law, under the Loan Documents, or
otherwise, and each of which shall be upon and against (a) any and all moneys, securities or other property (and the proceeds therefrom) of Borrower now or hereafter held or received by or in
transit to any Lender from or for the account of Borrower, whether for safekeeping, custody, pledge, transmission, collection or otherwise, (b) any and all deposits (general or special, time or
demand, provisional or final) of Borrower with any Lender, and (c) any other credits and claims of Borrower at any time existing against any Lender, including claims under certificates of
deposit. At any time and from time to time after the occurrence of any Default, each Lender is hereby authorized to foreclose upon, or to offset against the Obligations then due and payable (in either
case without notice to Borrower), any and all items hereinabove referred to. The remedies of foreclosure and offset are separate and cumulative, and either may be exercised independently of the other
without regard to procedures or restrictions applicable to the other. 

        Section 6.15.    Guaranties of Substantial Subsidiaries.    Each Substantial Subsidiary of Borrower, whether
existing or created, acquired or coming into existence after the date hereof, shall promptly execute and deliver to Agent an absolute and unconditional guaranty of the timely repayment of the 

28

 

Obligations and the due and punctual performance of the obligations of Borrower hereunder, which guaranty shall be substantially in the form of Exhibit I attached hereto. Each Substantial
Subsidiary existing on the date hereof shall duly execute and deliver such a guaranty prior to the making of any Loan hereunder. Borrower will cause each Substantial Subsidiary to deliver to Agent,
simultaneously with its delivery of such a guaranty, (a) written evidence satisfactory to Agent and its counsel that such Substantial Subsidiary has taken all corporate or partnership action
necessary to duly approve and authorize its execution, delivery and performance of such guaranty and any other documents which it is required to execute and (b) an acknowledgment in form and
substance satisfactory to Agent pursuant to which such Substantial Subsidiary acknowledges and agrees that it is a Restricted Person and is subject to all representations, warranties, covenants and
agreements of the Loan Documents which pertain to Restricted Persons. 

        Section 6.16.    Agreement to Deliver Security Documents.    Promptly upon any Subsidiary of Borrower becoming
a Substantial Subsidiary, Borrower shall deliver to Agent a pledge agreement substantially in the form of Exhibit J attached hereto pursuant to which Borrower shall grant a security interest in
all of Borrower's ownership interests in such Substantial Subsidiary. Borrower also agrees to deliver and to cause each other Restricted Person to deliver, to further secure the Obligations whenever
requested by Agent in its sole and absolute discretion, deeds of trust, mortgages, chattel mortgages, security agreements, financing statements continuation statements, extension agreements,
acknowledgments, and other Security Documents in form and substance satisfactory to Agent for the purpose of granting, confirming, protecting and perfecting Liens or security interests in any real or
personal property now owned or hereafter acquired by any Restricted Person. 

        Section 6.17.    Financial Covenants.    Borrower will comply with all financial covenants set forth in
Exhibit H attached hereto. 

 
 

ARTICLE VII—Negative Covenants of Borrower

        To
conform with the terms and conditions under which each Lender is willing to have credit outstanding to Borrower, and to induce each Lender to enter into this Agreement and make the
Loans, Borrower warrants, covenants and agrees that until the full and final payment of the Obligations and the termination of this Agreement, unless Majority Lenders have previously agreed otherwise: 

        Section 7.1.    Indebtedness.    No Restricted Person will in any manner owe or be liable for Indebtedness
except: 

        (a)  the
Obligations. 

        (b)  unsecured
Indebtedness among Borrower and the Guarantors arising in the ordinary course of business. 

        (c)  Indebtedness
outstanding under the Operative Documents. 

        (d)  existing
Indebtedness which is described in the Disclosure Schedule. 

        (e)  In
addition to the Indebtedness described in 7.1(a), (b), (c) and (d), the unsecured indebtedness of Borrower and other Restricted Persons incurred in the
ordinary course of business, other than for money borrowed, which, in the aggregate, shall not exceed [***]* at any time. 

        Section 7.2.    Limitation on Liens.    Except for Permitted Liens, no Restricted Person will create, assume or
permit to exist any Lien upon any of the properties or assets which it now owns or hereafter acquires. 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

29

 

        Section 7.3.    Hedging Contracts.    No Restricted Person will be a party to or in any manner be liable on any
Hedging Contract except contracts entered into by a Restricted Person with the purpose and effect of fixing interest rates on a principal amount of Indebtedness of such Restricted Person that is
accruing interest at a variable rate, provided that (i) the aggregate notional amount of such contracts never exceeds fifty percent (50%) of the anticipated outstanding principal balance of the
Indebtedness to be hedged by such contracts or an average of such principal balances calculated using a generally accepted method of matching interest swap contracts to declining principal balances,
(ii) the floating rate index of each such contract generally matches the index used to determine the floating rates of interest on the corresponding indebtedness to be hedged by such contract
and (iii) each such contract is with a counterparty or has a guarantor of the obligation of the counterparty who (unless such counterparty is a Lender or one of its Affiliates) at the time the
contract is made has long-term obligations rated AA or Aa2 or better, respectively, by either Rating Agency. 

        Section 7.4.    Limitation on Mergers, Issuances of Securities.    Other than to effect a Permitted
Acquisition, no Restricted Person will merge or consolidate with or into any other Person except that any Subsidiary of
Borrower may be merged into or consolidated with (a) another Subsidiary of Borrower, so long as a Guarantor is the surviving business entity, or (b) Borrower, so long as Borrower is the
surviving business entity. No Subsidiary of Borrower will issue any additional shares of its capital stock or other securities or any options, warrants or other rights to acquire such additional
shares or other securities except to Borrower and only to the extent not otherwise forbidden under the terms hereof. No Subsidiary of Borrower which is a partnership will allow any diminution of
Borrower's interest (direct or indirect) therein. 

        Section 7.5.    Limitation on Sales of Property.    No Restricted Person will sell, transfer, lease, exchange,
alienate or dispose of any of its material assets or properties or any material interest therein, or discount, sell, pledge or assign any notes payable to it, accounts receivable or future income in
excess of [***]*, provided that the proceeds of any such discount, sale, pledge or assignment, shall be used to prepay the principal of the Loans,
except, to the extent not otherwise forbidden under the Security Documents: 

        (a)  equipment
which is worthless or obsolete or which is replaced by equipment of equal suitability and value; 

        (b)  inventory
which is sold in the ordinary course of business on ordinary trade terms. 

        Section 7.6.    Limitation on Dividends and Redemptions.    No Restricted Person will declare or make any
Distribution, other than (a) Distributions payable to Borrower or to Guarantors which are Subsidiaries of Borrower, to the extent not in violation of the investment restrictions of
Section 7.7, (b) Distributions by a Restricted Person payable only in such Restricted Person's common stock, so long as Borrower's interest in any of its Subsidiaries is not thereby
reduced, (c) distributions by Borrower of its equity securities or rights to acquire securities to implement a shareholder rights plan, and (d) long as no Default or Event of Default
would exist after giving effect thereto(i) cash dividends to shareholders of Borrower and (ii) cash payments to shareholders of Borrower for the purpose of repurchasing Borrower's shares
pursuant to a stock repurchase program authorized by Borrower's board of directors; provided that (i) and (ii) combined in an aggregate amount shall not to exceed
[***]* of Net Income per Fiscal Year. 

        Section 7.7.    Limitation on Investments and New Businesses.    Except for Permitted Investments, no
Restricted Person will (a) make any expenditure or commitment or incur any obligation or enter into or engage in any transaction except in the ordinary course of business, (b) engage
directly or indirectly in any business or conduct any operations except in connection with or incidental to its present businesses and operations, or (c) make any acquisitions of or capital
contributions to or other Investments in any Person or property, other than Permitted Investments and Permitted Acquisitions. 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

30

 

        Section 7.8.    Limitation on Credit Extensions.    Except for Permitted Investments, no Restricted Person will
extend credit, make advances or make loans other than (a) normal and prudent extensions of credit to customers buying goods and services in the ordinary course of business, which extensions
shall not be for longer periods than those extended by similar businesses operated in a normal and prudent manner, (b) loans to Borrower, and (c) advances to employees in the ordinary
course of business. 

        Section 7.9.    Transactions with Affiliates.    Neither Borrower nor any of its Subsidiaries will engage in
any material transaction with any of its Affiliates on terms which are less favorable to it than those which would have been obtainable at the time in arm's-length dealing with Persons other than such
Affiliates, provided that such restriction shall not apply to transactions among Borrower and its wholly owned Subsidiaries. 

        Section 7.10.    Prohibited Contracts.    Except as expressly provided for in the Loan Documents, no Restricted
Person will, directly or indirectly, enter into, create, or otherwise allow to exist any contract or other consensual restriction on the ability of any Subsidiary of Borrower to: (a) pay
dividends or make other distributions to Borrower, (b) to redeem equity interests held in it by Borrower, (c) to repay loans and other indebtedness owing by it to Borrower, or
(d) to transfer any of its assets to Borrower. No Restricted Person will enter into any "take-or-pay" contract or other contract or arrangement for the purchase of goods
or services which obligates it to pay for such goods or service regardless of whether they are delivered or furnished to it. No Restricted Person will amend or permit any amendment to any contract or
lease which releases, qualifies, limits, makes contingent or otherwise detrimentally affects the rights and benefits of Agent or any Lender under or acquired pursuant to any Security Documents. No
ERISA Affiliate will incur any obligation to contribute to any Multiemployer Plan as defined in Section 4001 of ERISA. 

 
 

ARTICLE VIII—Events of Default and Remedies

        Section 8.1.    Events of Default.    Each of the following events constitutes an Event of Default under this
Agreement: 

        (a)  Any
Restricted Person fails to pay the outstanding principal amount of the Loans on the Maturity Date or, if earlier, the day on which the obligations of Lenders to make
Loans hereunder have been terminated or the Notes have been accelerated; 

        (b)  Any
Restricted Person fails to pay any Obligation (other than the Obligations in subsection (a) above) when due and payable, whether at a date for the payment of
a fixed installment or as a contingent or other payment becomes due and payable or as a result of acceleration or otherwise, within three Business Days after the same becomes due; 

        (c)  Any
"default" or "event of default" occurs under any Loan Document or any Operative Document which defines either such term, and the same is not remedied within the
applicable period of grace (if any) provided in such Loan Document or Operative Document; 

        (d)  Any
Restricted Person fails to duly observe, perform or comply with Section 6.4 or any provision of Article VII; 

        (e)  Any
Restricted Person fails (other than as referred to in subsections (a), (b), (c) or (d) above) to duly observe, perform or comply with any covenant,
agreement, condition or provision of any Loan Document, and such failure remains unremedied for a period of thirty (30) days after notice of such failure is given by Agent to Borrower; 

        (f)    Any
representation or warranty previously, presently or hereafter made in writing by or on behalf of any Restricted Person in connection with any Loan Document shall
prove to have been false or incorrect in any material respect on any date on or as of which made and either (i) the fact or 

31

 

condition which made such representation or warranty incorrect, false or misleading is not curable or remediable or (ii) the fact or condition which made such representation incorrect, false
or misleading shall not have been cured or remediated within thirty days after the earlier of (x) written notice thereof and (y) the date on which a senior officer of the applicable
Restricted Person shall have notice thereof, or any Loan Document at any time ceases to be valid, binding and enforceable as warranted in Section 5.5 for any reason other than its release or
subordination by Agent; 

        (g)  Any
Restricted Person fails to duly observe, perform or comply with any agreement with any Person or any term or condition of any instrument, if such agreement or
instrument is materially significant to Borrower or to Borrower and its Subsidiaries on a Consolidated basis or materially significant to any Guarantor, and such failure is not remedied within the
applicable period of grace (if any) provided in such agreement or instrument; 

        (h)  Any
Restricted Person (i) fails to pay any portion, when such portion is due, of any of its Indebtedness in excess of $1,000,000, or (ii) breaches or
defaults in the performance of any agreement or instrument by which any such Indebtedness in excess of $1,000,000 is issued, evidenced, governed, or
secured, and any such failure, breach or default continues beyond any applicable period of grace provided therefor; 

        (i)    Either
(i) any "accumulated funding deficiency" (as defined in Section 412(a) of the Internal Revenue Code) in excess of $100,000 exists with respect to
any Plan, whether or not waived by the Secretary of the Treasury or his delegate, or (ii) any ERISA Termination Event occurs with respect to any Plan and the then current value of such Plan's
benefit liabilities exceeds the then current value of such Plan's assets available for the payment of such benefit liabilities by more than $100,000 (or in the case of a ERISA Termination Event
involving the withdrawal of a substantial employer, the withdrawing employer's proportionate share of such excess exceeds such amount); 

        (j)    Any
Restricted Person: 

          (i)  suffers
the entry against it of a judgment, decree or order for relief by a Tribunal of competent jurisdiction in an involuntary proceeding commenced under any
applicable bankruptcy, insolvency or other similar Law of any jurisdiction now or hereafter in effect, including the federal Bankruptcy Code, as from time to time amended, or has any such proceeding
commenced against it which remains undismissed for a period of thirty days; or 

        (ii)  commences
a voluntary case under any applicable bankruptcy, insolvency or similar Law now or hereafter in effect, including the federal Bankruptcy Code, as from time to
time amended; or applies for or consents to the entry of an order for relief in an involuntary case under any such Law; or makes a general assignment for the benefit of creditors; or fails generally
to pay (or admits in writing its inability to pay) its debts as such debts become due; or takes corporate or other action to authorize any of the foregoing; or 

        (iii)  suffers
the appointment of or taking possession by a receiver, liquidator, assignee, custodian, trustee, sequestrator or similar official of all or a substantial part
of its assets or of any part of the Collateral in a proceeding brought against or initiated by it, and such appointment or taking possession is neither made ineffective nor discharged within thirty
days after the making thereof, or such appointment or taking possession is at any time consented to, requested by, or acquiesced to by it; or 

        (iv)  suffers
the entry against it of a final judgment for the payment of money in excess of [***]* (not covered by
insurance satisfactory to Agent in its discretion), unless the same is discharged within thirty days after the date of entry thereof or an appeal or appropriate proceeding for review thereof is taken
within such period and a stay of execution pending such appeal is obtained; or 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

32

 

        (v)  suffers
a writ or warrant of attachment or any similar process to be issued by any Tribunal against all or any substantial part of its assets or any part of the
Collateral, and such writ or warrant of attachment or any similar process is not stayed or released within thirty days after the entry or levy thereof or after any stay is vacated or set aside; 

        (k)  Any
Change of Control occurs; and 

        (l)    Any
Material Adverse Change occurs. 

Upon
the occurrence of an Event of Default described in subsection (j)(i), (j)(ii) or (j)(iii) of this section with respect to Borrower, all of the Obligations shall thereupon be
immediately due and payable, without demand, presentment, notice of demand or of dishonor and nonpayment, protest, notice of protest, notice of intention to accelerate, declaration or notice of
acceleration, or any other notice or declaration of any kind, all of which are hereby expressly waived by Borrower and each Restricted Person who at any time ratifies or approves this Agreement. Upon
any such acceleration, any obligation of any Lender to make any further Loans shall be permanently terminated. During the continuance of any other Event of Default, Agent at any time and from time to
time may (and upon written instructions from Majority Lenders, Agent shall), without notice to Borrower or any other Restricted Person, do either or both of the following: (1) terminate any
obligation of Lenders to make Loans hereunder, and (2) declare any or all of the Obligations immediately due and payable, and all such Obligations shall thereupon be immediately due and
payable, without demand, presentment, notice of demand or of dishonor and nonpayment, protest, notice of protest, notice of intention to accelerate, declaration or notice of acceleration, or any other
notice or declaration of any kind, all of which are hereby expressly waived by Borrower and each Restricted Person who at any time ratifies or approves this Agreement. 

        Section 8.2.    Remedies.    If any Default shall occur and be continuing, each Lender Party may protect and
enforce its rights under the Loan Documents by any appropriate proceedings, including proceedings for specific performance of any covenant or agreement contained in any Loan Document, and each Lender
Party may enforce the payment of any Obligations due it or enforce any other legal or equitable right which it may have. All rights, remedies and powers conferred upon Lender Parties under the Loan
Documents shall be deemed cumulative and not exclusive of any other rights, remedies or powers available under the Loan Documents or at Law or in equity. 

 
 
 

ARTICLE IX—Agent    
  

        Section 9.1.    Appointment and Authority.    Each Lender Party hereby irrevocably authorizes Agent, and Agent
hereby undertakes, to receive payments of principal, interest and other amounts due hereunder as specified herein and to take all other actions and to exercise such powers under the Loan Documents as
are specifically delegated to Agent by the terms hereof or thereof, together with all other powers reasonably incidental thereto. The relationship of Agent to the other Lender Parties is only that of
one commercial lender acting as administrative agent for others, and nothing in the Loan Documents shall be construed to constitute Agent a trustee or other fiduciary for any Lender Party or any
holder of any participation in a Note nor to impose on Agent duties and obligations other than those expressly provided for in the Loan Documents. With respect to any matters not expressly provided
for in the Loan Documents and any matters which the Loan Documents place within the discretion of Agent, Agent shall not be required to exercise any discretion or take any action, and it may request
instructions from Lenders with respect to any such matter, in which case it shall be required to act or to refrain from acting (and shall be fully protected and free from liability to all Lender
Parties in so acting or refraining from acting) upon the instructions of Majority Lenders (including itself), provided, however, that Agent shall not be required to take any action which exposes it to
a risk of personal liability that it considers unreasonable or which is contrary to the Loan Documents or to applicable Law. Upon receipt by Agent from Borrower of any communication calling 

33

 

for action on the part of Lenders or upon notice from any other Lender to Agent of any Default or Event of Default, Agent shall promptly notify each other Lender thereof. 

        Section 9.2.    Exculpation, Agent's Reliance, Etc.    Neither Agent nor any of its directors, officers,
agents, attorneys, or employees shall be liable for any action taken or omitted to be taken by any of them under or in connection with the Loan Documents, INCLUDING THEIR
NEGLIGENCE OF ANY KIND, except that each shall be liable for its own gross negligence or willful misconduct. Without limiting the generality of the foregoing, Agent
(a) may treat the payee of any Note as the holder thereof until Agent receives written notice of the assignment or transfer thereof in accordance with this Agreement, signed by such payee and
in form satisfactory to Agent; (b) may consult with legal counsel (including counsel for Borrower), independent public accountants and other experts selected by it and shall not be liable for
any action taken or omitted to be taken in good faith by it in accordance with the advice of such counsel, accountants or experts; (c) makes no warranty or representation to any other Lender
and shall not be responsible to any other Lender Party for any statements, warranties or representations made in or in connection with the Loan Documents; (d) shall not have any duty to
ascertain or to inquire as to the performance or observance of any of the terms, covenants or conditions of the Loan Documents on the part of any Restricted Person or to inspect the property
(including the books and records) of any Restricted Person; (e) shall not be responsible to any other Lender for the due execution, legality, validity, enforceability, genuineness, sufficiency
or value of any Loan Document or any instrument or document furnished in connection therewith; (f) may rely upon the representations and warranties of each Restricted Person or Lender Party in
exercising its powers hereunder; and (g) shall incur no liability under or in respect of the Loan Documents by acting upon any notice, consent, certificate or other instrument or writing
(including any facsimile, telegram, cable or telex) believed by it to be genuine and signed or sent by the proper Person or Persons. 

        Section 9.3.    Credit Decisions.    Each Lender Party acknowledges that it has, independently and without
reliance upon any other Lender Party, made its own analysis of Borrower and the transactions contemplated hereby and its own independent decision to enter into this Agreement and the other Loan
Documents. Each Lender Party also acknowledges that it will, independently and without reliance upon any other Lender Party and based on such documents and information as it shall deem appropriate at
the time, continue to make its own credit decisions in taking or not taking action under the Loan Documents. 

        Section 9.4. Indemnification. Each Lender agrees to indemnify Agent (to the extent not reimbursed by Borrower within ten (10) days after demand)
from and against such Lender's Percentage Share of any and all liabilities, obligations, claims, losses, damages, penalties, fines, actions, judgments, suits, settlements, costs, expenses or
disbursements (including reasonable fees of attorneys, accountants, experts and advisors) of any kind or nature whatsoever (in this section collectively called "liabilities and costs") which to any
extent (in whole or in part) may be imposed on, incurred by, or asserted against Agent growing out of, resulting from or in any other way associated with any of the Collateral, the Loan Documents and
the transactions and events (including the enforcement thereof) at any time associated therewith or contemplated therein (whether arising in contract or in tort and otherwise and including any
violation or noncompliance with any Environmental Laws by any Person or any liabilities or duties of any Person with respect to Hazardous Substances found in or released into the
environment).

        THE FOREGOING INDEMNIFICATION SHALL APPLY WHETHER OR NOT SUCH LIABILITIES AND COSTS ARE IN ANY WAY OR TO ANY EXTENT OWED, IN WHOLE OR IN PART, UNDER ANY CLAIM OR
THEORY OF STRICT LIABILITY, OR ARE CAUSED, IN WHOLE OR IN PART, BY ANY NEGLIGENT ACT OR OMISSION OF ANY KIND BY AGENT,

provided
only that no Lender shall be obligated under this section to indemnify Agent for that portion, if any, of any liabilities and costs which is proximately caused by Agent's own individual gross 

34

 

negligence or willful misconduct, as determined in a final judgment. Cumulative of the foregoing, each Lender agrees to reimburse Agent promptly upon demand for such Lender's Percentage Share of any
costs and expenses to be paid to Agent by Borrower under Section 10.4(a) to the extent that Agent is not timely reimbursed for such expenses by Borrower as provided in such section. As used in
this section the term "Agent" shall refer not only to the Person designated as such in Section 1.1 but also to each director, officer, agent, attorney, employee, representative and Affiliate of
such Person. 

        Section 9.5.    Rights as Lender.    In its capacity as a Lender, Agent shall have the same rights and
obligations as any Lender and may exercise such rights as though it were not Agent. Agent may accept deposits from, lend money to, act as trustee under indentures of, and generally engage in any kind
of business with any Restricted Person or their Affiliates, all as if it were not Agent hereunder and without any duty to account therefor to any other Lender. 

        Section 9.6.    Sharing of Set-Offs and Other Payments.    Each Lender Party agrees that if it
shall, whether through the exercise of rights under Security Documents or rights of banker's lien, set off, or counterclaim against Borrower or otherwise, obtain payment of a portion of the aggregate
Obligations owed to it which, taking into account all distributions made by Agent under Section 3.1, causes such Lender Party to have received more than it would have received had such payment
been received by Agent and distributed pursuant to Section 3.1, then (a) it shall be deemed to have simultaneously purchased and shall be obligated to purchase interests in the
Obligations as necessary to cause all Lender Parties to share all payments as provided for in Section 3.1, and (b) such other adjustments shall be made from time to time as shall be
equitable to ensure that Agent and all Lender Parties share all payments of Obligations as provided in Section 3.1; provided, however, that nothing herein contained shall in any way affect the
right of any Lender Party to obtain payment (whether by exercise of rights of banker's lien, set-off or counterclaim or otherwise) of indebtedness other than the Obligations. Borrower
expressly consents to the foregoing arrangements and agrees that any holder of any such interest or other participation in the Obligations, whether or not acquired pursuant to the foregoing
arrangements, may to the fullest extent permitted by Law exercise any and all rights of banker's lien, set-off, or counterclaim as fully as if such holder were a holder of the Obligations
in the amount of such interest or other participation. If all or any part of any funds transferred pursuant to this section is thereafter recovered from the seller under this section which received
the same, the purchase provided for in this section shall be deemed to have been rescinded to the extent of such recovery, together with interest, if any, if interest is required pursuant to the order
of a Tribunal order to be paid on account of the possession of such funds prior to such recovery. 

        Section 9.7.    Investments.    Whenever Agent in good faith determines that it is uncertain about how to
distribute to Lender Parties any funds which it has received, or whenever Agent in good faith determines that there is any dispute among Lender Parties about how such funds should be distributed,
Agent may choose to defer distribution of the funds which are the subject of such uncertainty or dispute. If Agent in good faith believes that the uncertainty or dispute will not be promptly resolved,
or if Agent is otherwise required to invest funds pending distribution to Lender Parties, Agent shall invest such funds pending distribution; all interest on any such Investment shall be distributed
upon the distribution of such Investment and in the same proportion and to the same Persons as such Investment. All moneys received by Agent for distribution to Lender Parties (other than to the
Person who is Agent in its separate capacity as a Lender Party) shall be held by Agent pending such distribution solely as Agent for such Lender Parties, and Agent shall have no equitable title to any
portion thereof. 

        Section 9.8.    Benefit of Article IX.    The provisions of this Article (other than the following
Section 9.9) are intended solely for the benefit of Lender Parties, and no Restricted Person shall be entitled to rely on any such provision or assert any such provision in a claim or defense
against any Lender. Lender Parties may waive or amend such provisions as they desire without any notice to or consent of Borrower or any Restricted Person. 

        Section 9.9.    Resignation.    Agent may resign at any time by giving written notice thereof to Lenders and
Borrower. Each such notice shall set forth the date of such resignation. Upon any such resignation Majority Lenders shall have the right to appoint a successor Agent. A successor must be appointed for
any retiring Agent, and such Agent's resignation shall become effective when such successor accepts such appointment. If, within thirty days after the date of the retiring Agent's 

35

 

resignation, no successor Agent has been appointed and has accepted such appointment, then the retiring Agent may appoint a successor Agent, which shall be a commercial bank organized or licensed to
conduct a banking or trust business under the Laws of the United States of America or of any state thereof. Upon the acceptance of any appointment as Agent hereunder by a successor Agent, the retiring
Agent shall be discharged from its duties and obligations under this Agreement and the other Loan Documents. After any retiring Agent's resignation hereunder the provisions of this Article IX
shall continue to inure to its benefit as to any actions taken or omitted to be taken by it while it was Agent under the Loan Documents. 

        Section 9.10    Certain Titles.    Notwithstanding any other provision of this Agreement or any of the other
Loan Documents, any Lenders designated on the cover page of this Agreement or elsewhere herein as "Syndication Agent," "Co-Agent" or any similar designation are named as such for
recognition purposes
only, and in their capacities as such shall have no powers, rights, duties, responsibilities or liabilities with respect to this Agreement and the other Loan Documents and the transactions
contemplated hereby and thereby. 

 
 
 

ARTICLE X—Miscellaneous    
  

        Section 10.1.    Waivers and Amendments; Acknowledgments.    

        (a)  Waivers and Amendments. No failure or delay (whether by course of conduct or otherwise) by any Lender in exercising any
right, power or remedy which such Lender Party may have under any of the Loan Documents shall operate as a waiver thereof or of any other right, power or remedy, nor shall any single or partial
exercise by any Lender Party of any such right, power or remedy preclude any other or further exercise thereof or of any other right, power or remedy. No waiver of any provision of any Loan Document
and no consent to any departure therefrom shall ever be effective unless it is in writing and signed as provided below in this section, and then such waiver or consent shall be effective only in the
specific instances and for the purposes for which given and to the extent specified in such writing. No notice to or demand on any Restricted Person shall in any case of itself entitle any Restricted
Person to any other or further notice or demand in similar or other circumstances. This Agreement and the other Loan Documents set forth the entire understanding between the parties hereto with
respect to the transactions contemplated herein and therein and supersede all prior discussions and understandings with respect to the subject matter hereof and thereof, and no waiver, consent,
release, modification or amendment of or supplement to this Agreement or the other Loan Documents shall be valid or effective against any party hereto unless the same is in writing and signed by
(i) if such party is Borrower, by Borrower, (ii) if such party is Agent, by such party, and (iii) if such party is a Lender, by such Lender or by Agent on behalf of Lenders with
the written consent of Majority Lenders (which consent has already been given as to the termination of the Loan Documents as provided in Section 10.9). Notwithstanding the foregoing or anything
to the contrary herein, Agent shall not, without the prior consent of each individual Lender, execute and deliver on behalf of such Lender any waiver or amendment which would: (1) waive any of
the conditions specified in Article IV (provided that Agent may in its discretion withdraw any request it has made under Section 4.2(g)), (2) increase the maximum amount which
such Lender is committed hereunder to lend, (3) reduce any fees payable to such Lender hereunder, or the principal of, or interest on, such Lender's Note, (4) postpone any date fixed for
any payment of any such fees, principal or interest, (5) amend the definition herein of "Majority Lenders" or otherwise change the aggregate amount of Percentage Shares which is required for
Agent, Lenders or any of them to take any particular action under the Loan Documents, (6) release Borrower from its obligation to pay such Lender's Note or any Guarantor from its guaranty of
such payment, (7) release all or substantially all of the Collateral, or (8) amend this Section 10.1(a). 

36

   
        (b)  Acknowledgments and Admissions. Borrower hereby represents, warrants, acknowledges and admits that (i) it has been
advised by counsel in the negotiation, execution and delivery of the Loan Documents to which it is a party, (ii) it has made an independent decision to enter into this Agreement and the other
Loan Documents to which it is a party, without reliance on any representation, warranty, covenant or undertaking by Agent or any Lender, whether written, oral or implicit, other than as expressly set
out in this Agreement or in another Loan Document delivered on or after the date hereof, (iii) there are no representations, warranties, covenants, undertakings or agreements by any Lender as
to the Loan Documents except as expressly set out in this Agreement or in another Loan Document delivered on or after the date hereof, (iv) no Lender has any fiduciary obligation toward
Borrower with respect to any Loan Document or the transactions contemplated thereby, (v) the relationship pursuant to the Loan Documents between Borrower and the other Restricted Persons, on
one hand, and each Lender, on the other hand, is and shall be solely that of debtor and creditor, respectively, (vi) no partnership or joint venture exists with respect to the Loan Documents
between any Restricted Person and any Lender, (vii) Agent is not Borrower's Agent, but Agent for Lenders, (viii) should an Event of Default or Default occur or exist, each Lender will
determine in its sole discretion and for its own reasons what remedies and actions it will or will not exercise or take at that time, (ix) without limiting any of the foregoing, Borrower is not
relying upon any representation or covenant by any Lender, or any representative thereof, and no such representation or covenant has been made, that any Lender will, at the time of an Event of Default
or Default, or at any other time, waive, negotiate, discuss, or take or refrain from taking any action permitted under the Loan Documents with respect to any such Event of Default or Default or any
other provision of the Loan Documents, and (x) all Lender Parties have relied upon the truthfulness of the acknowledgments in this section in deciding to execute and deliver this Agreement and
to become obligated hereunder. 

        (c)  Joint Acknowledgment. THIS WRITTEN AGREEMENT AND THE OTHER LOAN DOCUMENTS REPRESENT THE FINAL
AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES.

        THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.  

        Section 10.2.    Survival of Agreements; Cumulative Nature.    All of Restricted
Persons' various representations, warranties, covenants and agreements in the Loan Documents shall survive the execution and delivery of this Agreement and the other Loan Documents and the performance
hereof and thereof, including the making or granting of the Loans and the delivery of the Notes and the other Loan Documents, and shall further survive until all of the Obligations are paid in full to
each Lender Party and all of Lender Parties' obligations to Borrower are terminated. All statements and agreements contained in any certificate or other instrument delivered by any Restricted Person
to any Lender Party under any Loan
Document shall be deemed representations and warranties by Borrower or agreements and covenants of Borrower under this Agreement. The representations, warranties, indemnities, and covenants made by
Restricted Persons in the Loan Documents, and the rights, powers, and privileges granted to Lender Parties in the Loan Documents, are cumulative, and, except for expressly specified waivers and
consents, no Loan Document shall be construed in the context of another to diminish, nullify, or otherwise reduce the benefit to any Lender Party of any such representation, warranty, indemnity,
covenant, right, power or privilege. In particular and without limitation, no exception set out in this Agreement to any representation, warranty, indemnity, or covenant herein contained shall apply
to any similar representation, warranty, indemnity, or covenant contained in any other Loan Document, and each such similar representation, warranty, indemnity, or covenant shall be subject only to
those exceptions which are expressly made applicable to it by the terms of the various Loan Documents. 

        Section 10.3.    Notices.    All notices, demands, approvals, consents and other communications to be made
under any Loan Document to or by the parties thereto must, to be effective for purpose of such Loan Document, be in writing. Notices, demands and other communications required or permitted 

37

 

under any Loan Document are to be sent to Borrower and Restricted Persons at the address of Borrower specified on the signature pages hereto and to each Lender Party at its address specified on the
Lenders Schedule and shall be given by any of the following means: (A) personal service, with proof of delivery or attempted delivery retained; (B) electronic communication, whether by
telex, telegram or telecopying (if confirmed in writing sent by United States first class mail, return receipt requested); or (C) registered or certified first class mail, return receipt
requested. Such addresses may be changed by notice to the other parties given in the same manner as provided above. Any notice or other communication sent pursuant to clause (A) or
(B) hereof shall be deemed received upon such personal service or upon dispatch by electronic means, and, if sent pursuant to clause (C) shall be deemed received five days following
deposit in the mail; provided, however, that no Borrowing Notice shall become effective until actually received by Agent. 

        Section 10.4.    Payment of Expenses; Indemnity.    

        (a)  Payment of Expenses. Whether or not the transactions contemplated by this Agreement are consummated, Borrower will
promptly (and in any event, within 30 days after any invoice or other statement or notice) pay: (i) all transfer, stamp, mortgage, documentary or other similar taxes, assessments or
charges levied by any governmental or revenue authority in respect of this Agreement or any of the other Loan Documents or any other document or transaction referred to herein or therein,
(ii) all reasonable costs and expenses incurred by or on behalf of Agent (including without limitation attorneys' fees, consultants' fees and engineering fees, travel costs and miscellaneous
expenses) in connection with (1) the negotiation, preparation, execution and delivery of the Loan Documents, and any and all consents, waivers or other documents or instruments relating
thereto, (2) the filing, recording, refiling and re-recording of any Loan Documents and any other documents or instruments or further assurances required to be filed or recorded or
refiled or re-recorded by the terms of any Loan Document, (3) the borrowings hereunder and other action reasonably required in the course of administration hereof,
(4) monitoring or confirming (or preparation or negotiation of any document related to) any Restricted Person's compliance with any covenants or conditions contained in this Agreement or in any
Loan Document, and (iii) all reasonable costs and expenses incurred by or on behalf of any Lender Party (including without limitation attorneys' fees, consultants' fees and
accounting fees) in connection with the defense or enforcement of any of the Loan Documents (including this section), any attempt to cure any breach thereunder by any Restricted Person, or the defense
of any Lender Party's exercise of its rights thereunder. In addition to the foregoing, until all Obligations have been paid in full, Borrower will also pay or reimburse Agent for all reasonable
out-of-pocket costs and expenses of Agent or its agents or employees in connection with the continuing administration of the Loans and the related due diligence of Agent,
including travel and miscellaneous expenses and fees and expenses of Agent's outside counsel, reserve engineers and consultants engaged in connection with the Loan Documents. 

        (b)  Indemnity. Borrower agrees to indemnify each Lender Party, upon demand, from and against any and all liabilities,
obligations, broker's fees, claims, losses, damages, penalties, fines, actions, judgments, suits, settlements, costs, expenses or disbursements (including reasonable fees of attorneys, accountants,
experts and advisors) of any kind or nature whatsoever (in this section collectively called "liabilities and costs") which to any extent (in whole or in part) may be imposed on, incurred by, or
asserted against such Lender Party growing out of, resulting from or in any other way associated with any of the Collateral, the Loan Documents and the transactions and events (including the
enforcement or defense thereof) at any time associated therewith or contemplated therein (whether arising in contract or in tort or otherwise). Among other things, the foregoing indemnification covers
all liabilities and costs incurred by any Lender Party related to any breach of a Loan Document by a Restricted Person, any bodily injury to any Person or damage to any Person's property, or any
violation or noncompliance with any Environmental Laws by any Lender Party or any other Person or  

38

 

 any liabilities or duties of any Lender Party or any other Person with respect to Hazardous Substances found in or released into the environment.

        THE FOREGOING INDEMNIFICATION SHALL APPLY WHETHER OR NOT SUCH LIABILITIES AND COSTS ARE IN ANY WAY OR TO ANY EXTENT OWED, IN WHOLE OR IN PART, UNDER ANY CLAIM OR
THEORY OF STRICT LIABILITY OR CAUSED, IN WHOLE OR IN PART BY ANY NEGLIGENT ACT OR OMISSION OF ANY KIND BY ANY LENDER PARTY,

provided
only that no Lender Party shall be entitled under this section to receive indemnification for that portion, if any, of any liabilities and costs which is proximately caused by its own
individual gross negligence or willful misconduct, as determined in a final judgment. If any Person (including Borrower or any of its Affiliates) ever alleges such gross negligence or willful
misconduct by any Lender Party, the indemnification provided for in this section shall nonetheless be paid upon demand, subject to later adjustment or reimbursement, until such time as a court of
competent jurisdiction enters a final judgment as to the extent and effect of the alleged gross negligence or willful misconduct. As used in this section the term "Lender Party" shall refer not only
to each Person designated as such in Section 1.1 but also to each director, officer, agent, trustee, attorney, employee, representative and Affiliate of or for such Person. 

        Notwithstanding
the foregoing, for purposes of this section, Losses will not include and Borrower will not be required to pay (i) income taxes on the interest accruing on, or the
fee income required to be paid in connection with, the Loans, or (ii) legal fees or other costs incurred or suffered by anyone other
than Agent in connection with the negotiation or execution of this Agreement or in connection with due diligence undertaken before the execution of this Agreement. Losses will include, however, income
taxes payable by any Lender Party because of Borrower's payment or reimbursement of other Losses suffered by such Lender Party, to the extent (if any) such additional taxes are not offset by tax
savings to such Lender Party because of the other Losses paid or reimbursed by Borrower. 

        Further,
if any Lender Party receives a refund of Losses paid on its behalf or reimbursed to it by Borrower pursuant to this section, such Lender Party shall promptly shall pay to
Borrower the amount of such refund, plus or minus any net tax benefits or detriments realized by such Lender Party as a result of such refund and such payment to Borrower; provided, that the amount
payable to Borrower shall not exceed the amount of the indemnity payment in respect of such refunded Losses that was made by Borrower. If it is subsequently determined that the Lender Party was not
entitled to the refund, the portion of such refund that is repaid or recaptured will be treated as a Loss for which Borrower must indemnify such Lender Party pursuant to this section. If, in
connection any such refund, a Lender Party also receives an amount representing interest on the refund, the Lender Party shall promptly pay to Borrower the amount of such interest, plus or minus any
net tax benefits or detriments realized by the Lender Party as a result of the receipt or accrual of such interest and as a result of the such payment to Borrower; provided, that no Lender Party will
be required to make any such payment in respect of the interest (if any) that is fairly attributable to a period before Borrower paid for or reimbursed the Losses refunded. As used in this paragraph,
the term "tax benefit" will not include a reduction of taxes that are subject to indemnification by Borrower pursuant to this section except to the extent (if any) that Borrower has previously paid or
reimbursed such taxes. As used in this paragraph, the term "refund" shall be deemed to include credits to the extent they actually reduce taxes that would otherwise be payable by the Lender Party
receiving such credits and that are not subject to indemnification by Borrower pursuant to this section. Notwithstanding the foregoing, in no event shall any Lender Party be required to make any
payment to Borrower pursuant to the foregoing provisions when any Event of Default has occurred and is continuing. 

        Section 10.5.    Joint and Several Liability; Parties in Interest; Assignments.    

        (a)  All
Obligations which are incurred by two or more Restricted Persons shall be their joint and several obligations and liabilities. All grants, covenants and agreements
contained in the Loan 

39

 

Documents shall bind and inure to the benefit of the parties thereto and their respective successors and assigns; provided, however, that no Restricted Person may assign or transfer any of its rights
or delegate any of its duties or obligations under any Loan Document without the prior consent of Majority Lenders. Neither Borrower nor any Affiliates of Borrower shall directly or indirectly
purchase or otherwise retire any Obligations owed to any Lender nor will any Lender accept any offer to do so, unless each Lender shall have received substantially the same offer with respect to the
same Percentage Share of the Obligations owed to it. If Borrower or any Affiliate of Borrower at any time purchases some but less than all of the Obligations owed to all Lender Parties, such purchaser
shall not be entitled to any rights of any Lender under the Loan Documents unless and until Borrower or its Affiliates have purchased all of the Obligations. 

        (b)  No
Lender shall sell any participation interest in its commitment hereunder or any of its rights under its Loans or under the Loan Documents to any Person unless the
agreement between such Lender and such participant at all times provides: (i) that such participation exists only as a result of the agreement between such participant and such Lender and that
such transfer does not give such participant any right to vote as a Lender or any other direct claims or rights against any Person other than such Lender, (ii) that such participant is not
entitled to payment from any Restricted Person under Sections 3.2 through 3.6 of amounts in excess of those payable to such Lender under such sections (determined without regard to the sale of such
participation), and (iii) unless such participant is an Affiliate of such Lender, that such participant shall not be entitled to require such Lender to take any action under any Loan Document
or to obtain the consent of such participant prior to taking any action under any Loan Document, except for actions which would require the consent of all Lenders under subsection (a) of
Section 10.1. No Lender selling such a participation shall, as between the other parties hereto and such Lender, be relieved of any of its obligations hereunder as a result of the sale of such
participation. Each Lender which sells any such participation to any Person (other than an Affiliate of such Lender) shall give prompt notice thereof to Agent and Borrower. 

        (c)  Except
for sales of participations under the immediately preceding subsection, no Lender shall make any assignment or transfer of any kind of its commitments or any of
its rights under its Loans or under the Loan Documents, except for assignments to an Eligible Transferee, and then only if such assignment is made in accordance with the following requirements: 

          (i)  Each
such assignment shall apply to all Obligations owing to the assignor Lender hereunder and to the unused portion of the assignor Lender's commitments, so that after
such assignment is made the assignor Lender shall have a fixed (and not a varying) Percentage Share in its Loans and Note and be committed to make that Percentage Share of all future Loans, the
assignee shall have a fixed Percentage Share in such Loans and Note and be committed to make that Percentage Share of all future Loans, and the Percentage Share of the Maximum Credit Amount of both
the assignor and assignee shall equal or exceed $5,000,000. 

        (ii)  The
parties to each such assignment shall execute and deliver to Agent, for its acceptance and recording in the "Register" (as defined below in this section), an
Assignment and Acceptance in the form of Exhibit F, appropriately completed, together with the Note subject to such assignment and a processing fee payable to Agent of $2,500. Upon such
execution, delivery, and payment and upon the satisfaction of the conditions set out in such Assignment and Acceptance, then (1) Borrower shall issue new Notes to such assignor and assignee
upon return of the old Notes to Borrower, and (2) as of the "Settlement Date" specified in such Assignment and Acceptance the assignee thereunder shall be a party hereto and a Lender hereunder
and Agent shall thereupon deliver to Borrower and each Lender a schedule showing the revised Percentage Shares of such assignor Lender and such assignee Lender and the Percentage Shares of all other
Lenders. 

40

 

        (iii)  Each
assignee Lender which is not a United States person (as such term is defined in Section 7701(a)(30) of the Internal Revenue Code) for Federal income tax
purposes, shall (to the extent
it has not already done so) provide Agent and Borrower with the "Prescribed Forms" referred to in Section 3.6(d). 

        (d)  Nothing
contained in this section shall prevent or prohibit any Lender from assigning or pledging all or any portion of its Loans and Note to any Federal Reserve Bank as
collateral security pursuant to Regulation A of the Board of Governors of the Federal Reserve System and any Operating Circular issued by such Federal Reserve Bank; provided that no such
assignment or pledge shall relieve such Lender from its obligations hereunder. 

        (e)  By
executing and delivering an Assignment and Acceptance, each assignee Lender thereunder will be confirming to and agreeing with Borrower, Agent and each other Lender
Party that such assignee understands and agrees to the terms hereof, including Article IX hereof. 

        (f)    Agent
shall maintain a copy of each Assignment and Acceptance and a register for the recordation of the names and addresses of Lenders and the Percentage Shares of, and
principal amount of the Loans owing to, each Lender from time to time (in this section called the "Register"). The entries in the Register shall be conclusive, in the absence of manifest error, and
Borrower and each Lender Party may treat each Person whose name is recorded in the Register as a Lender hereunder for all purposes. The Register shall be available for inspection by Borrower or any
Lender Party at any reasonable time and from time to time upon reasonable prior notice. 

        Section 10.6.    Confidentiality.    Agent and each Lender (each, a "Lending
Party") agrees to keep confidential any information furnished or made available to it by any Restricted Person pursuant to this Agreement that is marked confidential;  provided
that nothing herein shall prevent any Lending Party from disclosing such information (a) to any other Lending Party or any Affiliate of
any Lending Party, or any officer, director, employee, agent, or advisor of any Lending Party or Affiliate of any Lending Party, (b) to any other Person if reasonably incidental to the
administration of the credit facility provided herein, (c) as required by any Law, (d) upon the order of any court or administrative agency, (e) upon the request or demand of any
Tribunal, (f) that is or becomes available to the public or that is or becomes available to any Lending Party other than as a result of a disclosure by any Lending Party prohibited by this
Agreement, (g) in connection with any litigation to which such Lending Party or any of its Affiliates may be a party, (h) to the extent necessary in connection with the exercise of any
right or remedy under this Agreement or any other Loan Document, and (i) subject to provisions substantially similar to those contained in this section, to any actual or proposed participant or
assignee. 

        Section 10.7.    Governing Law.    Except to the extent that the Law of another
jurisdiction is expressly elected in a Loan Document, the Loan Documents shall be deemed contracts and instruments made under the Laws of the State of California and shall be construed and enforced in
accordance with and governed by the Laws of the State of California and the Laws of the United States of America, without regard to principles of conflicts of law.

        Section 10.8.    Limitation on Interest.    Lender Parties, Restricted Persons and the other parties to the
Loan Documents intend to contract in strict compliance with applicable usury Law from time to time in effect. In furtherance thereof such persons stipulate and agree that none of the terms and
provisions contained in the Loan Documents shall ever be construed to provide for interest in excess of the maximum amount of interest permitted to be contracted for, charged, or received by
applicable Law from time to time in effect. Neither any Restricted Person nor any present or future guarantors, endorsers, or other Persons hereafter becoming liable for payment of any Obligation
shall ever be liable for unearned interest thereon or shall ever be required to pay interest thereon in excess of the maximum amount that may be lawfully contracted for, charged, or received under
applicable Law from 

41

 

time to time in effect, and the provisions of this section shall control over all other provisions of the Loan Documents which may be in conflict or apparent conflict herewith. 

        Section 10.9.    Termination; Limited Survival.    In its sole and absolute discretion Borrower may at any time
that no Obligations are owing elect in a written notice delivered to Agent to terminate this Agreement. Upon receipt by Agent of such a notice, if no Obligations are then owing this Agreement and all
other Loan Documents shall thereupon be terminated and the parties thereto released from all prospective obligations thereunder. Notwithstanding the foregoing or anything herein to the contrary, any
waivers or admissions made by any Restricted Person in any Loan Document, any Obligations under Sections 3.2 through 3.6, and any obligations which any Person may have to indemnify or compensate any
Lender Party shall survive any termination of this Agreement or any other Loan Document. At the request and expense of Borrower, Agent shall prepare and execute all necessary instruments to reflect
and effect such termination of the Loan Documents. Agent is hereby authorized to execute all such instruments on behalf of all Lenders, without the joinder of or further action by any Lender. 

        Section 10.10.    Severability.    If any term or provision of any Loan Document or the application thereof
shall to any extent be held by a court of competent jurisdiction to be invalid and unenforceable, the remainder of such document, or the application of such term or provision other than to the extent
to which it is invalid or unenforceable, shall not be affected thereby. 

        Section 10.11.    Counterparts; Fax.    This Agreement may be separately executed in any number of counterparts
and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to constitute one and the same Agreement. This Agreement and the Loan Documents may be validly
executed and delivered by facsimile or other electronic transmission. 

        Section 10.12.    Waiver of Jury Trial, Punitive Damages, etc.    Borrower and each
Lender Party hereby knowingly, voluntarily, intentionally, and irrevocably (a) waives, to the maximum extent not prohibited by Law, any right it may have to a trial by jury in respect of any
litigation based hereon, or directly or indirectly at any time arising out of, under or in connection with the Loan Documents or any transaction contemplated thereby or associated therewith, before or
after maturity; (b waives, to the maximum extent not prohibited by Law, any right it may have to claim or recover in any such litigation any "Special Damages", as defined below,
(c) certifies that no party hereto nor any representative or agent or counsel for any party hereto has represented, expressly or otherwise, or
implied that such party would not, in the event of litigation, seek to enforce the foregoing waivers, and (d) acknowledges that it has been induced to enter into this Agreement, the other Loan
Documents and the transactions contemplated hereby and thereby by, among other things, the mutual waivers and certifications contained in this section. As used in this section, "Special Damages"
includes all special, consequential, exemplary, or punitive damages (regardless of how named), but does not include any payments or funds which any party hereto has expressly promised to pay or
deliver to any other party hereto.

42

 

        IN
WITNESS WHEREOF, this Agreement is executed as of the date first written above. 

	 	 	SPECIALTY LABORATORIES, INC.

Borrower
	

 	
 	

By:	
 	

 
	 	 	 	 	/s/ Frank J. Spina
 Name: Frank J. Spina

Title: Chief Financial Officer
	

 	
 	

Address:

2211 Michigan Avenue

Santa Monica, California 90404

Attention: Frank J. Spina

Fax: (310) 586-7235

43

 

	 	 	BNP PARIBAS

Agent and Lender
	

 	
 	

By:	
 	

/s/  C. DAVID YATES      
	 	 	 	 	
 Name:    C. David Yates

Title:    Managing Director
	

 	
 	

Address:
	

 	
 	

787 7th Avenue, 32nd Floor

New York, New York 10019

Attention: Brock Harris

Fax: (212) 841-2292

 With a copy to:
	

 	
 	

Three Ravinia Drive

Suite 1750

Atlanta, Georgia 30346

Attention: David Yates

Fax: (770) 350-5922

44

 

	 	 	UNION BANK OF CALIFORNIA, N.A.,

Lender
	

 	
 	

By:	
 	

/s/  RICHARD A. MADSEN      
	 	 	 	 	
 Name:    Richard A. Madsen

Title:    Regional Vice President
	

 	
 	

Address:

445 South Figueroa Street, 10th Floor

MC: G10-080

Los Angeles, CA 90071

Attention: Richard A. Madsen

Fax: (213) 236-4013

45

 

	 	 	U.S. BANK NATIONAL ASSOCIATION,

Lender
	

 	
 	

By:	
 	

/s/  CHRISTIAN E. STEIN III      
	 	 	 	 	
 Name:    Christian E. Stein III

Title:    Vice President
	

 	
 	

Address:

One U.S. Bank Plaza

7th & Washington

St. Louis, MO 63101

Attention: Christian E. Stein III

Fax: (314) 481-8394

46

 

	 	 	ALLIED IRISH BANKS, P.L.C.,

Lender
	

 	
 	

By:	
 	

/s/  HILARY PATTERSON      
	 	 	 	 	
 Name:    Hilary Patterson

Title:    Vice President
	

 	
 	

By:	
 	

/s/  TONY O'REILLY      
	 	 	 	 	
 Name:    Tony O'Reilly

Title:    Vice President
	

 	
 	

Address:

AIB Corporate Banking NY

Allied Irish Banks plc

Suite 1005

405 Park Avenue

New York, New York 10022

Attention: Hilary Patterson

Fax: (212) 339.8325

47

 

	 	 	BANK LEUMI USA,

Lender
	

 	
 	

By:	
 	

/s/  JACQUES V. DELVOYE      
	 	 	 	 	
 Name:    Jacques V. Delvoye

Title:    Vice President
	

 	
 	

Address:

8383 Wilshire Blvd. #400

Beverly Hills, California 90211

Attention: Jacques Delvoye

Fax: (323) 966 4248

48

 

	 	 	MANUFACTURERS BANK, A California Banking Corporation, Lender
	

 	
 	

By:	
 	

/s/  SANDY LEE      
	 	 	 	 	
 Name:    Sandy Lee

Title:    Vice President
	

 	
 	

Address:

515 S. Figueroa Street

Los Angeles, CA 90071

Attention: Sandy Lee

Fax: (213) 489-6028

49

 

	 	 	FIRST UNION NATIONAL BANK,

Lender
	

 	
 	

By:	
 	

/s/  DOUGLAS T. DAVIS      
	 	 	 	 	
 Name:    Douglas T. Davis

Title:    Director
	

 	
 	

Address:

One Wachovia Center, 5th Floor

301 South College Street NC 0760

Charlotte, NC 28288-0760

Attention: Kirk Tesch

Fax: (704) 374-4793

50

SCHEDULE 1  

 
 

DISCLOSURE SCHEDULE    
  

        To supplement the following sections of the Agreement of which this Schedule is a part, Borrower hereby makes the following disclosures: 

	Section 5.6.	 	Initial Financial Statements:
	

 	
 	

[None.]
	

Section 5.7.	
 	
Other Obligations and Restrictions:
	

 	
 	

[None.]
	

Section 5.9.	
 	
Litigation:
	

 	
 	

[None.]
	

Section 5.10.	
 	
Labor Disputes and Acts of God:
	

 	
 	

[None.]
	

Section 5.11.	
 	
ERISA Plans and Liabilities:
	

 	
 	

[None.]
	

Section 5.12.	
 	
Environmental and Other Laws:
	

 	
 	

[None.]
	

Section 5.13.	
 	
Names and Places of Business:
	

 	
 	

[None.]
	

Section 5.14.	
 	
Borrower's Subsidiaries:
	

 	
 	

BVI Specialty Laboratories International, Ltd. ("SLIL"), which is a wholly-owned Subsidiary of Borrower
	 	 	Specialty Laboratories Asia Private, Ltd., which is 60% owned by SLIL, with the remaining 40% owned by partners that are not Affiliates of Borrower.
	

Section 7.1.	
 	
Existing Indebtedness:
	

 	
 	

Approximately $2.5 million in long term liabilities attributable to deferred compensation, annuity payments to a former employee and software installment costs.

SCHEDULE 2  

 
 

SECURITY SCHEDULE    
  

        1.    Security
Agreement of even date herewith executed by Borrower in favor of Agent for the benefit of Lenders. 

        2.    Financing
Statement naming Borrower as debtor and Agent as secured party filed with the Secretary of State of California. 

SCHEDULE 4  

 
 

LENDERS SCHEDULE    
  

	 
	 	Percentage Share
	 	Amount

	Domestic Lending Office:	 	 	 	 	 
	

BNP Paribas

787 7th Avenue, 32nd Floor

New York, New York 10019

Attention: Brock Harris

Fax: (212) 841-2292	
 	

20	
%	
$	

8,000,000
	
With a copy to:	
 	

 	
 	
 	

 
	

Three Ravinia Drive

Suite 1750

Atlanta, Georgia 30346

Attention: David Yates

Fax: (770) 350-5922	
 	

 	
 	
 	

 
	
Eurodollar Lending Office:	
 	

 	
 	
 	

 
	

Same.	
 	

 	
 	
 	

 
	
Domestic Lending Office:	
 	

 	
 	
 	

 
	

Union Bank of California, N.A.

445 South Figueroa Street, 10th Floor

MC: G10-080

Los Angeles, CA 90071

Attention: Richard A. Madsen

Fax: (213) 236-4013	
 	

20	
%	
$	

8,000,000
	
Eurodollar Lending Office:	
 	

 	
 	
 	

 
	

Same.	
 	

 	
 	
 	

 
	
Domestic Lending Office:	
 	

 	
 	
 	

 
	

U.S. Bank National Association

One U.S. Bank Plaza

7th & Washington

St. Louis, MO 63101

Attention: Christian E. Stein III

Fax: (314) 481-8394	
 	

20	
%	
$	

8,000,000
	
Eurodollar Lending Office:	
 	

 	
 	
 	

 
	

Same.	
 	

 	
 	
 	

 
	
 	
 	

 	
 	
 	

 

 

	
Domestic Lending Office:	
 	

 	
 	
 	

 
	

First Union National Bank

One Wachovia Center, 5th Floor

301 South College Street NC 0760

Charlotte, NC 28288-0760

Attention: Kirk Tesch

Fax: (704) 374-4793	
 	

20	
%	
$	

8,000,000
	
Eurodollar Lending Office:	
 	

 	
 	
 	

 
	

Same.	
 	

 	
 	
 	

 
	
Domestic Lending Office:	
 	

 	
 	
 	

 
	

Allied Irish Banks p.l.c.

AIB Corporate Banking NY

Allied Irish Banks plc

Suite 1005

405 Park Avenue

New York, New York 10022

Attention: Hilary Patterson

Fax: (212) 339.8325	
 	

10	
%	
$	

4,000,000
	
Eurodollar Lending Office:	
 	

 	
 	
 	

 
	

Same.	
 	

 	
 	
 	

 
	
Domestic Lending Office:	
 	

 	
 	
 	

 
	

Manufacturers Bank, A California Banking Corporation

515 S. Figueroa Street

Los Angeles, CA 90071

Attention: Sandy Lee

Fax: (213) 489-6028	
 	

5	
%	
$	

2,000,000
	
Eurodollar Lending Office:	
 	

 	
 	
 	

 
	

Same.	
 	

 	
 	
 	

 
	
Domestic Lending Office:	
 	

 	
 	
 	

 
	

Bank Leumi USA

8383 Wilshire Blvd. #400

Beverly Hills, California 90211

Attention: Jacques Delvoye

Fax: (323) 966 4248	
 	

5	
%	
$	

2,000,000
	
Eurodollar Lending Office:	
 	

 	
 	
 	

 
	

Same.	
 	

 	
 	
 	

 

2

  

EXHIBIT A  

 
 

PROMISSORY NOTE    
  

	 	 	 	 	 
	$                  	 	Santa Monica, California	 	*[Date]

        FOR
VALUE RECEIVED, the undersigned, Specialty Laboratories, Inc., a California corporation (herein called "Borrower"), hereby promises to pay to the order
of                        , a
*[                        state banking corporation] *[national banking association] (herein called "Lender"), the principal sum
of                        Dollars ($
                        ), or, if greater or less, the aggregate unpaid principal amount of the Loan made under this Note by
Lender to Borrower pursuant to the terms of the Credit Agreement (as hereinafter
defined), together with interest on the unpaid principal balance thereof as hereinafter set forth, both principal and interest payable as herein provided in lawful money of the United States of
America at the offices of Agent under the Credit Agreement,                        or at such other place within New York, New
York, as from time to time may be designated by the holder of this Note. 

        This
Note (a) is issued and delivered under that certain Credit Agreement dated as of March 22, 2002 among Borrower, BNP Paribas, as Agent, and the lenders (including
Lender) referred to therein
(herein, as from time to time supplemented, amended or restated, called the "Credit Agreement"), and is a "Note" as defined therein, (b) is subject to the terms and provisions of the Credit
Agreement, which contains provisions for payments and prepayments hereunder and acceleration of the maturity hereof upon the happening of certain stated events, and (c) is secured by and
entitled to the benefits of certain Security Documents (as identified and defined in the Credit Agreement). Payments on this Note shall be made and applied as provided herein and in the Credit
Agreement. Reference is hereby made to the Credit Agreement for a description of certain rights, limitations of rights, obligations and duties of the parties hereto and for the meanings assigned to
terms used and not defined herein and to the Security Documents for a description of the nature and extent of the security thereby provided and the rights of the parties thereto. 

        The
principal amount of this Note, together with all interest accrued hereon, shall be due and payable in full
on                        , 2005. 

        So
long as no Event of Default has occurred and is continuing, all Base Rate Loans (exclusive of any past due principal or interest) from time to time outstanding shall bear interest on
each day outstanding at the Base Rate in effect on such day. If an Event of Default has occurred and is continuing, all Base Rate Loans (exclusive of any past due principal or interest) from time to
time outstanding shall bear interest on each day outstanding at the applicable Default Rate in effect on such day. On each Interest Payment Date Borrower shall pay to the holder hereof all unpaid
interest which has accrued on the Base Rate Loans to but not including such Interest Payment Date. So long as no Event of Default has occurred and is continuing, each Eurodollar Loan (exclusive of any
past due principal or interest) shall bear interest on each day during the related Interest Period at the related Adjusted LIBOR Rate in effect on such day. If an Event of Default has occurred and is
continuing, all Eurodollar Loans (exclusive of any past due principal or interest) from time to time outstanding shall bear interest on each day outstanding at the applicable Default Rate in effect on
such day. On each Interest Payment Date relating to such Eurodollar Loan, Borrower shall pay to the holder hereof all unpaid interest which has accrued on such Eurodollar Loan to but not including
such Interest Payment Date. All past due principal of and past due interest on the Loans shall bear interest on each day outstanding at the Default Rate in effect on such day, and such interest shall
be due and payable daily as it accrues. Notwithstanding the foregoing provisions of this paragraph: (a) this Note shall never bear interest in excess of the Highest Lawful Rate, and
(b) if at any time the rate at which interest is payable on this Note is limited by the Highest Lawful Rate (by the foregoing subsection (a) or by 

1

 

reference to the Highest Lawful Rate in the definitions of Base Rate, LIBOR Rate, and Default Rate), this Note shall bear interest at the Highest Lawful Rate and shall continue to bear interest at
the Highest Lawful Rate until such time as the total amount of interest accrued hereon equals (but does not exceed) the total amount of interest which would have accrued hereon had there been no
Highest Lawful Rate applicable hereto. 

        Notwithstanding
the foregoing paragraph and all other provisions of this Note, in no event shall the interest payable hereon, whether before or after maturity, exceed the maximum
interest which, under applicable Law, may be contracted for, charged, or received on this Note, and this Note is expressly made subject to the provisions of the Credit Agreement which more fully set
out the limitations on how interest accrues hereon. 

        If
this Note is placed in the hands of an attorney for collection after default, or if all or any part of the indebtedness represented hereby is proved, established or collected in any
court or in any bankruptcy, receivership, debtor relief, probate or other court proceedings, Borrower and all endorsers, sureties and guarantors of this Note jointly and severally agree to pay
reasonable attorneys' fees and collection costs to the holder hereof in addition to the principal and interest payable hereunder. 

        Borrower
and all endorsers, sureties and guarantors of this Note hereby severally waive demand, presentment, notice of demand and of dishonor and nonpayment of this Note, protest, notice
of protest, notice of intention to accelerate the maturity of this Note, declaration or notice of acceleration of the maturity of this Note, diligence in collecting, the bringing of any suit against
any party and any notice of or defense on account of any extensions, renewals, partial payments or changes in any manner of or in this Note or in any of its terms, provisions and covenants, or any
releases or substitutions of any security, or any delay, indulgence or other act of any trustee or any holder hereof, whether before or after maturity. 

        This
Note and the rights and duties of the parties hereto shall be governed by the Laws of the State of California (without regard to principles of conflicts of law), except to the
extent the same are governed by applicable federal Law. 

	 	 	SPECIALTY LABORATORIES, INC.
	

 	
 	

By:	
 	

 
	 	 	 	 	
 Name:

Title:

2

EXHIBIT B  

 
 

BORROWING NOTICE    
  

        Reference is made to that certain Credit Agreement dated as of March 26, 2002 (as from time to time amended, the "Agreement"), by and among Specialty
Laboratories, Inc. ("Borrower"), BNP Paribas, as Agent, and certain financial institutions ("Lenders"). Terms which are defined in the Agreement are used herein with the meanings given them in
the Agreement. Pursuant to the terms of the Agreement Borrower hereby requests a Borrowing of new Loans to be advanced pursuant to Section 2.2(a) of the Agreement as follows: 

	Aggregate amount of Borrowing:	 	$                  
	

Type of Loans in Borrowing:	
 	

 
	

Date on which Loans are to be advanced:	
 	

 
	

Length of Interest Period for Eurodollar Loans (1, 3 or 6 months):	
 	

months
	

If combined with existing Loans see attached Continuation/Conversion Notice.	
 	

 

        To
induce Lenders to make such Loans, Borrower hereby represents, warrants, acknowledges, and agrees to and with Agent and each Lender that: 

        (a)  The
officer of Borrower signing this instrument is the duly elected, qualified and acting officer of Borrower as indicated below such officer's signature hereto having
all necessary authority to act for Borrower in making the request herein contained. 

        (b)  The
representations and warranties of Borrower set forth in the Agreement and the other Loan Documents are true and correct on and as of the date hereof (except to the
extent that the facts on which such representations and warranties are based have been changed by the extension of credit under the Agreement), with the same effect as though such representations and
warranties had been made on and as of the date hereof. 

        (c)  There
does not exist on the date hereof any condition or event which constitutes a Default which has not been waived in writing as provided in Section 10.1(a) of
the Agreement; nor will any such Default exist upon Borrower's receipt and application of the Advances requested hereby. Borrower will use the Advances hereby requested in compliance with
Section 2.4 of the Agreement*[.] *[for the following purposes:] 

        (d)  Except
to the extent waived in writing as provided in Section 10.1(a) of the Agreement, Borrower has performed and complied with all agreements and conditions in
the Agreement required to be performed or complied with by Borrower on or prior to the date hereof, and each of the conditions precedent to Advances contained in the Agreement remains satisfied. 

        (e)  The
aggregate outstanding amount of the Loans, after the making of the Loans requested hereby, will not be in excess of the Borrowing Base on the date requested for the
making of such Loans. 

        (f)    The
Loan Documents have not been modified, amended or supplemented by any unwritten representations or promises, by any course of dealing, or by any other means not
provided for in Section 10.1(a) of the Agreement. The Agreement and the other Loan Documents are hereby ratified, approved, and confirmed in all respects. 

        The
officer of Borrower signing this instrument hereby certifies that, to the best of his knowledge after due inquiry, the above representations, warranties, acknowledgments, and
agreements of Borrower are true, correct and complete. 

 

        IN
WITNESS WHEREOF, this instrument is executed as of                        , 20    . 

	

 	
 	

 	
 	

 
	

 	
 	

SPECIALTY LABORATORIES, INC.
	

 	

 	

By:	

 	

 
	

 	
 	

 	
 	

 Name:

Title:

2

EXHIBIT C  

 
 

CONTINUATION/CONVERSION NOTICE    
  

        Reference is made to that certain Credit Agreement dated as of March 26, 2002 (as from time to time amended, the "Agreement"), by and among Specialty
Laboratories, Inc. ("Borrower"), BNP Paribas, as Agent, and the lenders referred to therein ("Lenders"). Terms which are defined in the Agreement are used herein with the meanings given them in
the Agreement. 

        Borrower
hereby requests a Conversion or Continuation of existing Loans into a new Borrowing pursuant to Section 2.3 of the Agreement as follows: 

        Existing
Borrowing(s) to be continued or converted: 

        $                  of
Eurodollar Loans with Interest Period ending                  

        $                  of
Base Rate Loans 

        If
being combined with new Loans, $                  of new Loans to be advanced
on                  

	        Aggregate amount of new Borrowing:	 	$                  
	

        Type of Loans in new Borrowing:	
 	

 
	

        Type of Loans in new Borrowing:	
 	

 
	

        Date of Continuation or Conversion:	
 	

 
	

        Length of Interest Period for Eurodollar Loans (1, 3 or

        6 months):	
 	

months

        To
meet the conditions set out in the Agreement for such conversion/continuation, Borrower hereby represents, warrants, acknowledges, and agrees to and with Agent and each Lender that: 

        (a)  The
officer of Borrower signing this instrument is the duly elected, qualified and acting officer of Borrower as indicated below such officer's signature hereto having
all necessary authority to act for Borrower in making the request herein contained. 

        (b)  There
does not exist on the date hereof any condition or event which constitutes a Default which has not been waived in writing as provided in Section 10.1(a) of
the Agreement. 

        (c)  The
Loan Documents have not been modified, amended or supplemented by any unwritten representations or promises, by any course of dealing, or by any other means not
provided for in Section 10.1(a) of the Agreement. The Agreement and the other Loan Documents are hereby ratified, approved, and confirmed in all respects. 

        The
officer of Borrower signing this instrument hereby certifies that, to the best of his knowledge after due inquiry, the above representations, warranties, acknowledgments, and
agreements of Borrower are true, correct and complete. 

        IN
WITNESS WHEREOF this instrument is executed as of                        . 

	

 	
 	

 	
 	

 
	

 	
 	

SPECIALTY LABORATORIES, INC.
	

 	

 	

By:	

 	

 
	

 	
 	

 	
 	

 Name:

Title:

EXHIBIT D  

 
 

CERTIFICATE ACCOMPANYING
  FINANCIAL STATEMENTS    
  

        Reference
is made to that certain Credit Agreement dated as of March 26, 2002 (as from time to time amended, the "Agreement"), by and among Specialty Laboratories, Inc.
("Borrower"), BNP Paribas, as Agent, and certain financial institutions ("Lenders"), which Agreement is in full force and effect on the date hereof. Terms which are defined in the Agreement are used
herein with the meanings given them in the Agreement. 

        This
Certificate is furnished pursuant to Section 6.1(b) of the Agreement. Together herewith Borrower is furnishing to Agent and each Lender Borrower's
*[audited/unaudited] financial statements (the "Financial Statements") as at                        (the "Reporting Date").
Borrower hereby represents, warrants, and acknowledges to
Agent and each Lender that: 

        (a)  the
officer of Borrower signing this instrument is the duly elected, qualified and acting                        of Borrower and as
such is Borrower's chief financial officer; 

        (b)  the
Financial Statements are accurate and complete and satisfy the requirements of the Agreement; 

        (c)  attached
hereto is a schedule of calculations showing Borrower's compliance as of the Reporting Date with the requirements of the financial covenants set forth in
Exhibit H to the Agreement *[and Borrower's non-compliance as of such date with the requirements of the financial covenants set forth in Exhibit H to the
Agreement]; 

        (d)  on
the Reporting Date Borrower was, and on the date hereof Borrower is, in full compliance with the disclosure requirements of Section [6.4] of
the Agreement, and no Default otherwise existed on the Reporting Date or otherwise exists on the date of this instrument *[except for Default(s) under Section(s)
                        of the
Agreement, which *[is/are] more fully described on a schedule attached hereto]. 

        (e)  *[Unless
otherwise disclosed on a schedule attached hereto,] The representations and warranties of Borrower set forth in the Agreement and the
other Loan Documents are true and correct on and as of the date hereof (except to the extent that the facts on which such representations and warranties are based have been changed by the extension of
credit under the Agreement), with the same effect as though such representations and warranties had been made on and as of the date hereof. 

        The
officer of Borrower signing this instrument hereby certifies that he has reviewed the Loan Documents and the Financial Statements and has otherwise undertaken such inquiry as is in
his opinion necessary to enable him to express an informed opinion with respect to the above representations, warranties and acknowledgments of Borrower and, to the best of his knowledge, such
representations, warranties, and acknowledgments are true, correct and complete. 

        IN
WITNESS WHEREOF, this instrument is executed as of                        , 20    . 

	 	 	SPECIALTY LABORATORIES, INC.
	

 	
 	

By:	
 	

 Name:

Title:

EXHIBIT F  

 
 

ASSIGNMENT AND ACCEPTANCE    
  

        Reference
is made to the Credit Agreement dated as of , 20            (the "Credit Agreement") among Specialty
Laboratories, Inc., a California corporation (the "Borrower"), the Lenders (as defined in the Credit Agreement) and BNP Paribas, as agent for the
Lenders (the "Agent"). Terms defined in the Credit Agreement are used herein with the same meaning. 

        The
"Assignor" and the "Assignee" referred to on Schedule 1 agree as follows: 

        1.    The
Assignor hereby sells and assigns to the Assignee, without recourse and without representation or warranty except as expressly set forth herein, and the Assignee
hereby purchases and assumes from the Assignor, an interest in and to the Assignor's rights and obligations under the Credit Agreement and the other Loan Documents as of the date hereof equal to the
percentage interest specified on Schedule 1 of all outstanding rights and obligations under the Credit Agreement and the other Loan Documents. After giving effect to such sale and assignment,
the Assignee's Commitment and the amount of the Loans owing to the Assignee will be as set forth on Schedule 1. 

        2.    The
Assignor (i) represents and warrants that it is the legal and beneficial owner of the interest being assigned by it hereunder and that such interest is free
and clear of any adverse claim; (ii) makes no representation or warranty and assumes no responsibility with respect to any statements, warranties or representations made in or in connection
with the Loan Documents or the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Loan Documents or any other instrument or document furnished pursuant thereto;
(iii) makes no representation or warranty and assumes no responsibility with respect to the financial condition of any Restricted Person or the performance or observance by any Restricted
Person of any of its obligations under the Loan Documents or any other instrument or document furnished pursuant thereto; and (iv) attaches the Note held by the Assignor and requests that Agent
exchange such Note for new Notes payable to the order of the Assignee in an
amount equal to the Commitment assumed by the Assignee pursuant hereto and to the Assignor in an amount equal to the Commitment retained by the Assignor, if any, as specified on Schedule 1. 

        3.    The
Assignee (i) confirms that it has received a copy of the Credit Agreement, together with copies of the financial statements referred to in Section
[            ] thereof and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this Assignment and
Acceptance; (ii) agrees that it will, independently and without reliance upon Agent, the Assignor or any other Lender and based on such documents and information as it shall deem appropriate at
the time, continue to make its own credit decisions in taking or not taking action under the Credit Agreement; (iii) confirms that it is an Eligible Assignee; (iv) appoints and
authorizes Agent to take such action as agent on its behalf and to exercise such powers and discretion under the Credit Agreement as are delegated to Agent by the terms thereof, together with such
powers and discretion as are reasonably incidental thereto; (v) agrees that it will perform in accordance with their terms all of the obligations that by the terms of the Credit Agreement are
required to be performed by it as a Lender; and (vi) attaches any U.S. Internal Revenue Service or other forms required under Section [            ]. 

        4.    Following
the execution of this Assignment and Acceptance, it will be delivered to Agent for acceptance and recording by Agent. The effective date for this Assignment and
Acceptance (the "Effective Date") shall be the date of acceptance hereof by Agent, unless otherwise specified on Schedule 1. 

        5.    Upon
such acceptance and recording by Agent, as of the Effective Date, (i) the Assignee shall be a party to the Credit Agreement and, to the extent provided in
this Assignment and Acceptance, have the rights and obligations of a Lender thereunder and (ii) the Assignor shall, to the extent 

 

provided in this Assignment and Acceptance, relinquish its rights and be released from its obligations under the Credit Agreement. 

        6.    Upon
such acceptance and recording by Agent, from and after the Effective Date, Agent shall make all payments under the Credit Agreement and the Notes in respect of the
interest assigned hereby (including, without limitation, all payments of principal, interest and commitment fees with respect thereto) to the Assignee. The Assignor and Assignee shall make all
appropriate adjustments in payments under the Credit Agreement and the Notes for periods prior to the Effective Date directly between themselves. 

        7.    This
Assignment and Acceptance shall be governed by, and construed in accordance with, the Laws of the State of California. 

        8.    This
Assignment and Acceptance may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed
shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of Schedule 1 to this Assignment and
Acceptance by telecopier shall be effective as delivery of a manually executed counterpart of this Assignment and Acceptance. 

        IN
WITNESS WHEREOF, the Assignor and the Assignee have caused Schedule 1 to this Assignment and Acceptance to be executed by their officers thereunto duly authorized as of the
date specified thereon. 

2

 
 

SCHEDULE 1
  to
  ASSIGNMENT AND ACCEPTANCE    

	Percentage interest assigned:	 	      %
	

Assignee's Commitment:	
 	

$                  
	

Aggregate outstanding principal amount of Loans assigned:	
 	

$                  
	

Principal amount of Note payable to Assignee:	
 	

$                  
	

Principal amount of Note payable to Assignor:	
 	

$                  
	

Effective Date (if other than date of acceptance by Agent):	
 	

*            , 20    

	

 	
 	

 	

 
	

 	
 	

[NAME OF ASSIGNOR], as Assignor
	

 	

 	

By:	

 Title:
	

 	

 	

Dated:                        , 20    
	

 	

 	

[NAME OF ASSIGNEE], as Assignee
	

 	

 	

By:	

 Title:
	

 	

 	

Domestic Lending Office:
	

 	

 	

Eurodollar Lending Office:

	*
	This
date should be no earlier than five Business Days after the delivery of this Assignment and Acceptance to Agent. 

Accepted
[and Approved] **

this    day of                        , 20    

BNP
PARIBAS 

By:  ____________________________________

        Title: 

        **
Required if the Assignee is an Eligible Assignee solely by reason of subsection (iii) of the definition of "Eligible Assignee". 

  

 
 

EXHIBIT G
  Borrowing Base    

        Borrowing
Base Report for period beginning                        and
ending                        ("Current Period") delivered pursuant to that certain Credit Agreement dated as of March 26,
2002 (as from time to time amended, the "Agreement") by and among Specialty Laboratories, Inc., B.P. Paribas, as Agent, and certain financial institutions. Capitalized terms used and not
otherwise defined herein have the meanings given them in the Agreement. 

Accounts
Receivable 

	1.	 	Balance of Accounts as of the end of the Current Period	 	 	 	$
    

Ineligible
Accounts as of the end of the Current Period: 

	2.	 	Accounts more than 60 days from invoice date	 	$
    
	 	 
	

3.	
 	

All of the Accounts of Account Debtor(s) if 20% of the dollar amount of all Accounts of such Account Debtor(s) are ineligible Accounts	
 	

$
    
	
 	

 
	

4.	
 	

That portion of Accounts of Account Debtor(s) in excess of 20% of the dollar amount of the total Accounts for the Current Period (Line 1), except to the extent such portions have previously been excluded under other provisions hereof	
 	

$
    
	
 	

 
	

5.	
 	

Intercompany and Affiliate Accounts	
 	

  
    
	
 	

 
	

6.	
 	

Government Accounts	
 	

  
    
	
 	

 
	

7.	
 	

Accounts subject to any dispute or set off.	
 	

  
    
	
 	

 
	

8.	
 	

Foreign Accounts	
 	

  
    
	
 	

 
	

9.	
 	

Other ineligible Accounts	
 	

  
    
	
 	

 
	

10.	
 	

Total Ineligible Accounts for the Current Period (Add Lines 2 through 9)	
 	

$
    
	
 	

 
	
 	
 	

 	
 	

 	
 	

 

2

 

	

11.	
 	

Total Eligible Accounts for the Current Period (Line 1 - Line 10)	
 	

$
    
	
 	

 
	

12.	
 	

Multiplied by 85% (Borrowing Base)	
 	

$
    
	
 	

 
	

13.	
 	

Aggregate Loan balance per last Borrowing Base Report	
 	

 	
 	

$
    

	

14.	
 	

Less net payments	
 	

 	
 	

$
    

	

15.	
 	

Plus Loans since date of last Borrowing Base Report	
 	

 	
 	

$
    

	

16.	
 	

Total Balance (Line 13 minus line 14 plus line 15)	
 	

 	
 	

$
    

	

17.	
 	

Borrowing Base (Line 12) minus Total Balance (Line 16) which equals the amount available for borrowing, subject to the terms of the Agreement, if positive; or subject to the terms of the Agreement, amount to be repaid, if negative	
 	

 	
 	

$
    

        The
undersigned hereby certifies that the above information and computations are true and correct as of the date hereof and may be relied upon by Lenders as a basis for advancing any
credit to Borrower, and that no Default or Event of Default has occurred and is continuing under the Agreement. 

	

 	
 	

 	
 	

 
	

 	
 	

SPECIALTY LABORATORIES, INC.
	

 	

 	

By:	

 	

 
	

 	
 	

 	
 	

 Name:

3

  

EXHIBIT H  

 
 

FINANCIAL COVENANTS    
  

        This Exhibit H is attached to and made a part of the Credit Agreement dated as of March 26, 2002, among Specialty Laboratories, as borrower (in such
capacity, ABorrower@), BNP Paribas, as Agent, and the lenders referred to therein (as from time to time amended, modified or restated, the ACredit Agreement@). 

 
 

Part I—Defined Terms    
  

        In this Exhibit H, capitalized terms used but not defined herein shall have the meaning assigned to them in the Credit Agreement; and the following
capitalized terms shall have the following meanings: 

        "Adjusted EBITDA" means, for any fiscal period of Borrower, the Net Income for such period, plus the amounts (if any) which, in the
determination of such Net Income have been deducted for (a) interest expense, (b) income tax expense, (c) rent expense under the Operative Documents, (d) depreciation,
(e) amortization, (f) one-time non-recurring expenses, and (g) stock-based compensation. 

        AAdjusted
Current Assets@ means, as of any date of determination, the Consolidated Current Assets minus the sum of (without duplication) (a) the aggregate amount of cash and Cash
Equivalents of Borrower and its properly Consolidated Subsidiaries as of such date plus (b) the aggregate amount of all other unencumbered marketable securities of Borrower and its properly
Consolidated Subsidiaries which are classified as short term investments in accordance with GAAP. 

        ACapital
Expenditures@ means expenditures for the acquisition, construction, improvements or replacement of land, buildings, equipment or other fixed or capital assets or leaseholds. 

        ACash
Collateral Agreement@ means the Pledge Agreement of even date herewith executed in connection with the Operative Documents pursuant to which Borrower has granted a security
interest in cash collateral to secure its obligations under the Operative Documents. 

        "Consolidated Current Assets" means, as of any date of determination, the aggregate Current Assets of Borrower and its properly
Consolidated Subsidiaries. 

        "Consolidated Current Liabilities" means, as of any date of determination, the aggregate Current Liabilities of Borrower and its properly
Consolidated Subsidiaries. 

        "Consolidated Net Worth" means the excess of (a) the Consolidated Total Assets over (b) the Consolidated Total Liabilities. 

        AConsolidated
Senior Debt@ means, as of the date of determination thereof, the aggregate Indebtedness of Borrower and its properly Consolidated Subsidiaries which by its terms or by the
terms of any instrument or agreement relating thereto matures, or which is otherwise payable or unpaid, one year or more from, the date of the creation thereof and which has not been subordinated in
right of payment in any respect to the Obligations. 

        "Consolidated Total Assets" means, as of the date of any determination thereof, the total assets of Borrower and its properly Consolidated
Subsidiaries. 

        "Consolidated Total Liabilities" means, as of the date of any determination thereof, the total Liabilities of Borrower and its properly
Consolidated Subsidiaries. 

        "Current Assets" means, with respect to any Person, all assets of such Person treated as current assets in accordance with GAAP. 

1

 

        "Current Liabilities" means, with respect to any Person, all Liabilities of such Person treated as current Liabilities in accordance with
GAAP, including without limitation (a) all obligations payable on demand or within one year after the date in which the determination is made and (b) installment and sinking fund
payments required to be made within one year after the date on which determination is made, but excluding all such Liabilities or obligations which are renewable or extendable at the option of such
Person to a date more than one year from the date of determination. 

        "Fixed Charges" means, for any fiscal period of Borrower, the sum (without duplication of any item) of the following charges or costs
incurred or paid by Borrower and its properly Consolidated Subsidiaries: (a) gross interest expense, plus (b) amortization of principal, and debt discount in respect of all Indebtedness
during such period, plus (c) rent payable under the Operative Documents during such period, plus (d) cash taxes payable during such period, plus (e) cash dividends paid during
such period. 

        "Net Income" means, for any fiscal period of Borrower, the aggregate net income earned (or net losses incurred) during such period by
Borrower and its properly Consolidated Subsidiaries. 

        "Rolling Four Quarter Period" means a period of four consecutive Fiscal Quarters. 

        AStipulated
Loss Value@ has the meaning given such term in the Operative Documents. 

 
 

Part II—Financial Covenants    
  

        Borrower warrants, covenants and agrees that until the full and final payment of the Obligations and the termination of the Credit Agreement, unless Majority
Lenders have previously agreed otherwise: 

	1.
	Current Ratio. Borrower shall maintain a ratio of Adjusted Current Assets to Consolidated Current Liabilities of
[***]* on the last day of each Fiscal Quarter.

	2.
	Minimum Net Worth. Borrower shall not permit its Consolidated Net Worth as of the last day of each Fiscal Quarter to be less than the
sum of $100,000,000 plus fifty percent of Borrower's Consolidated Net Income (computed without deduction for net losses in any Fiscal Year) earned in each Fiscal Year since the Fiscal Year ending
December 31, 2001.

	3.
	Covenant Senior Leverage Ratio. Borrower shall not permit the ratio of (a) the remainder of
(i) [***]*

	4.
	Minimum Fixed Charge Coverage. Borrower shall not permit the ratio of (a) Adjusted EBITDA for any Rolling Four Quarter Period
minus the aggregate Capital Expenditures made by Borrower and its properly Consolidated Subsidiaries during such Rolling Four Quarter Period to (b) Fixed Charges for the same Rolling Four
Quarter Period, to be [***]*.

	5.
	Capital Expenditures. Borrower shall not permit the aggregate amount of Capital Expenditures made by Borrower and its properly
Consolidated Subsidiaries in any Fiscal Year to exceed [***]*; however, this limitation shall exclude any Capital Expenditures related to
Borrower's construction of its new facility in Valencia, California. 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

2

QuickLinks

CREDIT AGREEMENT

TABLE OF CONTENTS

CREDIT AGREEMENT

ARTICLE I— Definitions and References

ARTICLE II— The Loans

ARTICLE III— Payments to Lenders

ARTICLE IV— Conditions Precedent to Lending

ARTICLE V— Representations and Warranties

ARTICLE VI— Affirmative Covenants of Borrower

ARTICLE VII— Negative Covenants of Borrower

ARTICLE VIII— Events of Default and Remedies

ARTICLE IX—Agent

ARTICLE X—Miscellaneous

DISCLOSURE SCHEDULE

SECURITY SCHEDULE

LENDERS SCHEDULE

PROMISSORY NOTE

BORROWING NOTICE

CONTINUATION/CONVERSION NOTICE

CERTIFICATE ACCOMPANYING FINANCIAL STATEMENTS

ASSIGNMENT AND ACCEPTANCE

SCHEDULE 1 to ASSIGNMENT AND ACCEPTANCE

EXHIBIT G Borrowing Base

FINANCIAL COVENANTS

Part I—Defined Terms

Part II—Financial CovenantsQuickLinks
 -- Click here to rapidly navigate through this document
Exhibit 10.2  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN REDACTED PROVISIONS OF THIS AGREEMENT. THE REDACTED PROVISIONS ARE IDENTIFIED BY THREE ASTERISKS ENCLOSED BY BRACKETS AND
UNDERLINED. THE CONFIDENTIAL PORTIONS HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.  

LEASE AGREEMENT  

BETWEEN  

 BNP PARIBAS LEASING CORPORATION  

 ("BNPPLC")  

 AND  

 SPECIALTY LABORATORIES, INC.  

 ("Specialty Laboratories")  

 March 26, 2002  

 (Santa Clarita, California)  

  

 
 

TABLE OF CONTENTS    
  

	 
	 	 
	 	 
	 	Page

	1.	 	TERM; LEASE RIGHTS AND OBLIGATIONS DEFERRED UNTIL COMPLETION OF INITIAL IMPROVEMENTS; TERMINATION PRIOR TO LEASE COMMENCEMENT	 	2
	 	 	(A)	 	Scheduled Term; Deferral of Rights and Obligations	 	2
	 	 	(B)	 	Option of BNPPLC to Terminate	 	2
	 	 	(C)	 	Automatic Termination After a Failure by Specialty Laboratories to Complete Construction	 	3
	 	 	(D)	 	Option of Specialty Laboratories to Terminate After Accelerating the Designated Sale Date	 	3
	

2.	
 	
USE AND CONDITION OF THE PROPERTY	
 	

3
	 	 	(A)	 	Use	 	3
	 	 	(B)	 	Condition of the Property	 	4
	 	 	(C)	 	Consideration for and Scope of Waiver	 	4
	

3.	
 	
RENT	
 	

4
	 	 	(A)	 	Base Rent Generally	 	4
	 	 	(C)	 	Calculation of and Due Dates for Base Rent	 	5
	 	 	 	 	(1) Determination of Payment Due Dates Generally	 	5
	 	 	 	 	(2) Special Adjustments to Base Rent Payment Dates and Periods	 	5
	 	 	 	 	(3) Base Rent Formula	 	5
	 	 	(D)	 	Administrative Agency Fees	 	6
	 	 	(E)	 	Abatement of Base Rent and Administrative Agency Fees After 97-10/Prepayments	 	6
	 	 	(F)	 	Additional Rent	 	6
	 	 	(G)	 	No Demand or Setoff	 	6
	 	 	(H)	 	Default Interest and Order of Application	 	6
	

4.	
 	
NATURE OF THIS AGREEMENT	
 	

6
	 	 	(A)	 	"Net" Lease Generally	 	6
	 	 	(B)	 	No Termination	 	6
	 	 	(C)	 	Characterization of this Lease	 	7
	

5.	
 	
PAYMENT OF EXECUTORY COSTS AND LOSSES RELATED TO THE PROPERTY	
 	

9
	 	 	(A)	 	Impositions	 	9
	 	 	(B)	 	Increased Costs; Capital Adequacy Charges	 	9
	 	 	(C)	 	Specialty Laboratories' Payment of Other Losses; General Indemnification	 	10
	 	 	(D)	 	Exceptions and Qualifications to Indemnities	 	12
	 	 	(E)	 	Tax Reductions Related to Indemnity Payments by Specialty Laboratories	 	13
	 	 	(F)	 	Refunds and Credits Related to Losses Paid by Specialty Laboratories	 	13
	

6.	
 	
ADJUSTMENTS TO THE PROPERTY	
 	

14
	 	 	(A)	 	Status of Property	 	14
	 	 	(B)	 	Changes in the Land Covered by the Ground Lease	 	15
	

7.	
 	
ENVIRONMENTAL	
 	

15
	 	 	(A)	 	Environmental Covenants by Specialty Laboratories	 	15
	 	 	(B)	 	Right of BNPPLC to do Remedial Work Not Performed by Specialty Laboratories	 	15
	 	 	(C)	 	Environmental Inspections and Reviews	 	16
	 	 	(D)	 	Communications Regarding Environmental Matters	 	16

i

 

	

8.	
 	
INSURANCE REQUIRED AND CONDEMNATION	
 	

17
	 	 	(A)	 	Liability Insurance	 	17
	 	 	(B)	 	Property Insurance	 	17
	 	 	(C)	 	Failure to Obtain Insurance	 	18
	 	 	(D)	 	Condemnation	 	18
	 	 	(E)	 	Waiver of Subrogation	 	18
	

9.	
 	
APPLICATION OF INSURANCE AND CONDEMNATION PROCEEDS	
 	

19
	 	 	(A)	 	Collection and Application of Insurance and Condemnation Proceeds Generally	 	19
	 	 	(B)	 	Advances of Escrowed Proceeds to Specialty Laboratories	 	19
	 	 	(C)	 	Application of Escrowed Proceeds as a Qualified Prepayment	 	19
	 	 	(D)	 	Right of Specialty Laboratories to Receive and Apply Remaining Proceeds Below a Certain Level	 	20
	 	 	(E)	 	Special Provisions Applicable After a 97-10/Event or Event of Default	 	20
	 	 	(F)	 	Specialty Laboratories' Obligation to Restore	 	20
	 	 	(G)	 	Takings of All or Substantially All of the Property on or after the Completion Date	 	20
	

10.	
 	
ADDITIONAL REPRESENTATIONS, WARRANTIES AND COVENANTS OF SPECIALTY LABORATORIES CONCERNING THE PROPERTY	
 	

20
	 	 	(A)	 	Operation and Maintenance	 	20
	 	 	(B)	 	Debts for Construction, Maintenance, Operation or Development	 	21
	 	 	(C)	 	Repair, Maintenance, Alterations and Additions	 	22
	 	 	(D)	 	Permitted Encumbrances and Development Documents	 	23
	 	 	(E)	 	Books and Records Concerning the Property	 	23
	 	 	(F)	 	No Discrimination	 	23
	

11.	
 	
ASSIGNMENT AND SUBLETTING BY SPECIALTY LABORATORIES	
 	

24
	 	 	(A)	 	BNPPLC's Consent Required	 	24
	 	 	(B)	 	Standard for BNPPLC's Consent to Assignments and Certain Other Matters	 	24
	 	 	(C)	 	Consent Not a Waiver	 	24
	

12.	
 	
ASSIGNMENT BY BNPPLC	
 	

24
	 	 	(A)	 	Restrictions on Transfers	 	24
	 	 	(B)	 	Effect of Permitted Transfer or other Assignment by BNPPLC	 	25
	

13.	
 	
BNPPLC'S RIGHT OF ACCESS	
 	

25
	

14.	
 	
REMEDIES	
 	

25
	 	 	(A)	 	Basic Remedies	 	25
	 	 	(B)	 	Notice Required So Long As the Purchase Option and Specialty Laboratories' Initial Remarketing Right Continue Under the Purchase Agreement	 	27
	 	 	(C)	 	Enforceability	 	27
	 	 	(D)	 	Remedies Cumulative	 	27
	

15.	
 	
DEFAULT BY BNPPLC	
 	

27
	

16.	
 	
QUIET ENJOYMENT	
 	

28
	

17.	
 	
SURRENDER UPON TERMINATION	
 	

28
	

18.	
 	
HOLDING OVER BY SPECIALTY LABORATORIES	
 	

28
	

19.	
 	
RECORDING MEMORANDUM	
 	

28
	

20.	
 	
INDEPENDENT OBLIGATIONS EVIDENCED BY THE OTHER OPERATIVE DOCUMENTS	
 	

28

ii

 

	

21.	
 	
PROPRIETARY INFORMATION, CONFIDENTIALITY AND SECURITY	
 	

29
	 	 	(A)	 	Proprietary Information	 	29
	 	 	(B)	 	Confidentiality	 	29
	 	 	(C)	 	Building Security	 	29

Exhibits and Schedules  

	Exhibit A	 	Legal Description

iii

 
 

LEASE AGREEMENT    
  

        This LEASE AGREEMENT (this "Lease") is made and dated as of March 26, 2002 (the
"Effective Date") by and between BNP PARIBAS LEASING CORPORATION, a Delaware corporation ("BNPPLC"), and
SPECIALTY LABORATORIES, INC., a California corporation ("Specialty Laboratories"). 

RECITALS  

        Contemporaneously with the execution of this Lease, BNPPLC and Specialty Laboratories are executing a Common Definitions and Provisions Agreement dated as of the
Effective Date (the "Common Definitions and Provisions Agreement"), which by this reference is incorporated into and made a part of this Lease for all
purposes. As used in this Lease, capitalized terms defined in the Common Definitions and Provisions Agreement and not otherwise defined in this Lease are intended to have the
respective meanings assigned to them in the Common Definitions and Provisions Agreement.

        At
the request of Specialty Laboratories and to facilitate the transactions contemplated in the other Operative Documents, pursuant to the Ground Lease, BNPPLC is acquiring a leasehold
estate in the Land described in Exhibit A and any existing improvements thereon from Specialty Laboratories contemporaneously with the execution
of this Lease. 

        In
anticipation of BNPPLC's acquisition of the leasehold estate under the Ground Lease and other property described below, BNPPLC and Specialty Laboratories have reached agreement as to
the terms and conditions upon which BNPPLC is willing to sublease the Land to Specialty Laboratories and to lease to Specialty Laboratories any existing Improvements and the Improvements to be
constructed on the Land as hereinafter provided, and by this Lease BNPPLC and Specialty Laboratories desire to evidence such agreement. 

GRANTING CLAUSES  

        BNPPLC does hereby LEASE, DEMISE and LET unto Specialty Laboratories for the Term (as hereinafter defined) all right, title and interest of BNPPLC, now owned or
hereafter acquired, in and to: 

        (1)  the
Land, including the leasehold estate in the Land acquired by BNPPLC under the Ground Lease; 

        (2)  any
and all Improvements; 

        (3)  all
easements and other rights appurtenant to the Land under the Ground Lease or to the Improvements, whether now owned or hereafter acquired by BNPPLC; and 

        (4)  (A)
any land lying within the right-of-way of any street, open or proposed, adjoining the Land, (B) any sidewalks and alleys adjacent to
the Land, and (C) any strips and gores between the Land and abutting land. 

BNPPLC's
interest in all property described in clauses (1) through (4) above is hereinafter referred to collectively as the "Real
Property". 

        To
the extent, but only to the extent, that assignable rights or interests in, to or under the following have been or will be acquired by BNPPLC under the Ground Lease or acquired by
BNPPLC pursuant to Paragraph 6.(A) below, BNPPLC also hereby grants and assigns to Specialty Laboratories for the term of this Lease the right to use and enjoy (and, in the case of contract
rights, to enforce) such rights or interests of BNPPLC: 

        (a)  any
goods, equipment, furnishings, furniture and other tangible personal property of whatever nature that are located on the Real Property and all renewals or
replacements of or substitutions for any of the foregoing; 

 

        (b)  the
benefits, if any, conferred upon the owner of the Real Property by the Permitted Encumbrances and Development Documents; and 

        (c)  any
permits, licenses, franchises, certificates, and other rights and privileges against third parties related to the Real Property. 

Such
rights and interests of BNPPLC, whether now existing or hereafter arising, are hereinafter collectively called the "Personal Property". The Real
Property and the Personal Property are hereinafter sometimes collectively called the "Property." 

        However,
the leasehold estate conveyed hereby and Specialty Laboratories' rights hereunder are expressly made subject and subordinate to the terms and conditions of this Lease and the
Ground Lease, to the matters listed in Exhibit B to the Closing Certificate and all other Permitted Encumbrances, and to any other claims or
encumbrances not constituting Liens Removable by BNPPLC. 

GENERAL TERMS AND CONDITIONS  

        The Property is leased by BNPPLC to Specialty Laboratories and is accepted and is to be used and possessed by Specialty Laboratories upon and subject to the
following terms and conditions: 

1.    TERM; LEASE RIGHTS AND OBLIGATIONS DEFERRED UNTIL COMPLETION OF INITIAL IMPROVEMENTS; TERMINATION PRIOR TO LEASE
COMMENCEMENT. 

        (A)    Scheduled Term; Deferral of Rights and Obligations.    The term of this Lease (the
"Term") shall not commence until a Completion Date occurs because either (1) Specialty Laboratories shall give a Completion Notice to BNPPLC that  subparagraph 2(B)
 of the Construction Management Agreement requires of Specialty Laboratories after Specialty Laboratories substantially
completes the Construction Project, or (2) BNPPLC shall give a Completion Notice to Specialty Laboratories as described in  subparagraph 8(C) of the Construction Management Agreement, advising
Specialty Laboratories (after an Owner's Election to Complete Construction)
that construction of the Construction Project is substantially complete. The Term shall begin on and include any such Completion Date (the "Lease Commencement
Date"), but not otherwise. After it begins, the Term ends on the first Business Day of
October, 2008, unless sooner terminated as expressly herein provided. No delays in the Lease Commencement Date will extend the end of the Term. 

        BNPPLC
and Specialty Laboratories intend to be legally bound by this Lease when it is executed by them. They also intend, however, that this Lease will not confer rights nor impose
obligations upon either of them prior to the Lease Commencement Date, other than the options granted to BNPPLC and Specialty Laboratories in subparagraphs 1.(B) and 1.(D). Accordingly, except as
provided in subparagraphs 1.(B) and 1.(D), neither Specialty Laboratories nor BNPPLC shall have any rights or obligations under this Lease until the Lease Commencement Date. 

        Further,
should this Lease terminate before the Lease Commencement Date pursuant to any of subparagraphs 1.(B), 1.(C) or 1.(D), the Term will never commence and neither party shall have
any rights or obligations under this Lease following such termination. 

        Nothing
in this subparagraph 1.(A) nor any other provision of this Lease will defer or terminate the rights and obligations of the parties under the  other Operative Documents. Unlike this Lease, the other
Operative Documents will, when executed, immediately confer rights and impose obligations upon
BNPPLC and Specialty Laboratories. 

        (B)    Option of BNPPLC to Terminate.    BNPPLC shall have the option to terminate this Lease, which BNPPLC may
exercise by notice to Specialty Laboratories, at any time after any 97-10/Event or 

Lease Agreement - Page 2

 

after BNPPLC's receipt of a Pre-lease Force Majeure Notice. Such option may be exercised by BNPPLC as it deems appropriate in its sole and absolute discretion. 

        (C)    Automatic Termination After a Failure by Specialty Laboratories to Complete Construction.    If, following a
Termination of Specialty Laboratories' Work, BNPPLC gives Specialty Laboratories a Completion Notice, advising Specialty Laboratories that BNPPLC has decided to abandon or indefinitely suspend its
efforts to complete the Construction Project or advising Specialty Laboratories that BNPPLC has made a final determination not to exercise its right to continue construction, then the date upon which
BNPPLC so notifies Specialty Laboratories will be the Completion Date (as provided in the Construction Management Agreement), but such date will not constitute a Lease Commencement Date hereunder.
Also, if the Designated Sale Date is accelerated as provided in clauses (2) or (3) of the definition thereof before Specialty Laboratories or BNPPLC gives a Completion Notice as
described in subparagraph 1.(A), the Designated Sale Date shall constitute the Completion Date, but not a Lease Commencement Date. In either case, if the Completion Date occurs without causing the
Term to begin as provided in subparagraph 1.(A), this Lease will terminate automatically as of such Completion Date. 

        (D)    Option of Specialty Laboratories to Terminate After Accelerating the Designated Sale Date.    So long as no
97-10/Event has occurred, Specialty Laboratories shall be entitled to accelerate the Designated Sale
Date (and thus accelerate the purchase of BNPPLC's interest in the Property by Specialty Laboratories or by an Applicable Purchaser pursuant to the Purchase Agreement) by sending a notice to BNPPLC as
provided in clause (2) of the definition of "Designated Sale Date" in the Common Definitions and Provisions Agreement. In the event, because of Specialty Laboratories' election to so accelerate
the Designated Sale Date or for any other reason, the Designated Sale Date occurs before the end of the scheduled Term, Specialty Laboratories shall have the option to terminate this Lease on or after
the Designated Sale Date; provided, however, as a condition to exercising such option, Specialty Laboratories must have done the following prior to the termination: 

        (1)  purchased
or caused an Applicable Purchaser to purchase the Property pursuant to the Purchase Agreement; 

        (2)  satisfied
all of Specialty Laboratories' other obligations under the Purchase Agreement; and 

        (3)  paid
to BNPPLC all Base Rent and other Rent due on or before or accrued through the Designated Sale Date. 

The
failure of Specialty Laboratories to satisfy the foregoing conditions will not prevent a termination of this Lease pursuant to subparagraphs 1.(B) or 1.(C). 

2.    USE AND CONDITION OF THE PROPERTY. 

        (A)    Use.    Subject to the Permitted Encumbrances, the Development Documents and the terms hereof, Specialty
Laboratories may use and occupy the Property during the Term, but only for the following purposes and other lawful purposes incidental thereto: 

        (1)  scientific
research, development and small scale manufacturing related to businesses in which Specialty Laboratories is engaged, which may involve among other things the
construction and use of laboratories and a central utilities plant; 

        (2)  support
functions for such research, development and manufacturing uses, including parking, food services, library, processing, distribution, warehousing and similar
uses; 

        (3)  administrative
and office space; 

Lease Agreement - Page 3

 

        (4)  employee
amenities and other support facilities for people working in the Improvements or other facilities in the vicinity of the Improvements; and 

        (5)  other
lawful purposes approved in advance and in writing by BNPPLC, which approval will not be unreasonably withheld after completion of the Construction Project (but
Specialty Laboratories acknowledges that BNPPLC's withholding of such approval shall be reasonable if BNPPLC determines in good faith that giving the approval may materially increase BNPPLC's risk of
liability for any existing or future environmental problem). 

        (B)    Condition of the Property.    Specialty Laboratories acknowledges that it has carefully
and fully inspected the Property and accepts the Property in its present state, AS IS, and without any representation or warranty, express or implied,
as to the condition of such property or as to the use which may be made thereof. Specialty Laboratories also accepts the Property without any covenant, representation or warranty, express or implied,
by BNPPLC or its Affiliates regarding the title thereto or the rights of any parties in possession of any part thereof, except as expressly set forth in Paragraph 16. BNPPLC shall not be
responsible for any latent or other defect or change of condition in the Land or in the Improvements, fixtures and personal property forming a part of the Property or for any violations with respect
thereto of Applicable Laws. Further, BNPPLC shall not be required to furnish to Specialty Laboratories any facilities or services of any kind, including water, steam, heat, gas, air conditioning,
electricity, light or power.

        (C)    Consideration for and Scope of Waiver.    The provisions of subparagraph 2.(B) above have been negotiated by
BNPPLC and Specialty Laboratories after due consideration for the Rent payable hereunder and are intended to be a complete exclusion and negation of any representations or warranties of BNPPLC or its
Affiliates, express or implied, with respect to the Property that may arise pursuant to any law now or hereafter in effect or otherwise, except as expressly set forth herein. 

        However,
such exclusion of representations and warranties by BNPPLC is not intended to impair any representations or warranties made by other parties, including any architects, engineers
or contractors engaged to work on the Construction Project, the benefit of which may pass to Specialty Laboratories during the Term because of the definition of Personal Property and Property above. 

3.    RENT. 

        (A)    Base Rent Generally.    On each Base Rent Date through the end of the Term, Specialty Laboratories shall pay
BNPPLC rent ("Base Rent"), calculated as provided below. Each payment of Base Rent must be received by BNPPLC no later than 10:00 a.m. (Pacific
time) on the date it becomes due; if received after 10:00 a.m. (Pacific time) it will be considered for purposes of this Lease as received on the next following Business Day. At least five days
prior to any Base Rent Date upon which an installment of Base Rent shall become due, BNPPLC shall notify Specialty Laboratories in writing of the amount of each installment, calculated as provided
below. Any failure by BNPPLC to so notify Specialty Laboratories, however, shall not constitute a waiver of BNPPLC's right to payment, but absent such notice Specialty Laboratories shall not be in
default hereunder for any underpayment resulting therefrom if Specialty Laboratories, in good faith, reasonably estimates the payment required, makes a timely payment of the amount so estimated and
corrects any underpayment within three Business Days after being notified by BNPPLC of the underpayment. 

        (B)    Impact of Collateral Upon Formulas.    To ease the administrative burden of this Lease and the Pledge
Agreement, the formulas for calculating Base Rent set out below in subparagraph 3.(C) reflect a reduction in the Base Rent equal to the interest that would accrue on any Collateral provided in
accordance with the requirements of the Pledge Agreement from time to time if the Accounts (as defined in the Pledge Agreement) bore interest at the Effective Rate. BNPPLC has agreed to such reduction
to provide Specialty Laboratories with the economic equivalent of interest on such Collateral, and in return Specialty Laboratories has agreed to the provisions of the Pledge Agreement that excuse 

Lease Agreement - Page 4

 

the actual payment of interest on the Accounts. By incorporating such reduction of Base Rent into the formulas below, and by providing for noninterest bearing Accounts in the Pledge Agreement, the
parties will avoid an unnecessary and cumbersome periodic exchange of equal payments. It is not, however, the intent of the parties to understate Base Rent or interest for financial reporting
purposes. Accordingly, for purposes of any financial reports that this Lease requires of Specialty Laboratories from time to time, Specialty Laboratories may report Base Rent as if there had been no
such reduction and as if the Collateral from time to time provided in accordance with the requirements of the Pledge Agreement had been maintained in Accounts bearing interest at the Effective Rate. 

        (C)    Calculation of and Due Dates for Base Rent.    Unless Specialty Laboratories is excused from the obligation to
pay Base Rent pursuant to subparagraph 3.(E) after having paid BNPPLC one or more 97-10/Prepayments, the payments of Base Rent shall be calculated and become due as follows: 

        (1)    Determination of Payment Due Dates Generally.    For all Base Rent Periods subject to a Base Rate Period
Election or to a LIBOR Period Election of one month or three, Base Rent shall be due in one installment on the Base Rent Date upon which the Base Rent Period ends. For Base Rent Periods subject to a
LIBOR Period Election of six months, Base Rent shall be payable in two installments, with the first installment becoming due on the Base Rent Date that occurs on the first Business Day of the third
calendar month following the commencement of such Base Rent Period, and with the second installment becoming due on the Base Rent Date upon which the Base Rent Period ends. 

        (2)    Special Adjustments to Base Rent Payment Dates and Periods.    Notwithstanding the foregoing, if Specialty
Laboratories or any Applicable Purchaser purchases BNPPLC's interest in the Property pursuant to the Purchase Agreement, any accrued unpaid Base Rent and all outstanding Additional Rent shall be due
on the date of purchase in addition to the purchase price and other sums due BNPPLC under the Purchase Agreement. 

        (3)    Base Rent Formula.    Each installment of Base Rent payable for any Base Rent Period shall equal: 

	•
	Stipulated
Loss Value on the first day of such Base Rent Period, less Losses (if any) that BNPPLC suffered or incurred prior to the Term and that qualify as
Pre-lease Force Majeure Losses as defined in the Construction Management Agreement, times

	•
	the
sum of:

	(A)
	the
product of:

	(1)
	the
Collateral Percentage for such Base Rent Period, times

	(2)
	the
Secured Spread, plus 

	(B)
	the
product of:

	(1)
	one
minus the Collateral Percentage for such Base Rent Period, times

	(2)
	the
sum of the Effective Rate and the Unsecured Spread for the period from and including the preceding Base Rent Date to but not including the Base Rent Date upon which the
installment is due, times

	•
	the
number of days in the period from and including the preceding Base Rent Date to but not including the Base Rent Date upon which the installment is due,  divided by

	•
	three
hundred sixty. 

        Assume,
only for the purpose of illustration: that the Collateral Percentage for a hypothetical Base Rent Period is twenty percent (20%); that prior to the first day of such Base Rent
Period the 

Lease Agreement - Page 5

 

Construction Allowance has been fully funded, and no Pre-lease Force Majeure Losses have occurred, but Qualified Prepayments have been received by BNPPLC, leaving a Stipulated Loss Value
of $50,000,000; that the Effective Rate for the Base Rent Period is 6%; that the Secured Spread is fifty basis points (50/100 of 1%) and the Unsecured Spread is one hundred fifty basis points (150/100
of 1%); and that such Base Rent Period contains exactly thirty days. Under such assumptions, the Base Rent for the hypothetical Base Rent Period will equal: 

$50,000,000 ×{(20% × .50%) +([1 -20%] ×[6% + 1.50%])} ×30/360 =
$254,167 

        (D)    Administrative Agency Fees.    On each anniversary of the Effective Date after the Completion Date and prior to
the Designated Sale Date, Specialty Laboratories shall pay BNPPLC an administrative agency fee (an "Administrative Agency Fee") as provided in the Term
Sheet, unless Specialty Laboratories is excused from making such payments pursuant to subparagraph 3.(E) after having made one or more Issue 97-10/Prepayments. Each payment of an
Administrative Agency Fee hereunder shall represent Additional Rent for the first Construction Period or Base Rent Period during which it first becomes due. 

        (E)    Abatement of Base Rent and Administrative Agency Fees After 97-10/Prepayments.    If a Termination
of Specialty Laboratories' Work occurs prior to the Lease Commencement Date, if BNPPLC demands one or more 97-10/Prepayments from Specialty Laboratories pursuant to Paragraph 9 of
the Construction Management Agreement, and so long as Specialty Laboratories makes all such 97-10/Prepayments demanded by BNPPLC, Specialty Laboratories' obligation hereunder for payments
of Base Rent and Administrative Agency Fees will abate. 

        (F)    Additional Rent.    All amounts which Specialty Laboratories is required to pay to or on behalf of BNPPLC
pursuant to this Lease, together with every charge, premium, interest and cost set forth herein which may be added for nonpayment or late payment thereof, shall constitute rent (all such amounts,
other than Base Rent, are herein called "Additional Rent", and together Base Rent and Additional Rent are herein sometimes called
"Rent"). 

        (G)    No Demand or Setoff.    Except as expressly provided herein, Specialty Laboratories shall pay all Rent without
notice or demand and without counterclaim, deduction, setoff or defense. 

        (H)    Default Interest and Order of Application.    All Rent shall bear interest, if not paid when first due, at the
Default Rate in effect from time to time from the date due until paid; provided, that nothing herein contained will be construed as permitting the charging or collection of interest at a rate
exceeding the maximum rate permitted under Applicable Laws. BNPPLC shall be entitled to apply any amounts paid by or on behalf of Specialty Laboratories against any Rent then past due in the order the
same became due or in such other order as BNPPLC may elect. 

4.    NATURE OF THIS AGREEMENT. 

        (A)    "Net" Lease Generally.    Subject only to the exceptions listed in subparagraph 5.(D) below, it is the
intention of BNPPLC and Specialty Laboratories that Base Rent and other payments herein specified shall be absolutely net to BNPPLC and that Specialty Laboratories shall pay all costs, expenses and
obligations of every kind relating to the Property or this Lease which may arise or become due, including: (i) any taxes payable by virtue of BNPPLC's receipt of amounts paid to or on behalf of
BNPPLC in accordance with Paragraph 5; (ii) any amount for which BNPPLC is or becomes liable with respect to the Ground Lease, the Permitted Encumbrances or the Development Documents;
and (iii) any costs incurred by BNPPLC (including Attorneys' Fees) because of BNPPLC's acquisition or ownership of any interest in the Property or because of this Lease or the transactions
contemplated herein. 

        (B)    No Termination.    Except as expressly provided in this Lease itself, this Lease shall not terminate, nor shall
Specialty Laboratories have any right to terminate this Lease, nor shall Specialty 

Lease Agreement - Page 6

 

Laboratories be entitled to any abatement of the Rent, nor shall the obligations of Specialty Laboratories under this Lease be excused, for any reason whatsoever, including any of the following:
(i) any damage to or the destruction of all or any part of the Property from whatever cause, (ii) the taking of the Property or any portion thereof by eminent domain or otherwise for any
reason, (iii) the prohibition, limitation or restriction of Specialty Laboratories' use or development of all or any portion of the Property or any interference with such use by governmental
action or otherwise, (iv) any eviction of Specialty Laboratories or of anyone claiming through or under Specialty Laboratories, (v) any default on the part of BNPPLC under this Lease or
under any other agreement to which BNPPLC and Specialty Laboratories are parties, (vi) the inadequacy in any way whatsoever of the design, construction, assembly or installation of any
improvements, fixtures or tangible personal property included in the Property (it being understood that BNPPLC has not made, does not make and will not make any representation express or implied as to
the adequacy thereof), (vii) any latent or other defect in the Property or any change in the condition thereof or the existence with respect to the Property of any violations of Applicable
Laws, or (vii) any other cause whether similar or dissimilar to the foregoing. It is the intention of the parties hereto that the obligations of Specialty Laboratories hereunder shall be
separate and independent of the covenants and agreements of BNPPLC, that Base Rent and all other sums payable by Specialty Laboratories hereunder shall continue to be payable in all events and that
the obligations of Specialty Laboratories hereunder shall continue unaffected, unless the requirement to pay or perform the same shall have been terminated or limited pursuant to an express provision
of this Lease. Without limiting the foregoing, Specialty Laboratories waives to the extent permitted by Applicable Laws, except as otherwise expressly provided herein, all rights to which Specialty
Laboratories may now or hereafter be entitled by law (including any such rights arising because of any implied "warranty of suitability" or other warranty under Applicable Laws) (i) to quit,
terminate or surrender this Lease or the Property or any part thereof or (ii) to any abatement, suspension, deferment or reduction of the Rent. 

        However,
nothing in this subparagraph 4.(B) shall be construed as a waiver by Specialty Laboratories of any right Specialty Laboratories may have at law or in equity to the following
remedies, whether because of BNPPLC's failure to remove a Lien Removable by BNPPLC or because of any other default by BNPPLC under this Lease that continues beyond the period for cure provided in
Paragraph 15: (i) the recovery of monetary damages, (ii) injunctive relief in case of the violation, or attempted or threatened violation, by BNPPLC of any of the express
covenants, agreements, conditions or provisions of this Lease which are binding upon BNPPLC (including the confidentiality provisions set forth in Paragraph 25 below), or (iii) a decree
compelling performance by BNPPLC of any of the express covenants, agreements, conditions or provisions of this Lease which are binding upon BNPPLC. 

        (C)    Characterization of this Lease.    

        (1)  Both
Specialty Laboratories and BNPPLC intend and expect that: 

        (A)  For purposes of determining their respective federal, state and local income tax obligations, this Lease and the Purchase
Agreement will constitute a financing arrangement or conditional sale. Thus, Specialty Laboratories (and not BNPPLC) will be treated as the true owner of the Property for income tax purposes, thereby
entitling Specialty Laboratories (and not BNPPLC) to take depreciation deductions and other tax benefits available to the owner. REFERENCES IN THIS LEASE OR IN THE PURCHASE AGREEMENT TO "LEASE" OR TO
"LEASED PROPERTY" OR OTHER WORDS OF LIKE EFFECT DO NOT REFLECT ANY UNDERSTANDING CONTRARY TO THE FOREGOING ABOUT THE FORM OF THE TRANSACTIONS COVERED BY, OR THE PROPER CHARACTERIZATION OF, THIS LEASE
AND THE PURCHASE AGREEMENT FOR INCOME TAX PURPOSES. 

        (B)  For other purposes, including the determination of the appropriate financial accounting for this Lease and the determination of their respective
rights and remedies under state law, BNPPLC 

Lease Agreement - Page 7

 

and Specialty Laboratories believe and intend that (i) this Lease constitutes a true lease, not a financing arrangement, enforceable in accordance with its express terms and (ii) each
of the other Operative Documents, including the Purchase Agreement, shall constitute a separate and independent contract, enforceable in accordance with the express terms and conditions set forth
therein. In this regard, Specialty Laboratories acknowledges that Specialty Laboratories asked BNPPLC to participate in the transactions evidenced by this Lease and the other Operative Documents as a
landlord and owner of the Property, not as a lender. Although other transactions might have been used to accomplish similar results, Specialty Laboratories expects to receive certain material
accounting and other advantages through the use of a lease transaction. Accordingly, and notwithstanding the reporting for income tax
purposes, Specialty Laboratories cannot equitably deny that this Lease and the Purchase Agreement should be construed and enforced under applicable state law in accordance with their respective terms,
rather than as a mortgage or other security device, in any action brought by BNPPLC to enforce this Lease, the Purchase Agreement or the other Operative Documents. 

        (C)  If,
contrary to the intent of the parties as expressed in the preceding subparagraph (B), a judicial determination is made that this Lease and the other Operative
Documents constitute a financing arrangement under applicable state law, then BNPPLC will be deemed a lender making a loan to Specialty Laboratories in the principal amount equal to Stipulated Loss
Value, which is secured by (among other things) a mortgage lien against the Real Property (including a leasehold estate governed by the terms and conditions set forth in the Ground Lease), and
Specialty Laboratories shall be treated as the owner of the Property and will be entitled to, inter alia, all tax benefits available to the owner of the
Property. In furtherance of such intent, Specialty Laboratories hereby grants to BNPPLC a mortgage and security interest against all rights, titles and interests of Specialty Laboratories in and to
the Property. Further, if any court should decline to honor the parties intent to construe Specialty Laboratories' obligations under the Purchase Agreement as being separate and distinct from its
obligations under this Lease, then this Lease, the Purchase Agreement and the other Operative Documents shall be treated as a financing arrangement and mortgage. Accordingly, in no event will the
obligations of Specialty Laboratories under the Purchase Agreement be construed as obligations of a tenant under a lease in any proceedings affecting Specialty Laboratories or BNPPLC, including any
bankruptcy, insolvency or receivership proceedings or any enforcement or collection actions arising out of such proceedings. 

        (2)  Notwithstanding
the foregoing, Specialty Laboratories acknowledges and agrees that none of BNPPLC or the other Interested Parties has made, or shall be deemed to have
made, in the Operative Documents or otherwise, any representations or warranties concerning how this Lease and the other Operative Documents will be characterized or treated under applicable
accounting rules, income tax, regulatory, commercial or real estate law, bankruptcy, insolvency or receivership law or any other rules or concerning the tax, accounting or legal characteristics of the
Operative Documents. Specialty Laboratories further acknowledges and agrees that it has, as it deemed appropriate, obtained from and relied upon its own professional accountants, counsel and other
advisors for such tax, accounting and legal advice concerning the Operative Documents. 

        (3)  In
any event, without limiting Specialty Laboratories' obligations under subparagraph 5.(C) below, but subject to the exceptions listed in subparagraph 5.(D), Specialty
Laboratories must indemnify and hold harmless BNPPLC from and against all liabilities, costs, additional taxes and other expenses that may arise or become due because of any refusal of United States
taxing authorities to recognize and give effect to the intention of the parties as set forth in subparagraph 4.(C)(1) (including any additional income or capital gains tax that may become due because
of payments to BNPPLC of the purchase price upon any sale under the Purchase Agreement) because of the insistence of such taxing authorities that BNPPLC be treated as the "true owner" 

Lease Agreement - Page 8

 

of the Property for tax purposes, to the extent (if any) that such liabilities, costs, additional taxes and other expenses are not offset by tax savings to BNPPLC resulting from additional
depreciation deductions or other tax benefits available to BNPPLC as a result of the position taken by such taxing authorities. 

5.    PAYMENT OF EXECUTORY COSTS AND LOSSES RELATED TO THE PROPERTY. 

        (A)    Impositions.    Subject only to the exceptions listed in subparagraph 5.(D) below, Specialty Laboratories shall
pay or cause to be paid prior to delinquency all ad valorem taxes assessed against the Property and other Impositions. If requested by BNPPLC from time to time, Specialty Laboratories shall furnish
BNPPLC with receipts or other appropriate evidence showing payment of all Impositions at least ten days prior to the applicable delinquency date therefor. 

        Notwithstanding
the foregoing, Specialty Laboratories may in good faith, by appropriate proceedings, contest the validity, applicability or amount of any asserted Imposition, and pending
such contest Specialty Laboratories shall not be deemed in default under any of the provisions of this Lease because of the Imposition if (1) Specialty Laboratories diligently prosecutes such
contest to completion in a manner reasonably satisfactory to BNPPLC, and (2) Specialty Laboratories promptly causes to be paid any amount adjudged by a court of competent jurisdiction to be
due, with all costs, penalties and interest thereon, promptly after such judgment becomes final; provided, however, in any event each such contest shall be concluded and the contested Impositions must
be paid by Specialty Laboratories prior to the earlier of (i) the date that any criminal prosecution is instituted or overtly threatened against BNPPLC or its directors, officers or employees
because of the nonpayment thereof or (ii) the date any writ or order is issued under which any property owned or leased by BNPPLC (including the Property) may be seized or sold or any other
action is taken or overtly threatened against BNPPLC or against any property owned or leased by BNPPLC because of the nonpayment thereof, or (iii) any Designated Sale Date upon which, for any
reason, Specialty Laboratories or an Affiliate of Specialty Laboratories or any Applicable Purchaser shall not purchase BNPPLC's interest in the Property pursuant to the Purchase Agreement for a price
to BNPPLC (when taken together with any Supplemental Payment paid by Specialty Laboratories pursuant to the Purchase Agreement, in the case of a purchase by an Applicable Purchaser) equal to the Break
Even Price. 

        (B)    Increased Costs; Capital Adequacy Charges.    Subject only to the exceptions listed in subparagraph 5.(D)
below: 

        (1)  If
during the Term there shall be any increase in the cost to BNPPLC's Parent or any other Participant agreeing to make or making, funding or maintaining advances to
BNPPLC in connection with the Property because of any Banking Rules Change, then Specialty Laboratories shall from time to time, pay to BNPPLC for the account of BNPPLC's Parent or such other
Participant, as the case may be, additional amounts sufficient to compensate BNPPLC's Parent or the Participant for such increased cost. A certificate as to the amount of such increased cost,
submitted to BNPPLC and Specialty Laboratories by BNPPLC's Parent or the other Participant, shall be conclusive and binding upon Specialty Laboratories, absent clear and demonstrable error. 

        (2)  BNPPLC's
Parent or any other Participant may demand additional payments ("Capital Adequacy Charges") if BNPPLC's Parent
or the other Participant determines that any Banking Rules Change affects the amount of capital to be maintained by it and that the amount of such capital is increased by or based upon the existence
of advances made or to be made to BNPPLC to permit BNPPLC to maintain BNPPLC's investment in the Property. To the extent that BNPPLC's Parent or another Participant demands Capital Adequacy Charges as
compensation for the additional capital requirements reasonably allocable to such investment or advances, Specialty Laboratories shall pay to BNPPLC for the account of BNPPLC's Parent or the other
Participant, as the case may be, the amount so demanded. 

Lease Agreement - Page 9

 

        (3)  Notwithstanding
the foregoing provisions of this subparagraph 5.(B), Specialty Laboratories shall not be obligated to pay any claim for compensation pursuant to this
subparagraph 5.(B) arising or accruing more than nine months prior to the date Specialty Laboratories is notified that BNPPLC or a Participant intends to make the claim; provided, however, that
Specialty Laboratories shall not be excused by this subparagraph from providing such compensation for any period during which notice on behalf of BNPPLC or the Participant, as the case may be, could
not be provided because of the retroactive application of the statute, regulation or other basis for the claim. Further, BNPPLC shall cause BNPPLC's Parent and any other Participant that is an
Affiliate of BNPPLC to use commercially reasonable efforts—to the extent the Participant can do so without incurring any out-of-pocket costs other than costs which
are reimbursable by Specialty Laboratories hereunder—to reduce or eliminate any claim for compensation pursuant to this subparagraph 5.(B), including a change in the office of such
Participant through which it provides and maintains Funding Advances if such change will avoid the need for, or reduce the amount of, such compensation and will not, in the reasonable judgment of such
Participant, be otherwise disadvantageous to it. It is understood that Specialty Laboratories may also request similar commercial reasonable efforts on the part of any Participant that is not an
Affiliate of BNPPLC, but if a claim for additional compensation by any such Participant is not eliminated or waived, then Specialty Laboratories may request that BNPPLC replace such Participant under
the Participation Agreement. BNPPLC will endeavor in good faith to satisfy any such request; provided, that no 97-10/Event has occurred and no Event of Default has occurred and is
continuing; and, provided further, BNPPLC shall be entitled to impose the same conditions to any such replacement that subparagraph 4(G)(3)(c) of the
Construction Management Agreement allows BNPPLC to impose in the case of a replacement of a Defaulting Participant. (Nothing in this subparagraph will be construed to require BNPPLC's Parent or any
other Participant to create any new office through which to make or maintain Funding Advances.) 

        (4)  Any
amount required to be paid by Specialty Laboratories under this subparagraph 5.(B) shall be due thirty days after a notice requesting such payment is received by
Specialty Laboratories. 

        (C)    Specialty Laboratories' Payment of Other Losses; General Indemnification.    Subject only to the exceptions
listed in subparagraph 5.(D) below: 

        (1)  All
Losses (including Environmental Losses) asserted against or incurred or suffered by BNPPLC or other Interested Parties at any time and from time to time on or after
the Completion Date by reason of, in connection with or arising out of (A) their ownership or alleged ownership of any interest in the Property or the Rents, (B) the use and operation of
the Property, (C) the negotiation, administration or enforcement of the Operative Documents, (D) the making of Funding Advances, (E) any construction of or repairs or restoration
of any of the Improvements, (F) the breach by Specialty Laboratories of this Lease, any other Operative Document or any other document executed by Specialty Laboratories in connection herewith,
(G) any failure of the Property or Specialty Laboratories itself to comply with Applicable Laws, (H) Permitted Encumbrances, (I) Hazardous Substance Activities, including those
occurring prior to the Term, (J) any obligations of BNPPLC under the Ground Lease or the Closing Certificate, or (K) any bodily or personal injury or death or property damage occurring
in or upon or in the vicinity of the Property through any cause whatsoever, shall be paid by Specialty Laboratories, and Specialty Laboratories shall indemnify and defend BNPPLC and other Interested
Parties from and against all such Losses. 

        (2)  THE INDEMNITIES AND RELEASES PROVIDED HEREIN FOR THE BENEFIT OF BNPPLC AND OTHER INTERESTED PARTIES, INCLUDING THE INDEMNITY SET FORTH IN THE
PRECEDING SUBPARAGRAPH 5.(C)(1), SHALL APPLY EVEN IF AND WHEN THE SUBJECT MATTERS OF THE INDEMNITIES AND RELEASES ARE CAUSED BY OR ARISE  

Lease Agreement - Page 10

 

 OUT OF THE NEGLIGENCE OR STRICT LIABILITY OF BNPPLC OR ANOTHER INTERESTED PARTY. FURTHER, SUCH INDEMNITIES AND RELEASES WILL APPLY EVEN IF INSURANCE OBTAINED BY SPECIALTY LABORATORIES OR REQUIRED OF
SPECIALTY LABORATORIES BY THIS LEASE OR OTHER OPERATIVE DOCUMENTS IS NOT ADEQUATE TO COVER LOSSES AGAINST OR FOR WHICH THE INDEMNITIES AND RELEASES ARE PROVIDED. SPECIALTY LABORATORIES= LIABILITY,
HOWEVER, FOR ANY FAILURE TO OBTAIN INSURANCE REQUIRED BY THIS LEASE OR OTHER OPERATIVE DOCUMENTS WILL NOT BE LIMITED TO LOSSES AGAINST WHICH INDEMNITIES ARE PROVIDED HEREIN, IT BEING UNDERSTOOD THAT
SUCH INSURANCE IS INTENDED TO DO MORE THAN PROVIDE A SOURCE OF PAYMENT FOR LOSSES AGAINST WHICH BNPPLC AND OTHER INTERESTED PARTIES ARE ENTITLED TO INDEMNIFICATION BY THIS
LEASE.

        (3)  Costs
and expenses for which Specialty Laboratories shall be responsible pursuant to this subparagraph 5.(C) will include Attorneys' Fees incurred by BNPPLC with respect
to the Property or the administration of this Lease and the other Operative Documents. Such costs and expenses will also include all rent or other payments required of BNPPLC under the Ground Lease,
so long as this Lease shall remain in force. Further, if Specialty Laboratories receives approval from BNPPLC to expand the permitted uses of the Property as provided in subparagraph 2.(A)(5) and the
new permitted uses increase BNPPLC's administrative burden of complying with or monitoring Specialty Laboratories' compliance with the requirements of this Lease or other Operative Documents, then the
costs of meeting the increased burden (including a fair allocation of the salary of any person involved in meeting that burden) will be included in the costs and expenses for which Specialty
Laboratories shall be responsible pursuant to this subparagraph 5.(C). 

        (4)  Specialty
Laboratories' obligations under this subparagraph 5.(C) shall survive the termination or expiration of this Lease. Any amount to be paid by Specialty
Laboratories under this subparagraph
5.(C) shall be due thirty days after a notice requesting such payment is received by Specialty Laboratories. 

        (5)  If
an Interested Party notifies Specialty Laboratories of any claim or proceeding included in, or any investigation or allegation concerning, Losses for which Specialty
Laboratories is responsible pursuant to this subparagraph 5.(C), Specialty Laboratories shall assume on behalf of the Interested Party and conduct with due diligence and in good faith the
investigation and defense thereof and the response thereto with counsel selected by Specialty Laboratories, but reasonably satisfactory to the Interested Party; provided, that the Interested Party
shall have the right to be represented by advisory counsel of its own selection and at its own expense; and provided further, that if any such claim, proceeding, investigation or allegation involves
both Specialty Laboratories and the Interested Party and the Interested Party shall have reasonably concluded that there are legal defenses available to it which are inconsistent with those available
to Specialty Laboratories, then the Interested Party shall have the right to select separate counsel to participate in the investigation and defense of and response to such claim, proceeding,
investigation or allegation on its own behalf, and Specialty Laboratories shall pay or reimburse the Interested Party for all Attorney's Fees incurred by the Interested Party because of the selection
of such separate counsel. If Specialty Laboratories fails to assume promptly (and in any event within fifteen days after being notified of the applicable claim, proceeding, investigation or
allegation) the defense of the Interested Party, then the Interested Party may contest (or settle, with the prior consent of Specialty Laboratories, which consent will not be unreasonably withheld)
the claim, proceeding, investigation or allegation at Specialty Laboratories' expense using counsel selected by the Interested Party. Moreover, if any such failure by Specialty Laboratories continues
for thirty days or more after Specialty Laboratories is notified of any such claim, proceeding, investigation or allegation, then the Interested Party may provide an additional notice of its rights to
contest or 

Lease Agreement - Page 11

 

settle pursuant to this paragraph. And if such failure continues for yet another thirty days after such additional notice is given, then the Interested Party may elect not to contest or continue
contesting such claim, proceeding, investigation or allegation and instead, in accordance with the written advice of counsel, settle (or pay in full) any or all claims against the Interested Party
related thereto without Specialty Laboratories' consent and without releasing Specialty Laboratories from any obligations to the Interested Party under this subparagraph 5.(C). The right to settle as
described in the preceding sentence, however, shall not be construed as authorization to bind Specialty Laboratories itself to any admission of liability or responsibility or to any settlement
agreement or other contract made with a third party claimant. Further, it is understood that no Interested Party shall bind or purport to bind Specialty Laboratories to any such admission or
settlement agreement or other contract. 

        (D)    Exceptions and Qualifications to Indemnities.    

        (1)  BNPPLC
acknowledges and agrees that nothing in Paragraph 4 or the preceding subparagraphs of this Paragraph 5 shall be construed to require Specialty
Laboratories to pay or reimburse: 

        (a)  any
costs or expenses incurred by any Interested Party (including BNPPLC or any transferee of BNPPLC) to accomplish any Permitted Transfers described in clauses
(4) or (5) of the definition thereof in the Common Definitions and Provisions Agreement; 

        (b)  Excluded
Taxes; 

        (c)  Losses
incurred or suffered by any Interested Party that are proximately caused by (and attributed by any applicable principles of comparative fault to) the Established
Misconduct of that Interested Party; 

        (d)  Losses
incurred or suffered in connection with the execution of the Participation Agreement by Participants (or supplements making them parties thereto) or in connection
with any negotiation or due diligence Participants may undertake before entering into the Participation Agreement; or 

        (e)  any
decline in the value of the Property solely by reason of decline in general market conditions and not because of any breach of this Lease or other Operative
Documents by Specialty Laboratories. 

        (2)  Further,
if an Interested Party receives a written notice of Losses that such Interested Party believes are covered by the indemnity in subparagraph 5.(C)(1), then such
Interested Party will be expected to promptly furnish a copy of such notice to Specialty Laboratories. The failure to so provide a copy of the notice to Specialty Laboratories shall not excuse
Specialty Laboratories from its obligations under subparagraph 5.(C)(1); provided, that if such failure continues for more than fifteen days after the notice is received by such Interested Party and
Specialty Laboratories is unaware of the matters described in the notice, with the result that Specialty Laboratories is unable to assert defenses or to take other actions which could minimize its
obligations, then Specialty Laboratories shall be excused from its obligation to indemnify such Interested Party (and any Affiliate of such Interested Party) against the Losses, if any, which would
not have been incurred or suffered but for such failure. For example, if BNPPLC fails to provide Specialty Laboratories with a copy of a notice of an obligation covered by the indemnity set out in
subparagraph 5.(C)(1) and Specialty Laboratories is not otherwise already aware of such obligation, and if as a result of such failure BNPPLC becomes liable for penalties and interest covered by the
indemnity in excess of the penalties and interest that would have accrued if Specialty Laboratories had been promptly provided with a copy of the notice, then Specialty Laboratories will be excused
from any obligation to BNPPLC (or any Affiliate of BNPPLC) to pay the excess. 

Lease Agreement - Page 12

 

        (E)    Tax Reductions Related to Indemnity Payments by Specialty Laboratories.    

        (1)  As
used herein with respect to Losses for which Specialty Laboratories reimburses or indemnifies BNPPLC or another Interested Party, "Tax
Reduction" means the amount by which the taxes of BNPPLC or such Interested Party that are not subject to indemnification pursuant to this Paragraph 5 are reduced
(whether by reason of a deduction, credit, allocation, or apportionment of income or
otherwise) because of such Losses, less any increase in such taxes that occurs by reason of such reimbursement to or indemnification by Specialty Laboratories. 

        (2)  If
with respect to Losses that Specialty Laboratories reimburses to or pays for BNPPLC pursuant to this Paragraph 5, BNPPLC receives a Tax Reduction which has not
already been taken into account in calculating the amount of such reimbursement or payment by Specialty Laboratories, then BNPPLC shall pay to Specialty Laboratories the lesser of: (i) (A) the
amount of such Tax Reduction, plus (B) the amount of any further reduction of BNPPLC's taxes that are not subject to indemnification by Specialty Laboratories pursuant to this
Paragraph 5 because of the payments BNPPLC must make to Specialty Laboratories pursuant to this subparagraph; and (ii) the amount so reimbursed to or paid for BNPPLC by Specialty
Laboratories. If it is subsequently determined that BNPPLC was not entitled to such Tax Reduction, the portion of such Tax Reduction (or any tax savings taken into account in making any payment on an
after tax basis) that is repaid or recaptured will be treated as a Loss for which Specialty Laboratories must indemnify BNPPLC pursuant to this Paragraph 5 without regard to subparagraph
(C) hereof. 

        (3)  If
with respect to Losses that Specialty Laboratories reimburses to or pays to an Interested Party (other than BNPPLC) pursuant to this Paragraph 5, such
Interested Party receives a Tax Reduction which has not already been taken into account in calculating the amount of such reimbursement or payment by Specialty Laboratories, then Specialty
Laboratories may demand that such Interested Party pay to Specialty Laboratories the lesser of: (i)(A) the amount of such Tax Reduction, plus (B) the amount of any further reduction of such
Interested Party's taxes that are not subject to indemnification by Specialty Laboratories pursuant to this Paragraph 5 because of the payments such Interested Party must make to Specialty
Laboratories pursuant to this subparagraph; and (ii) the amount so reimbursed to or paid for such Interested Party by Specialty Laboratories. If it is subsequently determined that such
Interested Party was not entitled to such Tax Reduction, the portion of such Tax Reduction (or any tax savings taken into account in making any payment on an after tax basis) that is repaid or
recaptured will be treated as a Loss for which Specialty Laboratories must indemnify such Interested Party pursuant to this Paragraph 5 without regard to subparagraph (C) hereof. 

        (4)  Notwithstanding
the foregoing, in no event shall BNPPLC or any other Interested Party be required to make any payment to Specialty Laboratories pursuant to this
subparagraph 5.(E) when any Event of Default has occurred and is continuing. 

        (F)    Refunds and Credits Related to Losses Paid by Specialty Laboratories.    

        (1)  If
BNPPLC receives a refund of any Losses paid, reimbursed or advanced by Specialty Laboratories pursuant to this Paragraph 5, BNPPLC shall promptly shall pay to
Specialty Laboratories the amount of such refund, plus or minus any net tax benefits or detriments realized by BNPPLC as a result of such refund and such payment to Specialty Laboratories; provided,
that the amount payable to Specialty Laboratories shall not exceed the amount of the indemnity payment in respect of such refunded Losses that was made by Specialty Laboratories. If it is subsequently
determined that BNPPLC was not entitled to such refund, the portion of such refund that is repaid or recaptured will be treated as a Loss for which Specialty Laboratories must indemnify BNPPLC
pursuant to this Paragraph 5 without regard
to subparagraph (C) hereof. If, in connection any such refund, BNPPLC also receives an amount representing interest on such refund, BNPPLC shall promptly pay to Specialty Laboratories the
amount of such interest, plus or 

Lease Agreement - Page 13

 

minus any net tax benefits or detriments realized by BNPPLC as a result of the receipt or accrual of such interest and as a result of the such payment to Specialty Laboratories; provided that BNPPLC
will not be required to make any such payment in respect of the interest (if any) that is fairly attributable to a period before Specialty Laboratories paid, reimbursed or advanced the Losses refunded
to BNPPLC. 

        (2)  If
any Interested Party (other than BNPPLC itself) receives a refund of any Loss paid, reimbursed or advanced by Specialty Laboratories pursuant to this
Paragraph 5, Specialty Laboratories may demand that such Interested Party promptly pay to Specialty Laboratories the amount of such refund, plus or minus any net tax benefits or detriments
realized by such Interested Party as a result of such refund and such payment to Specialty Laboratories; provided, that the amount payable to Specialty Laboratories shall not exceed the amount of the
indemnity payment in respect of such refunded Losses that was made by Specialty Laboratories. If it is subsequently determined that such Interested Party was not entitled to such refund, the portion
of such refund that is repaid or recaptured will be treated as an Loss for which Specialty Laboratories must indemnify such Interested Party pursuant to this Paragraph 5 without regard to
subparagraph (C) hereof. If, in connection any such refund, such Interested Party also receives an amount representing interest on such refund, Specialty Laboratories may demand that such
Interested Party promptly pay to Specialty Laboratories the amount of such interest, plus or minus any net tax benefits or detriments realized by such Interested Party as a result of the receipt or
accrual of such interest and as a result of the such payment to Specialty Laboratories; provided that such Interested Party will not be required to make any such payment in respect of the interest (if
any) which is fairly attributable to a period before Specialty Laboratories paid, reimbursed or advanced the Losses refunded to BNPPLC. 

        (3)  As
used in this subparagraph 5.(F), the term "tax benefit" will not include a reduction of taxes that are subject to indemnification by Specialty Laboratories pursuant
to this Paragraph 5. Also, as used in this subparagraph 5.(F), the term "refund" shall be deemed to include credits to the extent they actually reduce taxes that would otherwise be payable by
the Interested Party receiving such credits and that are not subject to indemnification by Specialty Laboratories pursuant to this Paragraph 5; provided, however, that Specialty Laboratories
shall not be entitled to both a payment under the preceding subparagraph 5.(E) in respect of any such reduction and to a payment under this subparagraph 5.(F) in respect of the same reduction. 

        (4)  Notwithstanding
the foregoing, in no event shall BNPPLC or any other Interested Party be required to make any payment to Specialty Laboratories pursuant to this
subparagraph 5.(F) when any Event of Default has occurred and is continuing. 

6.    ADJUSTMENTS TO THE PROPERTY. 

        (A)    Status of Property.    All Improvements on the Land from time to time shall be owned by BNPPLC and shall
constitute "Property" covered by this Lease. Further, as provided in the Construction Management Agreement, to the extent heretofore or hereafter acquired (in whole or in part) with any portion of the
Initial Funding Advance or with any Construction Advances or with other funds for which Specialty Laboratories receives reimbursement from the Initial Funding Advance or Construction Advances, all
furnishings, furniture, chattels, permits, licenses, franchises, certificates and other personal property of whatever nature shall have been acquired on behalf of BNPPLC by Specialty Laboratories and
shall constitute "Property" covered by this Lease, as shall all renewals or replacements of or substitutions for any such Property. Upon request of BNPPLC, but not more often than once in any period
of twelve consecutive months, Specialty Laboratories shall deliver to BNPPLC an inventory describing all significant items of Personal Property (and, in the case of tangible personal property, showing
the make, model, serial number and location thereof) other than Improvements, with a certification by Specialty Laboratories that such inventory is true and complete and that all items specified in
the inventory are covered by this Lease free and clear of any Lien other than the Permitted Encumbrances or Liens Removable by BNPPLC. 

Lease Agreement - Page 14

   
        (B)    Changes in the Land Covered by the Ground Lease.    Upon any amendment of the definition of the "Land"
covered
by the Ground Lease, the "Land" as defined in and covered by this Lease and the other Operative Documents will also be so amended. 

7.    ENVIRONMENTAL. 

        (A)    Environmental Covenants by Specialty Laboratories.    Without limiting Specialty Laboratories' obligations
under the Ground Lease with respect to Hazardous Substances and Environmental Losses, Specialty Laboratories covenants that: 

        (1)  Specialty
Laboratories shall not conduct or permit others to conduct Hazardous Substance Activities on the Property, except Permitted Hazardous Substance Use and
Remedial Work. 

        (2)  Specialty
Laboratories shall not discharge or permit the discharge of anything (including Permitted Hazardous Substances) on or from the Property that would require any
permit under applicable Environmental Laws, other than (1) storm water runoff, (2) fume hood emissions, (3) waste water discharges through a publicly owned treatment works,
(4) discharges that are a necessary part of any Remedial Work, and (5) other similar discharges consistent with the definition herein of Permitted Hazardous Substance Use which do not
significantly increase the risk of Environmental Losses to BNPPLC, in each case in strict compliance with Environmental Laws. 

        (3)  Following
any discovery that Remedial Work is required by Environmental Laws or otherwise reasonably believed by BNPPLC to be required, and to the extent not
inconsistent with the other provisions of this Lease, Specialty Laboratories shall promptly perform and diligently and continuously pursue such Remedial Work, in each case in strict compliance with
Environmental Laws. 

        (4)  If
requested by BNPPLC in connection with any Remedial Work required by this subparagraph, Specialty Laboratories shall retain Environmental Consultants acceptable to
BNPPLC to evaluate any significant new information generated during Specialty Laboratories' implementation of the Remedial Work and to discuss with Specialty Laboratories whether such new information
indicates the need for
any additional measures that Specialty Laboratories should take to protect the health and safety of persons (including employees, contractors and subcontractors and their employees) or to protect the
environment. Specialty Laboratories shall implement any such additional measures to the extent required with respect to the Property by Environmental Laws or otherwise reasonably believed by BNPPLC to
be required and to the extent not inconsistent with the other provisions of this Lease. 

        (B)    Right of BNPPLC to do Remedial Work Not Performed by Specialty Laboratories.    If Specialty Laboratories'
failure to cure any breach of the covenants set forth in subparagraph 7.(A) continues beyond the Environmental Cure Period (as defined below), BNPPLC may, in addition to any other remedies available
to it, conduct all or any part of the Remedial Work. To the extent that Remedial Work is done by BNPPLC pursuant to the preceding sentence (including any removal of Hazardous Substances), the cost
thereof shall be a demand obligation owing by Specialty Laboratories to BNPPLC. As used in this subparagraph, "Environmental Cure Period" means the
period ending on the earlier of: (1) sixty days after Specialty Laboratories is notified of the breach which must be cured within such period, (2) the date that any writ or order is
issued for the levy or sale of any property owned by BNPPLC (including the Property) because of such breach, (3) the date that any criminal action is instituted or overtly threatened against
BNPPLC or any of its directors, officers or employees because of such breach, or (4) any Designated Sale Date upon which, for any reason, Specialty Laboratories or an Affiliate of Specialty
Laboratories or any Applicable Purchaser shall not purchase BNPPLC's interest in the Property pursuant to the Purchase Agreement for a net price to BNPPLC 

Lease Agreement - Page 15

 

(when taken together with any Supplemental Payment paid by Specialty Laboratories pursuant to the Purchase Agreement, in the case of a purchase by an Applicable Purchaser) equal to Stipulated Loss
Value. 

        (C)    Environmental Inspections and Reviews.    BNPPLC reserves the right to retain Environmental Consultants to
review any report prepared by Specialty Laboratories or to conduct BNPPLC's own investigation to confirm whether Specialty Laboratories is complying with the requirements of this Paragraph 7.
Specialty Laboratories grants to BNPPLC and to BNPPLC's agents, employees, consultants and contractors the right to enter upon the Property during reasonable hours and after reasonable notice to
inspect the Property and to perform such tests as BNPPLC deems necessary or appropriate to review or investigate Hazardous Substances in, on, under or about the Property or any discharge or suspected
discharge of Hazardous Substances into groundwater or surface water from the Property. Specialty Laboratories shall promptly reimburse BNPPLC for the fees of its environmental consultants and the
costs of any such inspections and tests; provided, however, BNPPLC's right to reimbursement for the reasonable fees of any consultant engaged as provided in this subparagraph or for the costs of any
inspections or test undertaken as provided in this subparagraph shall be limited to the following circumstances: (1) an Event of Default shall have occurred and be continuing at the time of
such engagement; (2) Specialty Laboratories shall not have exercised the Purchase Option and BNPPLC shall have retained the consultant to establish the condition of the Property prior to any
conveyance thereof pursuant to the Purchase Agreement or to the expiration of this Lease; (3) BNPPLC shall have retained the consultant to satisfy any regulatory requirements applicable to
BNPPLC or its Affiliates; or (4) BNPPLC shall have retained the consultant because BNPPLC has been notified of a violation of Environmental Laws concerning the Property by any governmental
authority having jurisdiction. 

        (D)    Communications Regarding Environmental Matters.    

        (1)  Specialty
Laboratories shall immediately advise BNPPLC and Participants of (1) any discovery known to Specialty Laboratories of any event or circumstance which
would render any of the representations of Specialty Laboratories herein or in any of the other Operative Documents concerning environmental matters materially inaccurate or misleading if made at the
time of such discovery and assuming that Specialty Laboratories was aware of all relevant facts, (2) any Remedial Work (or change in Remedial Work) required or undertaken by Specialty
Laboratories or its Affiliates in response to any (A) discovery of any Hazardous Substances on, under or about the Property other than Permitted Hazardous Substances or (B) any claim for
damages resulting from Hazardous Substance Activities, (3) any discovery known to Specialty Laboratories of any occurrence or condition on any real property adjoining or in the vicinity of the
Property which is not disclosed in the existing Approved Plans and which would or could reasonably be expected to cause the Property or any part thereof to be subject to any ownership, occupancy,
transferability or use restrictions under Environmental Laws, or (4) any investigation or inquiry known to Specialty Laboratories of any failure or alleged failure by Specialty Laboratories to
comply with Environmental Laws affecting the Property by any governmental authority responsible for enforcing Environmental Laws. In such event, Specialty Laboratories shall deliver to BNPPLC within
thirty days after BNPPLC's request (or such longer period as may be reasonably required), a preliminary written environmental plan setting forth a general description of the action that Specialty
Laboratories proposes to take with respect thereto, if any, to bring the Property into compliance with Environmental Laws or to correct any breach by Specialty Laboratories of this Paragraph 7,
including any proposed Remedial Work, the estimated cost and time of completion, the name of the contractor and a copy of the construction contract, if any, and such additional data, instruments,
documents, agreements or other materials or information as BNPPLC may reasonably request. 

Lease Agreement - Page 16

 

        (2)  Specialty
Laboratories shall provide BNPPLC and Participants with copies of all material written communications with federal, state and local governments, or agencies
relating to the matters listed in the preceding clause (1). Specialty Laboratories shall also provide BNPPLC and Participants with copies of any correspondence from third Persons which threaten
litigation over any significant failure or alleged significant failure of Specialty Laboratories to maintain or operate the Property in accordance with Environmental Laws. 

        (3)  Prior
to Specialty Laboratories' submission of a Material Environmental Communication to any governmental or regulatory agency or third party, Specialty Laboratories
shall, to the extent practicable, deliver to BNPPLC and Participants a draft of the proposed submission (together with the proposed date of submission), and in good faith assess and consider any
comments of BNPPLC regarding the same. Promptly after BNPPLC's request, Specialty Laboratories shall meet with BNPPLC to discuss the submission, shall provide any additional information reasonably
requested by BNPPLC and shall provide a written explanation to BNPPLC addressing the issues raised by comments (if any) of BNPPLC regarding the submission, including a reasoned analysis supporting any
decision by Specialty Laboratories not to modify the submission in accordance with comments of BNPPLC. 

8.    INSURANCE REQUIRED AND CONDEMNATION. 

        (A)    Liability Insurance.    Throughout the Term Specialty Laboratories shall maintain commercial general liability
insurance against claims for bodily and personal injury, death and property damage occurring in or upon or resulting from any occurrence in or upon the Property under one or more insurance policies
that satisfy the Minimum Insurance Requirements. Specialty Laboratories shall deliver and maintain with BNPPLC for each liability insurance policy required by this Lease written confirmation of the
policy and the scope of the coverage provided thereby issued by the applicable insurer or its authorized agent, which confirmation must also satisfy the Minimum Insurance Requirements. 

        (B)    Property Insurance.    Throughout the Term Specialty Laboratories will keep all Improvements (including all
alterations, additions and changes made to the Improvements) insured against fire and other casualty under one or more property insurance policies that satisfy the Minimum Insurance Requirements.
Specialty Laboratories shall deliver and maintain with BNPPLC for each property insurance policy required by this Lease written confirmation of the policy and the scope of the coverage provided
thereby issued by the applicable insurer or its authorized agent, which confirmation must also satisfy the Minimum Insurance Requirements. If any of the Property is destroyed or damaged by fire,
explosion, windstorm, hail or by any other casualty against which insurance shall have been required hereunder, (i) BNPPLC may, but shall not be obligated to, make proof of loss if not made
promptly by Specialty Laboratories after notice from BNPPLC, (ii) each insurance company concerned is hereby authorized and directed to make payment for such loss directly to BNPPLC for
application as required by Paragraph 9, and (iii) BNPPLC may settle, adjust or compromise any and all claims for loss, damage or destruction under any policy or policies of insurance
(provided, that if any such claim is for less than [***]*, if no 97-10/Event shall have occurred and no Event of Default shall have
occurred and be continuing, Specialty Laboratories shall have the right to settle, adjust or compromise the claim as Specialty Laboratories deems appropriate; and, provided further, that so long as no
97-10/Event shall have occurred and no Event of Default shall have occurred and be continuing, BNPPLC must provide Specialty Laboratories with at least forty-five days notice
of BNPPLC's intention to settle any such claim before settling it unless Specialty Laboratories shall already have approved of the settlement by BNPPLC). BNPPLC shall not be in any event or
circumstances liable or responsible for failure to collect, or to exercise diligence in the collection of, any insurance proceeds. If any casualty shall result in damage to or loss or destruction of
the Property, Specialty Laboratories shall give prompt notice thereof to BNPPLC and Paragraph 9 shall apply. 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

Lease Agreement - Page 17

 

        (C)    Failure to Obtain Insurance.    If Specialty Laboratories fails to obtain any insurance or to provide
confirmation of any such insurance as required by this Lease, and shall not cure such default within three Business Days after any Responsible Financial Office of Specialty Laboratories shall become
aware of such failure, BNPPLC shall be entitled (but not required) to obtain the insurance that Specialty Laboratories has failed to obtain or for which Specialty Laboratories has not provided the
required confirmation and, without limiting BNPPLC's other remedies under the circumstances, BNPPLC may require Specialty Laboratories to reimburse BNPPLC for the cost of such insurance and to pay
interest thereon computed at the Default Rate from the date such cost was paid by BNPPLC until the date of reimbursement by Specialty Laboratories. 

        (D)    Condemnation.    Immediately upon obtaining knowledge of the institution of any proceedings for the
condemnation of the Property or any portion thereof, or any other similar governmental or quasi-governmental proceedings arising out of injury or damage to the Property or any portion thereof, each
party shall promptly notify the other (provided, however, BNPPLC shall have no liability for its failure to provide such notice) of the pendency of such proceedings. Specialty Laboratories shall, at
its expense, diligently prosecute any such proceedings and shall consult with BNPPLC, its attorneys and experts and cooperate with them as reasonably requested in the carrying on or defense of any
such proceedings. All proceeds of condemnation awards or proceeds of sale in lieu of condemnation with respect to the Property and all judgments, decrees and awards for injury or damage to the
Property shall be paid to BNPPLC as Escrowed Proceeds, and all such proceeds will be applied as provided in Paragraph 9. BNPPLC is hereby authorized, in its own name or in the name of Specialty
Laboratories or in the name of both, at any time after a 97-10/Event or when an Event of Default shall have occurred and be continuing, but not otherwise without Specialty Laboratories'
prior consent, to execute and deliver valid acquittances for, and to appeal from, any such judgment, decree or award concerning condemnation of any of the Property. BNPPLC shall not be in any event or
circumstances liable or responsible for failure to collect, or to exercise diligence in the collection of, any such proceeds, judgments, decrees or awards. 

        Notwithstanding
the foregoing provisions of this subparagraph, if condemnation proceeds totaling not more than [***]* are to be
recovered as a result of a taking of less than all or substantially all of the Property, Specialty Laboratories may directly receive and hold such proceeds so long as no Event of Default shall have
occurred and be continuing and so long as Specialty Laboratories applies such proceeds as required herein. 

        (E)    Waiver of Subrogation.    Specialty Laboratories, for itself and for any Person claiming through it (including
any insurance company claiming by way of subrogation), waives any and every claim which arises or may arise in its favor against BNPPLC or any other Interested Party for any and all Losses, to the
extent that Specialty Laboratories is compensated by insurance or would be compensated by the insurance policies contemplated in this Lease, but for any deductible or self-insured
retention maintained under such insurance or but for a failure of Specialty Laboratories to maintain the insurance as required by this Lease. Specialty Laboratories agrees to have such insurance
policies properly endorsed so as to make them valid notwithstanding this waiver, if such endorsement is required to prevent a loss of insurance. 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

Lease Agreement - Page 18

 

9.    APPLICATION OF INSURANCE AND CONDEMNATION PROCEEDS. 

        (A)    Collection and Application of Insurance and Condemnation Proceeds Generally.    This Paragraph 9 shall
govern the application of proceeds received by BNPPLC or Specialty Laboratories during the Term from any third party (1) under any property insurance policy as a result of damage to the
Property (including proceeds payable under any insurance policy covering the Property which is maintained by Specialty Laboratories), (2) as compensation for any restriction placed upon the use
or development of the Property or for the condemnation of the Property or any portion thereof, or (3) because of any judgment, decree or award for injury or damage to the Property (e.g.,damage
resulting from a third party's release of Hazardous Materials onto the Property); excluding, however, any funds paid to BNPPLC by BNPPLC's Parent, by an Affiliate of BNPPLC or by any Participant that
is made to compensate BNPPLC for any Losses BNPPLC may suffer or incur in connection with this Lease or the Property. Except as provided in subparagraph 9.(D), Specialty Laboratories will promptly pay
over to BNPPLC any insurance, condemnation or other proceeds covered by this Paragraph 9 which Specialty Laboratories may receive from any insurer, condemning authority or other third party.
All proceeds covered by this Paragraph 9, including those received by BNPPLC from Specialty Laboratories or third parties, shall be applied as follows: 

        (1)  First,
proceeds covered by this Paragraph 9 will be used to reimburse BNPPLC for any costs and expenses, including Attorneys' Fees, that BNPPLC incurred to
collect the proceeds. 

        (2)  Second,
the proceeds remaining after such reimbursement to BNPPLC (hereinafter, the "Remaining Proceeds") will be
applied, as hereinafter more particularly provided, either as a Qualified Prepayment or to reimburse Specialty Laboratories or BNPPLC for the actual out-of-pocket costs of
repairing or restoring the Property. Until, however, any Remaining Proceeds received by BNPPLC are applied by BNPPLC as a Qualified Prepayment or applied by BNPPLC to reimburse costs of repairs to or
restoration of the Property pursuant to this Paragraph 9, BNPPLC shall hold and maintain such Remaining Proceeds as Escrowed Proceeds in an interest bearing account, and all interest earned on
such account shall be added to and made a part of such Escrowed Proceeds. 

        (B)    Advances of Escrowed Proceeds to Specialty Laboratories.    Except as otherwise provided below in this
Paragraph 9, BNPPLC shall advance all Remaining Proceeds held by it as Escrowed Proceeds to reimburse Specialty Laboratories for the actual out-of-pocket cost to
Specialty Laboratories of repairing
or restoring the Property in accordance with the requirements of this Lease and the other Operative Documents as the applicable repair or restoration, progresses and upon compliance by Specialty
Laboratories with such terms, conditions and requirements as may be reasonably imposed by BNPPLC. In no event, however, shall BNPPLC be required to pay Escrowed Proceeds to Specialty Laboratories in
excess of the actual out-of-pocket cost to Specialty Laboratories of the applicable repair, restoration or replacement, as evidenced by invoices or other documentation
reasonably satisfactory to BNPPLC, it being understood that BNPPLC may retain and apply any such excess as a Qualified Prepayment. 

        (C)    Application of Escrowed Proceeds as a Qualified Prepayment.    Provided no 97-10/Event has occurred
and no Event of Default shall have occurred and be continuing, BNPPLC shall apply any Remaining Proceeds paid to it (or other amounts available for application as a Qualified Prepayment) as a
Qualified Prepayment on any date that BNPPLC is directed to do so by a notice from Specialty Laboratories; however, if such a notice from Specialty Laboratories specifies an effective date for a
Qualified Prepayment that is less than five Business Days after BNPPLC's actual receipt of the notice, BNPPLC may postpone the date of the Qualified Prepayment to any date not later than five Business
Days after BNPPLC's receipt of the notice. In any event, except when BNPPLC is required by the preceding sentence to apply Remaining Proceeds or other amounts as a Qualified Prepayment on an Advance
Date or Base Rent Date, BNPPLC may deduct Breakage Costs incurred in connection with any Qualified Prepayment from the Remaining Proceeds or other amounts available for application as 

Lease Agreement - Page 19

 

the Qualified Prepayment, and Specialty Laboratories will reimburse BNPPLC upon request for any such Breakage Costs that BNPPLC incurs but does not deduct. 

        (D)    Right of Specialty Laboratories to Receive and Apply Remaining Proceeds Below a Certain Level.    If, after the
Completion Date, any taking by condemnation of any portion of the Property or any casualty resulting in the diminution, destruction, demolition or damage to any portion of the Property shall (in the
good faith judgment of BNPPLC) reduce the then current "AS IS" market value by less than $1,000,000 and (in the good faith estimation of BNPPLC) be unlikely to result in Remaining Proceeds of more
than $1,000,000, and if no 97-10/Event shall have occurred and no Event of Default shall have occurred and be continuing, then BNPPLC will, upon Specialty Laboratories' request, instruct
the condemning authority or insurer, as applicable, to pay the Remaining Proceeds resulting therefrom directly to Specialty Laboratories. Specialty Laboratories shall apply any such Remaining Proceeds
to the repair or restoration of the Property to a safe and secure condition and to a value of no less than the value before taking or casualty. 

        (E)    Special Provisions Applicable After a 97-10/Event or Event of Default.    Notwithstanding the
foregoing, after any 97-10/Event, and when any Event of Default shall have occurred and be continuing, BNPPLC shall be entitled to receive and collect all insurance, condemnation or other
proceeds governed by this Paragraph 9 and to apply all Remaining Proceeds, when and to the extent deemed appropriate by BNPPLC in its sole discretion, either (A) to the reimbursement of
Specialty Laboratories or BNPPLC for the out-of-pocket cost of repairing or restoring the Property, or (B) as Qualified Prepayments. 

        (F)    Specialty Laboratories' Obligation to Restore.    Regardless of the adequacy of any Remaining Proceeds
available to Specialty Laboratories hereunder, if on or after the Completion Date, the Property is
damaged by fire or other casualty or less than all or substantially all of the Property is taken by condemnation, Specialty Laboratories must promptly restore or improve the Property or the remainder
thereof to a value no less than Stipulated Loss Value and to a reasonably safe and sightly condition. If for some reason Specialty Laboratories is unable to restore the Property or remainder thereof
to a value of no less than Stipulated Loss Value, then Specialty Laboratories must nevertheless promptly restore the Property or remainder thereof to a reasonably safe and sightly condition and pay to
BNPPLC for application as a Qualified Prepayment the amount (if any), as determined by BNPPLC, needed to reduce Stipulated Loss Value to no more than the then current "AS IS" market value of the
Property or remainder thereof. 

        (G)    Takings of All or Substantially All of the Property on or after the Completion Date.    In the event of any
taking of all or substantially all of the Property on or after the Completion Date, BNPPLC shall be entitled to apply all Remaining Proceeds as a Qualified Prepayment. In addition, if Stipulated Loss
Value immediately prior to any such taking exceeds the sum of the Remaining Proceeds resulting from such condemnation, then BNPPLC shall be entitled to recover the excess from Specialty Laboratories
upon demand as an additional Qualified Prepayment, whereupon this Lease shall terminate. Any taking of so much of the Property as, in BNPPLC's good faith judgment, makes it impracticable to restore or
improve the remainder thereof as required by part (2) of the preceding subparagraph shall be considered a taking of substantially all the Property for purposes of this Paragraph 9. 

10.    ADDITIONAL REPRESENTATIONS, WARRANTIES AND COVENANTS OF SPECIALTY LABORATORIES CONCERNING THE PROPERTY.    Specialty
Laboratories represents, warrants and covenants as follows: 

        (A)    Operation and Maintenance.    During the Term, Specialty Laboratories shall operate and maintain the Property
in a good and workmanlike manner and substantially in compliance with all Applicable Laws and will pay or cause to be paid all fees or charges of any kind in connection therewith. (If Specialty
Laboratories does not promptly correct any failure of the Property to comply with Applicable Laws that is the subject of a written notice given to Specialty Laboratories or BNPPLC 

Lease Agreement - Page 20

 

by any governmental authority, then for purposes of the preceding sentence, Specialty Laboratories shall be considered not to have maintained the Property "substantially in accordance with Applicable
Laws" whether or not the noncompliance would be substantial in the absence of the notice.) During the Term, Specialty Laboratories shall not use or occupy, or allow the use or occupancy of, the
Property in any manner which violates any Applicable Law or which constitutes a public or private nuisance or which makes void, voidable or cancelable any insurance then in force with respect thereto.
During the Term, to the extent that any of the following would, individually or in the aggregate, increase the likelihood of a 97-10/Event or materially and adversely affect the value of
the Property or the use of the Property for purposes permitted by this Lease, Specialty Laboratories shall not, without BNPPLC's prior consent: (i) initiate or permit any zoning
reclassification of the Property; (ii) seek any variance under existing zoning ordinances applicable to the Property; (iii) use or permit the use of the Property in a manner that would
result in such use becoming a nonconforming use under applicable zoning ordinances or similar laws, rules or regulations; (iv) execute or file any subdivision plat affecting the Property; or
(v) consent to the annexation of the Property to any municipality. If during the Term (A) a change in the zoning or other Applicable Laws affecting the permitted use or development of
the Property shall occur after the Completion Date that (in BNPPLC's good faith judgment) materially reduces the value of the Property, or (B) conditions or circumstances on or about the
Property are discovered after the Completion Date (such as the presence of an endangered species) which
substantially impede development and thereby (in BNPPLC's good faith judgment) materially reduce the value of the Property, then Specialty Laboratories shall upon demand pay BNPPLC an amount equal to
such reduction (as determined by BNPPLC in good faith) for application as a Qualified Prepayment. Specialty Laboratories shall not cause or permit any drilling or exploration for, or extraction,
removal or production of, minerals from the surface or subsurface of the Property, and Specialty Laboratories shall not do anything that could reasonably be expected to significantly reduce the market
value of the Property. If Specialty Laboratories receives a notice or claim from any federal, state or other governmental authority that the Property is not in compliance with any Applicable Law, or
that any action may be taken against BNPPLC because the Property does not comply with any Applicable Law, Specialty Laboratories shall promptly furnish a copy of such notice or claim to BNPPLC. 

        Notwithstanding
the foregoing, Specialty Laboratories may in good faith, by appropriate proceedings, contest the validity and applicability of any Applicable Law with respect to the
Property, and pending such contest Specialty Laboratories shall not be deemed in default hereunder because of the violation of such Applicable Law, if Specialty Laboratories diligently prosecutes such
contest to completion in a manner reasonably satisfactory to BNPPLC, and if Specialty Laboratories promptly causes the Property to comply with any such Applicable Law upon a final determination by a
court of competent jurisdiction that the same is valid and applicable to the Property; provided, however, in any event such contest shall be concluded and the violation of such Applicable Law must be
corrected by Specialty Laboratories and any claims asserted against BNPPLC or the Property because of such violation must be paid by Specialty Laboratories, all prior to the earlier of (i) the
date that any criminal prosecution is instituted or overtly threatened against BNPPLC or any of its directors, officers or employees because of such violation, (ii) the date that any action is
taken or overtly threatened by any governmental authority against BNPPLC or any property owned by BNPPLC (including the Property) because of such violation, or (iii) a Designated Sale Date upon
which, for any reason, Specialty Laboratories or an Affiliate of Specialty Laboratories or any Applicable Purchaser shall not purchase BNPPLC's interest in the Property pursuant to the Purchase
Agreement for a price to BNPPLC (when taken together with any Supplemental Payment paid by Specialty Laboratories pursuant to the Purchase Agreement, in the case of a purchase by an Applicable
Purchaser) equal to the Break Even Price. 

        (B)    Debts for Construction, Maintenance, Operation or Development.    Specialty Laboratories shall cause all debts
and liabilities incurred in the construction, maintenance, operation or development of the Property, including all debts and liabilities for labor, material and equipment and all debts and 

Lease Agreement - Page 21

 

charges for utilities servicing the Property, to be promptly paid; provided, that nothing in this subparagraph will be construed to require Specialty Laboratories to remove Liens Removable by BNPPLC. 

        Notwithstanding
the foregoing, Specialty Laboratories may in good faith, by appropriate proceedings, contest the validity, applicability or amount of any asserted mechanic's or
materialmen's lien and pending such contest Specialty Laboratories shall not be deemed in default under this subparagraph because of the contested lien if (1) within thirty days after being
asked to do so by BNPPLC, Specialty Laboratories bonds over to BNPPLC's reasonable satisfaction all such contested liens against the Property alleged to secure an amount in excess of $5,000,000
(individually or in the aggregate), (2) Specialty Laboratories diligently prosecutes such contest to completion in a manner reasonably
satisfactory to BNPPLC, and (3) Specialty Laboratories promptly causes to be paid any amount adjudged by a court of competent jurisdiction to be due, with all costs and interest thereon,
promptly after such judgment becomes final; provided, however, that in any event each such contest shall be concluded and the lien, interest and costs must be paid by Specialty Laboratories prior to
the earlier of (i) the date that any criminal prosecution is instituted or overtly threatened against BNPPLC or its directors, officers or employees because of the nonpayment thereof,
(ii) the date that any writ or order is issued under which the Property or any other property in which BNPPLC has an interest may be seized or sold or any other action is taken or overtly
threatened against BNPPLC or any property in which BNPPLC has an interest because of the nonpayment thereof, or (iii) a Designated Sale Date upon which, for any reason, Specialty Laboratories
or an Affiliate of Specialty Laboratories or any Applicable Purchaser shall not purchase BNPPLC's interest in the Property pursuant to the Purchase Agreement for a price to BNPPLC (when taken together
with any Supplemental Payment paid by Specialty Laboratories pursuant to the Purchase Agreement, in the case of a purchase by an Applicable Purchaser) equal to the Break Even Price. 

        (C)    Repair, Maintenance, Alterations and Additions.    Specialty Laboratories shall keep the Property in good
order, operating condition and appearance and shall cause all necessary repairs, renewals and replacements to be promptly made. Specialty Laboratories will not allow any of the Property to be
materially misused, abused or wasted, and Specialty Laboratories shall promptly replace any worn-out fixtures and Personal Property with fixtures and Personal Property comparable to the
replaced items when new. Specialty Laboratories shall not, without the prior consent of BNPPLC, (i) remove from the Property any fixture or Personal Property having significant value except
such as are replaced by Specialty Laboratories by fixtures or Personal Property of equal suitability and value, free and clear of any lien or security interest (and for purposes of this clause
"significant value" will mean any fixture or Personal Property that has a value of more than $100,000 or that, when considered together with all other fixtures and Personal Property removed and not
replaced by Specialty Laboratories by items of equal suitability and value, has an aggregate value of $500,000 or more) or (ii) make material new Improvements or alter Improvements in any
material respect following completion of the Work contemplated in the Construction Management Agreement. 

        However,
provided that no 97-10/Event has occurred, and so long as no Event of Default has occurred and is continuing, BNPPLC will not unreasonably withhold a consent
requested by Specialty Laboratories pursuant to the preceding sentence. Specialty Laboratories acknowledges, however, that BNPPLC's refusal or failure to give such consent shall be deemed reasonable
if BNPPLC believes in good faith that the action for which Specialty Laboratories is requesting consent will have a material adverse impact upon the value of the Property (taken as whole), or if
Specialty Laboratories has not provided BNPPLC with adequate information to allow BNPPLC to properly evaluate such impact on value. 

        Without
limiting the foregoing, Specialty Laboratories will notify BNPPLC before making any significant alterations to the Improvements after the completion of the Construction Project. 

Lease Agreement - Page 22

 

        (D)    Permitted Encumbrances and Development Documents.    Specialty Laboratories shall during the Term comply with
and will cause to be performed all of the covenants, agreements and obligations imposed upon the owner of any interest in the Property by the Permitted Encumbrances or the Development Documents.
Without limiting the foregoing, Specialty Laboratories shall cause all amounts to be paid when due, the payment of which is secured by any Lien against the Property created by the Permitted
Encumbrances. Without the prior consent of BNPPLC, Specialty Laboratories shall not enter into, initiate, approve or consent to any modification of any Permitted Encumbrance or Development Document
that would create or expand or purport to create or expand obligations or restrictions which would encumber BNPPLC's interest in the Property. (Whether BNPPLC must give any such consent requested by
Specialty Laboratories during the Term of this Lease shall be governed by subparagraph 3(A) of the Closing Certificate.) 

        Notwithstanding
the foregoing, Specialty Laboratories may in good faith, by appropriate proceedings, contest the validity and applicability of any Permitted Encumbrance described in  Exhibit B to the Closing
Certificate, and pending such contest Specialty Laboratories shall not be deemed in default hereunder because of the
violation of such Permitted Encumbrance, if Specialty Laboratories diligently prosecutes such contest to completion in a manner reasonably satisfactory to BNPPLC, and if Specialty Laboratories
promptly causes the Property to comply with any such Permitted Encumbrance upon a final determination by a court of competent jurisdiction that the same is valid and applicable to the Property;
provided, however, in any event such contest shall be concluded and the violation of such Permitted Encumbrance must be corrected by Specialty Laboratories and any claims asserted against BNPPLC or
the Property because of such violation must be paid by Specialty Laboratories, all prior to the earlier of (i) the date that any criminal prosecution is instituted or overtly threatened against
BNPPLC or any of its directors, officers or employees because of such violation, (ii) the date that any action is taken by any governmental authority against BNPPLC or any property owned by
BNPPLC (including the Property) because of such violation, or (iii) a Designated Sale Date upon which, for any reason, Specialty Laboratories or an Affiliate of Specialty Laboratories or any
Applicable Purchaser shall not purchase BNPPLC's interest in the Property pursuant to the Purchase Agreement for a price to BNPPLC (when taken together with any Supplemental Payments paid by Specialty
Laboratories pursuant to the Purchase Agreement, in the case of a purchase by an Applicable Purchaser) equal to the Break Even Price. 

        (E)    Books and Records Concerning the Property.    Specialty Laboratories shall keep books and records that are
accurate and complete in all material respects for the Property and, subject to Paragraph 21, will permit all such books and records (including all contracts, statements, invoices, bills and
claims for labor, materials and services supplied for the construction and operation of any Improvements) to be inspected and copied by BNPPLC. This subparagraph shall not be construed as requiring
Specialty Laboratories to regularly maintain separate books and records relating exclusively to the Property; provided, however, that upon request, Specialty Laboratories shall construct or abstract
from its regularly maintained books and records information required by this subparagraph relating to the Property. 

        (F)    No Discrimination.    As required by one of the Development Documents, Specialty Laboratories agrees for itself
and its successors and permitted assigns that: 

There
shall be no discrimination against or segregation of any person or group of persons on account of race, color, creed, religion, sex, marital status, national origin or ancestry, in the leasing,
subleasing,
transferring, use, occupancy, tenure or enjoyment of the premises herein leased, nor shall Specialty Laboratories itself, or any person claiming under or through Specialty Laboratories, establish or
permit any such practice or practices of discrimination or segregation with reference to the selection, location, number, use or occupancy of tenants, lessees, subtenants, sublessees or vendees in the
premises herein leased. 

Lease Agreement - Page 23

 

11.  ASSIGNMENT AND SUBLETTING BY SPECIALTY LABORATORIES. 

        (A)    BNPPLC's Consent Required.    Without the prior consent of BNPPLC, Specialty Laboratories shall not assign,
transfer, mortgage, pledge or hypothecate this Lease or any interest of Specialty Laboratories hereunder and shall not sublet all or any part of the Property, by operation of law or otherwise;
provided, that subject to subparagraph 11.(C) below, so long as no 97-10/Event has occurred and no Event of Default has occurred and is continuing, Specialty Laboratories shall be entitled
to sublet (1) to Affiliates of Specialty Laboratories, or (2) no more than thirty-three percent (33%) (computed on the basis of square footage) of the useable space in then existing and
completed building Improvements to Persons who are not Specialty Laboratories' Affiliates; provided, that (1) any sublease by Specialty Laboratories must be made expressly subject and
subordinate to the terms hereof, (2) such sublease must have a term equal to or less than the remainder of the then effective Term of this Lease, and (3) the use permitted by such
sublease must be expressly limited to uses consistent with subparagraph 2.(A) or other uses approved in advance by BNPPLC as uses that will not present any extraordinary risk of uninsured
environmental or other liability. 

        (B)    Standard for BNPPLC's Consent to Assignments and Certain Other Matters.    Consents and approvals of BNPPLC
which are required by this Paragraph 11 will not be unreasonably withheld, but Specialty Laboratories acknowledges that BNPPLC's withholding of such consent or approval shall be reasonable if
BNPPLC determines in good faith that (1) giving the approval may increase BNPPLC's risk of liability for any existing or future environmental problem, (2) giving the approval is likely
to substantially increase BNPPLC's administrative burden of complying with or monitoring Specialty Laboratories' compliance with the requirements of this Lease, or (3) any transaction for which
Specialty Laboratories has requested the consent or approval would negate Specialty Laboratories' representations in the Operative Documents regarding ERISA or cause any of the Operative Documents (or
any exercise of BNPPLC's rights thereunder) to constitute a violation of any provision of ERISA. 

        (C)    Consent Not a Waiver.    No consent by BNPPLC to a sale, assignment, transfer, mortgage, pledge or
hypothecation of this Lease or Specialty Laboratories' interest hereunder, and no assignment or subletting of the Property or any part thereof in accordance with this Lease or otherwise with BNPPLC's
consent, shall release Specialty Laboratories from liability hereunder; and any such consent shall apply only to the specific transaction thereby authorized and shall not relieve Specialty
Laboratories from any requirement of obtaining the prior consent of BNPPLC to any further sale,
assignment, transfer, mortgage, pledge or hypothecation of this Lease or any interest of Specialty Laboratories hereunder. 

12.  ASSIGNMENT BY BNPPLC. 

        (A)    Restrictions on Transfers.    Except by a Permitted Transfer, BNPPLC shall not assign, transfer, mortgage,
pledge, encumber or hypothecate this Lease or the other Operative Documents or any interest of BNPPLC in and to the Property during the Term without the prior consent of Specialty Laboratories, which
consent Specialty Laboratories may withhold in its sole discretion. Further, notwithstanding anything to the contrary herein contained, if withholding taxes are imposed on the rents and other amounts
payable to BNPPLC hereunder because of BNPPLC's assignment of this Lease to any citizen of, or any corporation or other entity formed under the laws of, a country other than the United States,
Specialty Laboratories shall not be required to compensate BNPPLC or any such assignee for the withholding tax. If, BNPPLC transfers the Property or any part thereof by a conveyance or that does not
constitute a Permitted Transfer, with the result that additional transfer taxes or other Impositions are assessed against the Property or the owner thereof, BNPPLC shall be required to pay such
additional transfer taxes or other Impositions. 

Lease Agreement - Page 24

 

        (B)    Effect of Permitted Transfer or other Assignment by BNPPLC.    If, by a Permitted Transfer, BNPPLC sells or
otherwise transfers the Property and assigns to the transferee all of BNPPLC's rights under this Lease and under the other Operative Documents, and if the transferee expressly assumes all of BNPPLC's
obligations under this Lease and under the other Operative Documents, then BNPPLC shall thereby be released from any obligations arising after such assumption under this Lease or under the other
Operative Documents (other than any liability for a breach of any continuing obligation to provide Construction Advances under the Construction Management Agreement), and Specialty Laboratories shall
look solely to each successor in interest of BNPPLC for performance of such obligations. 

13.  BNPPLC'S RIGHT OF ACCESS. 

        (A)  BNPPLC
and BNPPLC's representatives may (subject to subparagraph 21.(C), which concerns building security) enter the Property to Specialty Laboratories for the purpose
of making inspections or performing any work BNPPLC is authorized to undertake by the next subparagraph or for the purpose confirming whether Specialty Laboratories has complied with the requirements
of this Lease or the other Operative Documents. So long as no Event of Default has occurred and is continuing, BNPPLC
will give Specialty Laboratories at least five Business Days notice before any making any such entry over the objection of Specialty Laboratories and will limit any such entry to normal business
hours. 

        (B)  If
Specialty Laboratories fails to perform any act or to take any action required of it by this Lease or the Closing Certificate, or to pay any money which Specialty
Laboratories is required by this Lease or the Closing Certificate to pay, and if such failure or action constitutes an Event of Default or renders BNPPLC or any director, officer, employee or
Affiliate of BNPPLC at risk of criminal prosecution or renders BNPPLC's interest in the Property or any part thereof at risk of forfeiture by forced sale or otherwise, then in addition to any other
remedies specified herein or otherwise available, BNPPLC may, perform or cause to be performed such act or take such action or pay such money. Any expenses so incurred by BNPPLC, and any money so paid
by BNPPLC, shall be a demand obligation owing by Specialty Laboratories to BNPPLC. Further, BNPPLC, upon making such payment, shall be subrogated to all of the rights of the person, corporation or
body politic receiving such payment. But nothing herein shall imply any duty upon the part of BNPPLC to do any work which under any provision of this Lease Specialty Laboratories may be required to
perform, and the performance thereof by BNPPLC shall not constitute a waiver of Specialty Laboratories' default. BNPPLC may during the progress of any such work permitted by BNPPLC hereunder on or in
the Property keep and store upon the Property all necessary materials, tools, and equipment. BNPPLC shall not in any event be liable for inconvenience, annoyance, disturbance, loss of business, or
other damage to Specialty Laboratories or the subtenants or invitees of Specialty Laboratories by reason of the performance of any such work, or on account of bringing materials, supplies and
equipment into or through the Property during the course of such work, and the obligations of Specialty Laboratories under this Lease shall not thereby be excused in any manner. 

14.  REMEDIES. 

        (A)    Basic Remedies.    At any time after an Event of Default and after BNPPLC has given any notice required by
subparagraph 14.(B), BNPPLC shall be entitled at BNPPLC's option (and without limiting BNPPLC in the exercise of any other right or remedy BNPPLC may have, and without any further demand or notice
except as expressly described in this subparagraph 14.(A)), to exercise any one or more of the following remedies: 

        (1)  By
notice to Specialty Laboratories, BNPPLC may terminate Specialty Laboratories' right to possession of the Property. A notice given in connection with unlawful
detainer proceedings specifying a time within which to cure a default shall terminate Specialty Laboratories' right to possession if Specialty Laboratories fails to cure the default within the time
specified in the notice. 

Lease Agreement - Page 25

 

        (2)  Upon
termination of Specialty Laboratories' right to possession and without further demand or notice, BNPPLC may re-enter the Property in any manner not
prohibited by Applicable Law and take
possession of all improvements, additions, alterations, equipment and fixtures thereon and remove any persons in possession thereof. Any property in the Property may be removed and stored in a
warehouse or elsewhere. The cost of any such removal and storage shall be at the expense and risk of and for the account of Specialty Laboratories. 

        (3)  Upon
termination of Specialty Laboratories' right to possession, this Lease shall terminate and BNPPLC may recover from Specialty Laboratories: 

        (a)  The
worth at the time of award of the unpaid Rent which had been earned at the time of termination; 

        (b)  The
worth at the time of award of the amount by which the unpaid Rent which would have been earned after termination until the time of award exceeds the amount of such
rental loss that Specialty Laboratories proves could have been reasonably avoided; 

        (c)  The
worth at the time of award of the amount by which the unpaid Rent for the balance of the scheduled Term after the time of award exceeds the amount of such rental
loss that Specialty Laboratories proves could be reasonably avoided; and 

        (d)  Any
other amount necessary to compensate BNPPLC for all the detriment proximately caused by Specialty Laboratories' failure to perform Specialty Laboratories'
obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, including the costs and expenses (including Attorneys' Fees, advertising costs and brokers'
commissions) of recovering possession of the Property, removing persons or property therefrom, placing the Property in good order, condition, and repair, preparing and altering the Property for
reletting, all other costs and expenses of reletting, and any loss incurred by BNPPLC as a result of Specialty Laboratories' failure to perform Specialty Laboratories' obligations under the other
Operative Documents. 

        (e)  Such
other amounts in addition to or in lieu of the foregoing as may be permitted from time to time by applicable California law. 

The
"worth at the time of award" of the amounts referred to in subparagraph 14.(A)(3)(a) and subparagraph 14.(A)(3)(b) shall be computed by allowing
interest at the Default Rate. The "worth at the time of award" of the amount referred to in subparagraph 14.(A)(3)(c) shall be computed by discounting
such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one percent (1%). 

        (4)  BNPPLC
may continue this Lease in force even after Specialty Laboratories' breach and abandonment and recover rent as it becomes due. Accordingly, even if Specialty
Laboratories has breached this Lease and abandoned the Property, this Lease shall continue in effect for so long as BNPPLC does not terminate Specialty Laboratories' right to possession, and BNPPLC
may enforce all of BNPPLC's rights and remedies under this Lease, including the right to recover the Rent as it becomes due under this Lease. Specialty Laboratories' right to possession shall not be
deemed to have been terminated by BNPPLC except pursuant to subparagraph 14.(A)(1) hereof. The following shall not constitute a termination of Specialty Laboratories' right to possession: 

        (a)  Acts
of maintenance or preservation or efforts to relet the Property; 

        (b)  The
appointment of a receiver upon the initiative of BNPPLC to protect BNPPLC's interest under this Lease; or 

        (c)  Reasonable
withholding of consent to an assignment or subletting, or terminating a subletting or assignment by Specialty Laboratories. 

Lease Agreement - Page 26

 

        (B)    Notice Required So Long As the Purchase Option and Specialty Laboratories' Initial Remarketing Right Continue Under the Purchase
Agreement.    Once the Term actually commences and so long as Specialty Laboratories remains in possession of the Property and there has been no termination of the
Purchase Option and Specialty Laboratories' Initial Remarketing Right as provided Paragraph 6 of the Purchase Agreement, BNPPLC's right to
exercise remedies provided in subparagraph 14.(A) will be subject to the condition precedent that BNPPLC shall have notified Specialty Laboratories, at a time when an Event of Default shall have
occurred and be continuing, of BNPPLC's intent to exercise remedies provided in subparagraph 14.(A) at least one hundred twenty days prior to exercising the remedies. The condition precedent is
intended to provide Specialty Laboratories with an opportunity to exercise the Purchase Option or Specialty Laboratories' Initial Remarketing Right before losing possession of the Property pursuant to
subparagraph 14.(A). The condition precedent is not, however, intended to extend any period for curing an Event of Default. Accordingly, if an Event of Default has occurred, and regardless of whether
any Event of Default is then continuing, BNPPLC may proceed immediately to exercise remedies provided in subparagraph 14.(A) at any time after the earlier of (i) sixty days after BNPPLC has
given such a notice to Specialty Laboratories, (ii) any date upon which Specialty Laboratories relinquishes possession of the Property, or (iii) any termination of the Purchase Option
and Specialty Laboratories' Initial Remarketing Right. 

        (C)    Enforceability.    This Paragraph 14 shall be enforceable to the maximum extent not prohibited by
Applicable Law, and the unenforceability of any provision in this Paragraph shall not render any other provision unenforceable. 

        (D)    Remedies Cumulative.    No right or remedy herein conferred upon or reserved to BNPPLC is intended to be
exclusive of any other right or remedy, and each and every such right and remedy shall be cumulative and in addition to any other right or remedy given to BNPPLC hereunder or now or hereafter existing
in favor of BNPPLC under Applicable Law or in equity. In addition to other remedies provided in this Lease, BNPPLC shall be entitled, to the extent permitted by Applicable Law or in equity, to
injunctive relief in case of the violation, or attempted or threatened violation, of any of the covenants, agreements, conditions or provisions of this Lease, or to a decree compelling performance of
any of the other covenants, agreements, conditions or provisions of this Lease to be performed by Specialty Laboratories, or to any other remedy allowed to BNPPLC at law or in equity. Nothing
contained in this Lease shall limit or prejudice the right of BNPPLC to prove for and obtain in proceedings for bankruptcy or insolvency of Specialty Laboratories by reason of the termination of this
Lease, an amount equal to the maximum allowed by any statute or rule of law in effect at the time when, and governing the proceedings in which, the damages are to be proved, whether or not the amount
be greater, equal to, or less than the amount of the loss or damages referred to above. Without limiting the generality of the foregoing, nothing contained herein shall modify, limit or impair any of
the rights and remedies of BNPPLC under the Purchase Agreement, and BNPPLC shall not be required to give the sixty day notice described in subparagraph 14.(B) as a condition precedent to any
acceleration of the Designated Sale Date or to taking any action to enforce the Purchase Agreement. 

15.    DEFAULT BY BNPPLC.    If BNPPLC should default in the performance of any of its obligations under
this Lease, BNPPLC shall have the time reasonably required, but in no event less than thirty days, to cure such default after receipt of notice from Specialty Laboratories specifying such default and
specifying what action Specialty Laboratories believes is necessary to cure the default. If Specialty Laboratories prevails in any litigation brought against BNPPLC because of BNPPLC's failure to cure
a default within the time required by the preceding sentence, then Specialty Laboratories shall be entitled to an award against BNPPLC for the monetary damages proximately caused to Specialty
Laboratories by such default (including Attorneys' Fees). 

        Notwithstanding
the foregoing, BNPPLC's right to cure as provided in this Paragraph 15 will not in any event extend the time within which BNPPLC must remove Liens Removable by
BNPPLC as required by Paragraph 16 beyond the Designated Sale Date. 

Lease Agreement - Page 27

 

16.    QUIET ENJOYMENT.    Provided Specialty Laboratories pays the Base Rent and all Additional Rent payable hereunder as and when
due and payable and keeps and fulfills all of the terms, covenants, agreements and conditions to be performed by Specialty Laboratories hereunder, BNPPLC shall not during the Term disturb Specialty
Laboratories' peaceable and quiet enjoyment of the Property; however, such enjoyment shall be subject to the terms, provisions, covenants, agreements and conditions of this Lease, to the Ground Lease,
to Permitted Encumbrances, to Development Documents and to any other claims not constituting Liens Removable by BNPPLC. If any Lien Removable by BNPPLC is claimed against the Property, BNPPLC will
remove the Lien Removable by BNPPLC promptly. Any breach by BNPPLC of this Paragraph shall render BNPPLC liable to Specialty Laboratories for any monetary damages proximately caused thereby, but as
more specifically provided in subparagraph 4.(B) above, no such breach shall entitle Specialty Laboratories to terminate this Lease or excuse Specialty Laboratories from its obligation to pay Rent. 

17.    SURRENDER UPON TERMINATION.    Unless Specialty Laboratories or an Applicable Purchaser purchases or has purchased BNPPLC's
entire interest in the Property pursuant to the terms of the Purchase Agreement and BNPPLC's entire interest in Property, Specialty Laboratories shall, upon the termination of Specialty Laboratories'
right to occupancy, surrender to BNPPLC the Property, including Improvements constructed by Specialty Laboratories and fixtures and furnishings included in the Property, free of all Hazardous
Substances (including Permitted Hazardous Substances) and tenancies and, to the extent required by BNPPLC, with all Improvements in substantially the same condition as of the date the same were
initially completed, excepting only (i) ordinary wear and tear that occurs between the maintenance, repairs and replacements required by other provisions of this Lease, and
(ii) demolition, alterations and additions which are expressly permitted by the terms of this Lease and which have been completed by Specialty Laboratories in a good and workmanlike manner in
accordance with all Applicable Laws. Any movable furniture or movable personal property belonging to Specialty Laboratories or any party claiming under Specialty Laboratories, if not removed at the
time of such termination and if BNPPLC shall so elect, shall be deemed abandoned and become the property of BNPPLC without any payment or offset therefor. If BNPPLC shall not so elect, BNPPLC may
remove such property from the Property and store it at Specialty Laboratories' risk and expense. Specialty Laboratories shall bear the expense of repairing any damage to the Property caused by such
removal by BNPPLC or Specialty Laboratories. 

18.    HOLDING OVER BY SPECIALTY LABORATORIES.    Should Specialty Laboratories not purchase BNPPLC's right, title and interest in
the Property as provided in the Purchase Agreement, but nonetheless continue to hold the Property after the termination of this Lease without BNPPLC's consent, whether such termination occurs by lapse
of time or otherwise, such holding over shall constitute and be construed as a tenancy from day to day only, at a daily Base Rent equal to: (i) Stipulated Loss Value on the day in question,
times (ii) (A) the Prime Rate in effect for such day so long as the holdover period does not extend beyond ninety days and (B) for each such day beginning with the ninety-first
day after the holdover commences, [***]*; divided by (iii) three hundred and sixty; subject, however, to all of the terms, provisions,
covenants and agreements on the part of Specialty Laboratories hereunder. No payments of money by Specialty Laboratories to BNPPLC after the termination of this Lease shall reinstate, continue or
extend the Term of this Lease and no extension of this Lease after the termination thereof shall be valid unless and until the same shall be reduced to writing and signed by both BNPPLC and Specialty
Laboratories. 

19.    RECORDING MEMORANDUM.    Contemporaneously with the execution of this Lease, the parties shall execute and record a
memorandum of this Lease for purposes of effecting constructive notice to all Persons of Specialty Laboratories' rights hereunder. 

20.    INDEPENDENT OBLIGATIONS EVIDENCED BY THE OTHER OPERATIVE DOCUMENTS.    Specialty Laboratories acknowledges and agrees that
nothing contained in this Lease shall limit, modify or otherwise affect any of Specialty Laboratories' obligations under the other Operative Documents, which obligations are intended to be separate,
independent and in addition to, and not in lieu of, the obligations set forth herein. Further, in the event of any inconsistency between the express terms and provisions of the Purchase Agreement and
the express terms and provisions of this Lease, the express terms and provisions of the Purchase Agreement shall control. 

*
PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

Lease Agreement - Page 28

 

21.  PROPRIETARY INFORMATION, CONFIDENTIALITY AND SECURITY. 

        (A)    Proprietary Information.    Specialty Laboratories shall have no obligation to provide proprietary information
(as defined in the next sentence) to BNPPLC, except and to the extent that (1) BNPPLC reasonably determines that BNPPLC cannot accomplish the purposes of BNPPLC's inspection of the Property
pursuant to the various provisions hereof without evaluating such information, and (2) before conducting any inspections of the Property permitted hereunder BNPPLC shall, if requested by
Specialty Laboratories, confirm and ratify the confidentiality agreements covering such proprietary information set forth herein. For purposes of this Lease and the other Operative Documents,
"proprietary information" means Specialty Laboratories' intellectual property, trade secrets and other confidential information of value to Specialty
Laboratories about, among other things, Specialty Laboratories' manufacturing processes, products, marketing and corporate strategies, but in no event will "proprietary information" include any
disclosure of substances and materials (and their chemical composition) which are or previously have been present in, on or under the Property at the time of any inspections by BNPPLC, nor will
"proprietary information" include any additional disclosures reasonably required to permit BNPPLC to determine whether the presence of such substances and materials has constituted a violation of
Environmental Laws or this Lease. 

        (B)    Confidentiality.    BNPPLC will endeavor in good faith to use reasonable precautions to keep confidential any
proprietary information that BNPPLC may receive from Specialty Laboratories or otherwise discover with respect to Specialty Laboratories or Specialty Laboratories' business in connection with the
administration of this Lease or any investigation by BNPPLC hereunder. This provision will not, however, render BNPPLC liable for any disclosures of proprietary information made by it or its employees
or representatives, unless the disclosure is intentional and made for no reason other than to do substantial harm to Specialty Laboratories' business. Also, this provision will not apply to
disclosures: (i) specifically and previously authorized in writing by Specialty Laboratories; (ii) to any assignee of BNPPLC as to any interest in the Property so long as such assignee
has agreed in writing to use its reasonable efforts to keep such information confidential in accordance with the terms of this paragraph; (iii) to legal counsel, accountants, auditors,
environmental consultants and other professional advisors to BNPPLC so long as BNPPLC shall inform such persons in writing (if practicable) of the confidential nature of such information and shall
direct them to treat such information confidentially; (iv) to regulatory officials having jurisdiction over BNPPLC or BNPPLC's Parent (provided that the disclosing party shall request
confidential treatment of the disclosed information, if practicable); (v) as required by legal process (provided that the disclosing party shall request confidential treatment of the disclosed
information, if practicable); (vi) of information which has previously become publicly available through the actions or inactions of a person other than BNPPLC not, to BNPPLC's knowledge, in
breach of an obligation of confidentiality to Specialty Laboratories; and (vii) to any Participant so long as the Participant is bound by and has not repudiated a confidentiality provision
concerning Specialty Laboratories' proprietary information set forth in the Participation Agreement. 

        (C)    Building Security.    So long as Specialty Laboratories remains in possession of the Property, BNPPLC or
BNPPLC's representative will, before making any inspection or performing any work on the Property authorized by this Lease, if then requested to do so by Specialty Laboratories in order to maintain
Specialty Laboratories' security: (i) sign in at Specialty Laboratories' security or information desk if Specialty Laboratories has such a desk on the premises, (ii) wear a visitor's
badge or other reasonable identification, (iii) permit an employee of Specialty Laboratories to observe such inspection or work, and (iv) comply with other similar reasonable
nondiscriminatory security requirements of Specialty Laboratories that do not, individually or in the aggregate, significantly interfere with inspections or work of BNPPLC authorized by this Lease. 

[The
signature pages follow.] 

Lease Agreement - Page 29

        IN WITNESS WHEREOF, Specialty Laboratories and BNPPLC have caused this Lease Agreement to be executed as of March 26, 2002. 

	 	 	"Specialty Laboratories"
	

 	
 	

SPECIALTY LABORATORIES, INC., a California corporation
	

 	
 	

By:	
 	

/s/ Frank J. Spina
	 	 	 	 	

	 	 	 	 	Name:	Frank J. Spina
	 	 	 	 	 	

	 	 	 	 	Title:	Chief Financial Officer
	 	 	 	 	 	

[Continuation
of signature pages to Lease Agreement dated to be effective as of March 26, 2002] 

	 	 	"BNPPLC"
	

 	
 	

BNP PARIBAS LEASING CORPORATION, a Delaware corporation
	

 	
 	

By:	
 	

/s/ Barry Mendelsohn
	 	 	 	 	
 Barry Mendelsohn, Vice President

  

 
 

Exhibit A    
    
    Legal Description    
  

        The real property is located in the State of California, County of Los Angeles and is described as follows: 

Parcel A: 

        LOT
3 OF TRACT 43735, IN THE CITY OF SANTA CLARITA, AS PER MAP RECORDED IN BOOK 1074, PAGES 37 TO 39 INCLUSIVE OF MAPS, IN THE OFFICE OF THE COUNTY RECORDER OF SAID COUNTY. 

Parcel B: 

        LOT
1 OF TRACT 43736, IN THE CITY OF SANTA CLARITA, AS PER MAP RECORDED IN BOOK 1076, PAGES 38 TO 41 INCLUSIVE OF MAPS, IN THE OFFICE OF THE COUNTY RECORDER OF SAID COUNTY. 

Parcel C: 

        THAT
PORTION OF LOT 2 OF TRACT 43736, IN THE CITY OF SANTA CLARITA, AS SHOWN ON MAP FILED IN BOOK 1076 PAGES 38 TO 41 INCLUSIVE OF MAPS, IN THE OFFICE OF THE COUNTY RECORDER OF SAID
COUNTY, DESCRIBED AS FOLLOWS: 

        BEGINNING
AT THE NORTHWESTERLY CORNER OF SAID LOT 2; THENCE 

	1.
	ALONG
THE NORTHERLY LINE OF SAID LOT 2 NORTH 77° 25' 56" EAST 531.27 FEET TO THE NORTHEASTERLY CORNER OF SAID LOT 2, SAID CORNER BEING A POINT ON A CURVE CONCAVE WESTERLY
HAVING A RADIUS OF 458.00 FEET, A RADIAL LINE TO SAID CORNER BEARS NORTH 72° 49' 01" EAST; THENCE

	2.
	SOUTHERLY
ALONG THE EASTERLY LINE OF SAID LOT 2 AND ALONG SAID CURVE THROUGH A CENTRAL ANGLE OF 4° 36' 54" AN ARC DISTANCE OF 36.89 FEET; THENCE

	3.
	TANGENT
TO SAID CURVE SOUTH 12° 34' 04" EAST 140.43 FEET TO THE BEGINNING OF A TANGENT CURVE CONCAVE WESTERLY HAVING A RADIUS OF 3958.00 FEET; THENCE

	4.
	SOUTHERLY
ALONG SAID CURVE THROUGH A CENTRAL ANGLE OF 1° 27' 13" AN ARC DISTANCE OF 100.42 FEET TO A POINT ON LAST SAID CURVE, A RADIAL LINE TO SAID POINT BEARS NORTH
78° 53' 09" EAST; THENCE

	5.
	PARALLEL
TO THE SOUTHERLY LINE OF SAID LOT 2 SOUTH 77° 25' 56" WEST 472.58 FEET TO THE WESTERLY LINE OF SAID LOT 2; THENCE

	6.
	ALONG
SAID WESTERLY LINE OF LOT 2 NORTH 36° 20' 00" EAST 41.06 FEET; THENCE

	7.
	NORTH
54° 00' 00" WEST 95.00 FEET; THENCE

	8.
	NORTH
1° 50' 00" EAST 24.00 FEET; THENCE

	9.
	NORTH
48° 20' 00" EAST 59.00 FEET; THENCE

	10.
	NORTH
42° 10' 00" WEST 54.00 FEET; THENCE

	11.
	NORTH
68° 14' 55" WEST 55.60 FEET; THENCE 

Exhibit A - Page 1

 

	12.
	NORTH
26° 10' 00" WEST 55.66 FEET TO THE POINT OF BEGINNING. 

SAID
LAND IS SHOWN AS PARCEL 3 OF CERTIFICATE OF COMPLIANCE NO. 91-001, A COPY OF WHICH RECORDED MAY 1, 1991 AS INSTRUMENT NO. 91-627467. 

Parcel D: 

        LOT
3 AND THOSE PORTIONS OF LOTS 2 AND 4 OF TRACT 43736, IN THE CITY OF SANTA CLARITA, AS PER MAP RECORDED IN BOOK 1076 PAGES 38 TO 41 INCLUSIVE OF MAPS, IN THE OFFICE OF THE COUNTY
RECORDER OF SAID COUNTY, DESCRIBED AS FOLLOWS: 

        BEGINNING
AT THE NORTHWESTERLY CORNER OF LOT 4; THENCE 

	1.
	ALONG
THE WESTERLY LINE OF SAID LOT 4 SOUTH 44°40'00" EAST 32.29 FEET; THENCE

	2.
	SOUTH
10°40'00" WEST 80.00 FEET TO A POINT DISTANT THEREON NORTH 10°40'00" EAST 18.00 FEET FROM THE SOUTHWESTERLY TERMINUS OF THAT COURSE IN SAID WESTERLY LINE
SHOWN AS NORTH 10°40'00" EAST 98.00 FEET; THENCE

	3.
	PARALLEL
WITH THE SOUTHERLY LINE OF SAID LOT 4 NORTH 77°25'56" EAST 455.86 FEET TO THE EASTERLY LINE OF SAID LOT 4; THENCE

	4.
	ALONG
SAID EASTERLY LINE AND THE EASTERLY LINE OF SAID LOTS 3 AND 2 NORTH 05°20'37" WEST 2.71 FEET TO THE BEGINNING OF A TANGENT CURVE CONCAVE WESTERLY HAVING A RADIUS OF
3958.00; THENCE

	5.
	NORTHERLY
ALONG SAID EASTERLY LINE AND ALONG SAID CURVE THROUGH A CENTRAL ANGLE OF 05°46'14" AN ARC DISTANCE OF 398.63 FEET TO A POINT ON SAID CURVE, A RADIAL LINE TO SAID
POINT BEARS NORTH 78°53'09" EAST; THENCE

	6.
	PARALLEL
TO THE NORTHERLY LINE OF SAID LOT 3 SOUTH 77°25'56" WEST 472.58 FEET TO THE WESTERLY LINE OF SAID LOT 2; THENCE

	7.
	ALONG
SAID WESTERLY LINE AND THE WESTERLY LINE OF SAID LOT 3 SOUTH 36°20'00" WEST 29.94 FEET; THENCE

	8.
	SOUTH
01°10'00" WEST 133.00 FEET; THENCE

	9.
	SOUTH
63°00'00" EAST 76.00 FEET; THENCE

	10.
	SOUTH
12°50'00" WEST 68.00; THENCE

	11.
	SOUTH
44°40'00" EAST 47.71 FEET TO THE POINT OF BEGINNING. 

SAID
LAND IS SHOWN AS PARCEL 2 OF CERTIFICATE OF COMPLIANCE NO. 91-001, A COPY OF WHICH RECORDED MAY 1, 1991 AS INSTRUMENT NO. 91-627467. 

        TAX
ASSESSOR PARCELS 2861-001-049,050,110,111,093 AND 094. 

        EXCEPTING FROM PARCELS A THROUGH D ABOVE THE FOLLOWING RIGHTS, WHICH HAVE BEEN RESERVED TO GRANTOR IN THAT CERTAIN GRANT DEED RECORDED
DECEMBER 14, 2001 IN THE REAL PROPERTY RECORDS OF THE RECORDER OF LOS ANGELES COUNTY, CALIFORNIA, AS DOCUMENT NUMBER 01 2394274: 

        ALL
OIL, OIL RIGHTS, MINERALS, MINERAL RIGHTS, NATURAL GAS RIGHTS AND OTHER HYDROCARBONS BY WHATSOEVER NAME KNOWN, GEOTHERMAL STEAM AND 

Exhibit A - Page 2

 

ALL PRODUCTS DERIVED FROM ANY OF THE FOREGOING, THAT MAY BE WITHIN OR UNDER THE REAL PROPERTY REFERRED TO ABOVE, TOGETHER WITH THE PERPETUAL RIGHT OF DRILLING, MINING, EXPLORING AND OPERATING
THEREFOR AND STORING IN AND REMOVING THE SAME FROM SUCH REAL PROPERTY OR ANY OTHER PROPERTY, INCLUDING THE RIGHT TO WHIPSTOCK OR DIRECTIONALLY DRILL AND MINE FROM PROPERTIES OTHER THAN THE REAL
PROPERTY REFERRED TO
ABOVE, OIL OR GAS WELLS, TUNNELS AND SHAFTS INTO, THROUGH OR ACROSS THE SUBSURFACE OF THE REAL PROPERTY REFERRED TO ABOVE, AND TO THE BOTTOM SUCH WHIPSTOCKED OR DIRECTIONALLY DRILLED WELLS, TUNNELS
AND SHAFTS UNDER AND BENEATH OR BEYOND THE EXTERIOR LIMITS THEREOF, AND TO REDRILL, RETUNNEL, EQUIP, MAINTAIN, REPAIR, DEEPEN AND OPERATE ANY SUCH WELLS OR MINES; PROVIDED, HOWEVER, ALL OF THE
FOREGOING IS WITHOUT THE RIGHT TO DRILL, MINE, STORE, EXPLORE OR OPERATE THROUGH THE SURFACE OF THE REAL PROPERTY REFERRED TO ABOVE OR THE UPPER 500 FEET OF THE SUBSURFACE OF SUCH REAL PROPERTY. 

        ALSO EXCEPTING FROM PARCELS A THROUGH D ABOVE THE FOLLOWING RIGHTS, WHICH HAVE BEEN RESERVED TO GRANTOR IN THAT CERTAIN GRANT DEED
RECORDED DECEMBER 14, 2001 IN THE REAL PROPERTY RECORDS OF THE RECORDER OF LOS ANGELES COUNTY, CALIFORNIA, AS DOCUMENT NUMBER 01 2394274: 

        ALL
WATER AND WATER RIGHTS NOW IN OR IN THE FUTURE OWNED BY SELLER APPURTENANT TO OR RELATED IN ANY WAY TO THE REAL PROPERTY REFERRED TO ABOVE OR USED BY SELLER IN CONNECTION WITH OR
RELATED TO SUCH REAL PROPERTY (NO MATTER HOW ACQUIRED BY SELLER) TOGETHER WITH THE RIGHT AND POWER TO EXPLORE, DRILL, REDRILL, REMOVE AND STORE THE SAME FROM, UNDER OR IN THE REAL PROPERTY REFERRED TO
ABOVE OR TO DIVERT OR OTHERWISE UTILIZE SUCH WATER, RIGHTS OR INTERESTS ON ANY OTHER PROPERTY OWNED OR LEASED BY SELLER AND THE RIGHT AND POWER TO CONDUCT WATER OVER OR TO STORE WATER UNDERNEATH THE
REAL PROPERTY REFERRED TO ABOVE BY SUCH MEANS AS SELLER DEEMS REASONABLE. THE WATER AND WATER RIGHTS EXCEPTED AND RESERVED TO SELLER INCLUDE, BUT ARE NOT LIMITED TO, ALL RIPARIAN WATER RIGHTS, ALL
APPROPRIATIVE WATER RIGHTS, ALL WATER RIGHTS AND RIGHTS TO STORE WATER IN SUBSURFACE RESERVOIRS BASED ON OVERLYING LAND OWNERSHIP, ALL LITTORAL WATER RIGHTS, ALL RIGHTS TO PERCOLATING WATER, ALL
PRESCRIPTIVE WATER RIGHTS, ALL ADJUDICATED, STATUTORY OR CONTRACTUAL WATER RIGHTS, ALL RIGHTS TO AQUIFERS, RESERVOIRS, SUBSURFACE AND SURFACE WATERS, AND ALL RIGHTS TO TAKE, USE AND DEVELOP FOR USE
ANY AND ALL WATER THAT MAY NOW EXIST OR MAY IN THE FUTURE EXIST UPON, IN OR UNDER THE REAL PROPERTY REFERRED TO ABOVE; PROVIDED, HOWEVER, ALL OF THE FOREGOING IS WITHOUT THE RIGHT TO USE OR ALTER THE
SURFACE OF THE REAL PROPERTY OR TO OTHERWISE INTERFERE WITH THE USE AND ENJOYMENT OF THE SAME BY GRANTEE AND ITS HEIRS, PERSONAL REPRESENTATIVES, SUCCESSORS AND ASSIGNS. 

Exhibit A - Page 3

QuickLinks

TABLE OF CONTENTS

LEASE AGREEMENT

Exhibit A Legal Description

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}]]